[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGxvr3NVf3kR9UzrRtyIO3YWsHXzzYxRoem6Y09Z_kV0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"The University of Hong Kong",[4,6],"The University of Hong Kong-Shenzhen Hospital",1257,false,314,63,1411833,85,969,[15,18,21,24,27,29,32,34],{"name":16,"count":17},"Smoking Cessation",57,{"name":19,"count":20},"Insomnia",32,{"name":22,"count":23},"Depressive Symptoms",19,{"name":25,"count":26},"Smoking",18,{"name":28,"count":26},"Cancer",{"name":30,"count":31},"Hypertension",17,{"name":33,"count":31},"Depression",{"name":35,"count":36},"Stroke",15,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04541797","Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)","2024-05-08","Empagliflozin 10 MG",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04064840","GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET","2024-09-01","IVF: Decapeptyl and hCG",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04988945","TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma","2024-12-01","Durvalumab",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06310148","Evaluation of the Chronic Disease Co-Care Pilot Scheme","2025-07-01","The Chronic Disease Co-Care (CDCC) Pilot Scheme",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04431245","Stopping Antiviral Treatment in Chronic Hepatitis B","2025-08-31","Entecavir",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT02957890","Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong","2025-09","Inactivated influenza vaccine",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06782646","Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine","2025-12","Berberine",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT03859921","Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET","2025-12-30","Dydrogesterone",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06918769","The Application of a Novel Urinalysis System (UF-5000) for Reducing Unnecessary Antibiotic Use in Clinical Suspected UTI Patients","2025-12-31","Empirical antibiotics",{"nctId":84,"briefTitle":85,"date":81,"intervention":86},"NCT05811169","Quest for Tumour Evolution of Non-small Cell Lung Cancer","Next generation sequencing",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,149,193,211,240,269,287,305,323,341,366,396,422,448,473,491,543,576,620,668,692,717,745,763,790,816,842,873,891,909,934,952,976,994,1012,1030,1058,1111,1145,1182,1204,1265,1295,1325,1362,1392,1421,1445,1474,1498,1530,1548,1566,1584,1610,1628,1653,1671,1694,1717,1750,1788,1813,1891,1933,1972,2006,2028,2069,2103,2127,2150,2176,2194,2216,2243,2267,2286,2304,2326,2352,2378,2401,2419,2443,2461,2532,2588,2631,2662,2698,2729,2751,2773,2809,2848,2885,2907,2934,2958,2976,3000,3018,3044,3062,3080,3098,3121,3139,3165,3183,3201,3224,3251,3277,3295,3318,3343,3361,3379,3403,3426,3444,3462,3480,3506,3524,3552,3570,3588,3615,3643,3661,3679,3703,3721,3748,3766,3793,3811,3837,3860,3885,3903,3926,3952,3970,3996,4014,4042,4060,4078,4096,4121,4139,4157,4182,4206,4230,4255,4280,4298,4322,4347,4365,4389,4422,4453,4471,4497,4515,4540,4558,4576,4594,4618,4640,4658,4685,4703,4721,4739,4766,4784,4810,4828,4853,4871,4898,4916,4934,4960,4978,4996,5021,5039,5068,5092,5110,5135,5153,5180,5198,5216,5234,5257,5275,5302,5328,5346,5364,5382,5407,5474,5536,5566,5598,5620,5642,5669,5687,5705,5728,5753,5771,5796,5814,5832,5850,5877,5902,5927,5945,5966,5991,6009,6027,6045,6072,6090,6112,6135,6158,6184,6202,6224,6248,6271,6289,6313,6336,6359,6384,6402,6430,6448,6466,6484,6507,6525,6549,6575,6593,6617,6639,6662,6687,6705,6728,6750,6774,6798,6816,6839,6864,6882,6905,6981,7015,7045,7091,7123,7158,7187,7217,7245,7278,7316,7348,7373,7400,7426,7451,7473,7497,7521,7545,7571,7594,7616,7638,7656,7681,7704,7729,7752,7774,7797,7820,7845,7863,7888,7906,7924,7942,7967,7985,8010,8033,8057,8075,8102,8120,8138,8164,8182,8207,8225,8247,8271,8289,8307,8325,8348,8371,8399,8422,8444,8462,8486,8504,8529,8547,8571,8589,8607,8625,8651,8669,8696,8718,8736,8754,8776,8801,8819],{"intervention":42,"totalTrials":96,"cells":97},3,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":138},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":137,"soonestReadout":126},[109,121],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT04642261","Effect of Empagliflozin on Liver Fat in Non-diabetic Patients","COMPLETED",[92],"2023-05-31","2023-06-30","2021-01-01",98,[119],"Non-alcoholic Fatty Liver Disease",[42],{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":136},"NCT05147090","Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients","ACTIVE_NOT_RECRUITING",[92],"2027-12-31","2022-01-02",106,[130,131,132,133,134,135],"Chronic Hepatitis b","NAFLD","Cirrhosis","Fibrosis, Liver","Empagliflozin","SGLT2 Inhibitors",[42],1,{"trials":139,"activeCount":137,"soonestReadout":41},[140],{"nctId":39,"briefTitle":40,"status":124,"phases":141,"primaryCompletion":41,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":148},[93],"2025-02-28","2020-10-01",160,[146,147],"Type 2 Diabetes","Microvascular Coronary Artery Disease",[42],{"intervention":150,"totalTrials":151,"cells":152},"Dabigatran etexilate",2,{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":176,"NA":191},{"trials":154,"activeCount":100},[],{"trials":156,"activeCount":100},[],{"trials":158,"activeCount":100},[],{"trials":160,"activeCount":100},[161],{"nctId":162,"briefTitle":163,"status":164,"phases":165,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":174},"NCT03240120","A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism","UNKNOWN",[91],"2021-05-31","2021-12-31","2017-09-01",99,[171,172,173],"Venous Thromboembolism","Deep Vein Thrombosis","Pulmonary Embolism",[150,175],"Tinzaparin",{"trials":177,"activeCount":137,"soonestReadout":182},[178],{"nctId":179,"briefTitle":180,"status":124,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":189},"NCT04045093","Dabigatran for Mitral Stenosis Atrial Fibrillation",[92],"2026-09-30","2027-09-30","2020-10-22",370,[187,188],"Atrial Fibrillation","Mitral Stenosis",[150,190],"Warfarin",{"trials":192,"activeCount":100},[],{"intervention":190,"totalTrials":137,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":209},{"trials":196,"activeCount":100},[],{"trials":198,"activeCount":100},[],{"trials":200,"activeCount":100},[],{"trials":202,"activeCount":100},[],{"trials":204,"activeCount":137,"soonestReadout":182},[205],{"nctId":179,"briefTitle":180,"status":124,"phases":206,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":207,"interventions":208},[92],[187,188],[150,190],{"trials":210,"activeCount":100},[],{"intervention":212,"totalTrials":137,"cells":213},"SGLT2 inhibitor",{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":238},{"trials":215,"activeCount":100},[],{"trials":217,"activeCount":100},[],{"trials":219,"activeCount":100},[],{"trials":221,"activeCount":100},[],{"trials":223,"activeCount":137,"soonestReadout":229},[224],{"nctId":225,"briefTitle":226,"status":227,"phases":228,"primaryCompletion":229,"completion":229,"start":230,"enrollment":128,"conditions":231,"interventions":237},"NCT06668389","Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial","RECRUITING",[92],"2026-12-31","2025-05-12",[232,233,234,235,236],"Congenital Heart Disease","Repaired Tetralogy of Fallot (rTOF)","Pulmonary Regurgitation","Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor","Dapagliflozin (Forxiga)",[212],{"trials":239,"activeCount":100},[],{"intervention":241,"totalTrials":137,"cells":242},"Ketorolac 15mg",{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":251,"NA":267},{"trials":244,"activeCount":100},[],{"trials":246,"activeCount":100},[],{"trials":248,"activeCount":100},[],{"trials":250,"activeCount":100},[],{"trials":252,"activeCount":137,"soonestReadout":229},[253],{"nctId":254,"briefTitle":255,"status":227,"phases":256,"primaryCompletion":229,"completion":257,"start":258,"enrollment":259,"conditions":260,"interventions":262},"NCT07006168","Effects Of Intra-Operative Intra-Articular Cocktail Injection In Patella Open Reduction And Internal Fixation",[92],"2027-07-31","2024-11-01",56,[261],"Patella Fracture",[241,263,264,265,266],"Triamcinolone Acetonide 40mg","Ropivacaine HCL 1% 15ml","0.9 % Normal Saline 35ml","Adrenaline 1:1000 0.5ml",{"trials":268,"activeCount":100},[],{"intervention":263,"totalTrials":137,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":285},{"trials":272,"activeCount":100},[],{"trials":274,"activeCount":100},[],{"trials":276,"activeCount":100},[],{"trials":278,"activeCount":100},[],{"trials":280,"activeCount":137,"soonestReadout":229},[281],{"nctId":254,"briefTitle":255,"status":227,"phases":282,"primaryCompletion":229,"completion":257,"start":258,"enrollment":259,"conditions":283,"interventions":284},[92],[261],[241,263,264,265,266],{"trials":286,"activeCount":100},[],{"intervention":264,"totalTrials":137,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":303},{"trials":290,"activeCount":100},[],{"trials":292,"activeCount":100},[],{"trials":294,"activeCount":100},[],{"trials":296,"activeCount":100},[],{"trials":298,"activeCount":137,"soonestReadout":229},[299],{"nctId":254,"briefTitle":255,"status":227,"phases":300,"primaryCompletion":229,"completion":257,"start":258,"enrollment":259,"conditions":301,"interventions":302},[92],[261],[241,263,264,265,266],{"trials":304,"activeCount":100},[],{"intervention":265,"totalTrials":137,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":321},{"trials":308,"activeCount":100},[],{"trials":310,"activeCount":100},[],{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":137,"soonestReadout":229},[317],{"nctId":254,"briefTitle":255,"status":227,"phases":318,"primaryCompletion":229,"completion":257,"start":258,"enrollment":259,"conditions":319,"interventions":320},[92],[261],[241,263,264,265,266],{"trials":322,"activeCount":100},[],{"intervention":266,"totalTrials":137,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":339},{"trials":326,"activeCount":100},[],{"trials":328,"activeCount":100},[],{"trials":330,"activeCount":100},[],{"trials":332,"activeCount":100},[],{"trials":334,"activeCount":137,"soonestReadout":229},[335],{"nctId":254,"briefTitle":255,"status":227,"phases":336,"primaryCompletion":229,"completion":257,"start":258,"enrollment":259,"conditions":337,"interventions":338},[92],[261],[241,263,264,265,266],{"trials":340,"activeCount":100},[],{"intervention":342,"totalTrials":137,"cells":343},"Dulaglutide 0.75mg subcutaneous",{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":352,"NA":364},{"trials":345,"activeCount":100},[],{"trials":347,"activeCount":100},[],{"trials":349,"activeCount":100},[],{"trials":351,"activeCount":100},[],{"trials":353,"activeCount":137,"soonestReadout":358},[354],{"nctId":355,"briefTitle":356,"status":227,"phases":357,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":361,"interventions":363},"NCT06324461","GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery",[92],"2028-12-31","2024-03-20",372,[362],"Myocardial Injury",[342],{"trials":365,"activeCount":100},[],{"intervention":367,"totalTrials":137,"cells":368},"Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy",{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":394},{"trials":370,"activeCount":100},[],{"trials":372,"activeCount":100},[],{"trials":374,"activeCount":100},[],{"trials":376,"activeCount":100},[],{"trials":378,"activeCount":137,"soonestReadout":384},[379],{"nctId":380,"briefTitle":381,"status":382,"phases":383,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":393},"NCT07482943","The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure","NOT_YET_RECRUITING",[92],"2028-04","2026-04",30,[388,389,390,391,392],"Fontan","Heart Failure","Dapagliflozin","Cardiovascular Diseases","Sodium-GLucose coTransporter-2 Inhibitors",[367],{"trials":395,"activeCount":100},[],{"intervention":397,"totalTrials":137,"cells":398},"Bupivacaine",{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":420},{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"trials":404,"activeCount":100},[],{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":137,"soonestReadout":413},[409],{"nctId":410,"briefTitle":411,"status":382,"phases":412,"primaryCompletion":413,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":418},"NCT04003506","Effectiveness of Adductor Canal Block Using Liposomal Bupivacaine",[92],"2026-10","2024-03-01",90,[417],"Pain, Postoperative",[419,397],"Liposomal bupivacaine",{"trials":421,"activeCount":100},[],{"intervention":423,"totalTrials":137,"cells":424},"Ivabradine + Usual Care",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":433,"NA":446},{"trials":426,"activeCount":100},[],{"trials":428,"activeCount":100},[],{"trials":430,"activeCount":100},[],{"trials":432,"activeCount":100},[],{"trials":434,"activeCount":137,"soonestReadout":439},[435],{"nctId":436,"briefTitle":437,"status":382,"phases":438,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":442,"interventions":445},"NCT07135258","Atrial Fibrillation: In Search for the Optimal Target for Rate Control",[92],"2027-10-01","2025-10-01",200,[443,444],"Atrial Fibrillation (Permanent)","Atrial Fibrillation (AF)",[423],{"trials":447,"activeCount":100},[],{"intervention":449,"totalTrials":137,"cells":450},"Live attenuated influenza vaccine",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":471},{"trials":452,"activeCount":100},[],{"trials":454,"activeCount":100},[],{"trials":456,"activeCount":100},[],{"trials":458,"activeCount":100},[],{"trials":460,"activeCount":137,"soonestReadout":465},[461],{"nctId":462,"briefTitle":463,"status":124,"phases":464,"primaryCompletion":465,"completion":465,"start":440,"enrollment":466,"conditions":467,"interventions":469},"NCT07240922","The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study",[92],"2030-10-01",600,[468],"Influenza",[449,470],"recombinant hemagglutinin influenza vaccine",{"trials":472,"activeCount":100},[],{"intervention":470,"totalTrials":137,"cells":474},{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":489},{"trials":476,"activeCount":100},[],{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":100},[],{"trials":482,"activeCount":100},[],{"trials":484,"activeCount":137,"soonestReadout":465},[485],{"nctId":462,"briefTitle":463,"status":124,"phases":486,"primaryCompletion":465,"completion":465,"start":440,"enrollment":466,"conditions":487,"interventions":488},[92],[468],[449,470],{"trials":490,"activeCount":100},[],{"intervention":419,"totalTrials":492,"cells":493},4,{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":514,"NA":530},{"trials":495,"activeCount":100},[],{"trials":497,"activeCount":100},[],{"trials":499,"activeCount":100},[],{"trials":501,"activeCount":100},[502],{"nctId":503,"briefTitle":504,"status":164,"phases":505,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":512},"NCT05084573","Continuous Interscalene Block vs Liposomal Bupivacaine After Proximal Humerus Fracture Surgery",[91],"2022-07-31","2023-03-31","2020-08-01",92,[511],"Shoulder Fractures",[419,513],"Standard bupivacaine",{"trials":515,"activeCount":137,"soonestReadout":413},[516,526],{"nctId":517,"briefTitle":518,"status":112,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":525},"NCT04928664","Continuous vs Liposomal Bupivacaine Interscalene Block for Proximal Humeral Fracture (CLIP)",[92],"2025-12-13","2026-03-05","2020-09-09",78,[511],[419,513],{"nctId":410,"briefTitle":411,"status":382,"phases":527,"primaryCompletion":413,"completion":413,"start":414,"enrollment":415,"conditions":528,"interventions":529},[92],[417],[419,397],{"trials":531,"activeCount":100},[532],{"nctId":533,"briefTitle":534,"status":112,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":542},"NCT04916392","Observation Study of the Pharmacokinetics of Adductor Canal Block",[],"2022-03-31","2023-04-04","2020-09-01",10,[541],"Toxicity, Drug",[419],{"intervention":67,"totalTrials":151,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":551,"PHASE4":553,"NA":563},{"trials":546,"activeCount":100},[],{"trials":548,"activeCount":100},[],{"trials":550,"activeCount":100},[],{"trials":552,"activeCount":100},[],{"trials":554,"activeCount":137,"soonestReadout":66},[555],{"nctId":64,"briefTitle":65,"status":124,"phases":556,"primaryCompletion":66,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},[92],"2026-09","2016-11-18",400,[561],"Influenza, Human",[67,67],{"trials":564,"activeCount":100},[565],{"nctId":566,"briefTitle":567,"status":112,"phases":568,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":574},"NCT00792051","Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children",[93],"2010-12","2008-09",2800,[573],"Influenza Virus Infection",[67,575],"Saline",{"intervention":77,"totalTrials":96,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":584,"PHASE4":616,"NA":618},{"trials":579,"activeCount":100},[],{"trials":581,"activeCount":100},[],{"trials":583,"activeCount":100},[],{"trials":585,"activeCount":137,"soonestReadout":76},[586,596,608],{"nctId":587,"briefTitle":588,"status":112,"phases":589,"primaryCompletion":590,"completion":590,"start":591,"enrollment":592,"conditions":593,"interventions":595},"NCT02128685","Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Threatened Miscarriage",[91],"2018-05-31","2016-03",406,[594],"Pregnancy",[77],{"nctId":597,"briefTitle":598,"status":164,"phases":599,"primaryCompletion":600,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":606},"NCT03428685","Progesterone to Prevent Preterm Delivery",[90,91],"2021-01","2023-01","2019-01-15",1714,[605],"Preterm Birth",[607],"Dydrogesterone Oral",{"nctId":74,"briefTitle":75,"status":227,"phases":609,"primaryCompletion":76,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":615},[91],"2026-11-30","2021-07-01",716,[614],"Subfertility",[77],{"trials":617,"activeCount":100},[],{"trials":619,"activeCount":100},[],{"intervention":72,"totalTrials":96,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":664,"NA":666},{"trials":623,"activeCount":100},[],{"trials":625,"activeCount":100},[],{"trials":627,"activeCount":100},[],{"trials":629,"activeCount":137,"soonestReadout":71},[630,639,649],{"nctId":69,"briefTitle":70,"status":631,"phases":632,"primaryCompletion":71,"completion":633,"start":634,"enrollment":635,"conditions":636,"interventions":638},"ENROLLING_BY_INVITATION",[90,91],"2026-03","2024-08-01",100,[637],"Hyperlipidemia",[72],{"nctId":640,"briefTitle":641,"status":112,"phases":642,"primaryCompletion":643,"completion":643,"start":644,"enrollment":645,"conditions":646,"interventions":648},"NCT03770325","A Mechanistic Randomized Controlled Trial on the Cardiovascular Effect of Berberine",[90,91],"2020-11-01","2019-04-01",84,[647],"Cardiovascular Risk Factor",[72],{"nctId":650,"briefTitle":651,"status":112,"phases":652,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":661},"NCT02983188","Berberine as Adjuvant Treatment for Schizophrenia Patients",[90,91],"2020-12-30","2021-01-04","2018-04-25",113,[658,659,660],"Schizophrenia","Schizophrenia Spectrum and Other Psychotic Disorders","Metabolic Syndrome x",[72,662,663],"Placebos","Antipsychotic Agents",{"trials":665,"activeCount":100},[],{"trials":667,"activeCount":100},[],{"intervention":134,"totalTrials":137,"cells":669},{"EARLY_PHASE1":670,"PHASE1":672,"PHASE2":674,"PHASE3":676,"PHASE4":688,"NA":690},{"trials":671,"activeCount":100},[],{"trials":673,"activeCount":100},[],{"trials":675,"activeCount":100},[],{"trials":677,"activeCount":137,"soonestReadout":682},[678],{"nctId":679,"briefTitle":680,"status":631,"phases":681,"primaryCompletion":682,"completion":683,"start":684,"enrollment":144,"conditions":685,"interventions":687},"NCT07065357","Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor",[91],"2026-08","2026-12","2025-08-13",[686],"Metabolic Syndrome",[134],{"trials":689,"activeCount":100},[],{"trials":691,"activeCount":100},[],{"intervention":693,"totalTrials":137,"cells":694},"Yulinzhu",{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":701,"PHASE4":713,"NA":715},{"trials":696,"activeCount":100},[],{"trials":698,"activeCount":100},[],{"trials":700,"activeCount":100},[],{"trials":702,"activeCount":137,"soonestReadout":707},[703],{"nctId":704,"briefTitle":705,"status":382,"phases":706,"primaryCompletion":707,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":712},"NCT07550998","Yulinzhu for Women With Diminished Ovarian Reserve",[91],"2027-10-31","2026-04-24",60,[711],"Diminished Ovarian Reserve (DOR)",[693],{"trials":714,"activeCount":100},[],{"trials":716,"activeCount":100},[],{"intervention":718,"totalTrials":137,"cells":719},"Levonorgestrel",{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":726,"PHASE4":741,"NA":743},{"trials":721,"activeCount":100},[],{"trials":723,"activeCount":100},[],{"trials":725,"activeCount":100},[],{"trials":727,"activeCount":137,"soonestReadout":732},[728],{"nctId":729,"briefTitle":730,"status":227,"phases":731,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":738},"NCT06727734","Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception",[91],"2027-09","2027-10","2025-01-18",980,[737],"Contraception",[718,739,740],"Piroxicam","Ulipristal Acetate",{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":100},[],{"intervention":739,"totalTrials":137,"cells":746},{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":759,"NA":761},{"trials":748,"activeCount":100},[],{"trials":750,"activeCount":100},[],{"trials":752,"activeCount":100},[],{"trials":754,"activeCount":137,"soonestReadout":732},[755],{"nctId":729,"briefTitle":730,"status":227,"phases":756,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":757,"interventions":758},[91],[737],[718,739,740],{"trials":760,"activeCount":100},[],{"trials":762,"activeCount":100},[],{"intervention":764,"totalTrials":137,"cells":765},"semaglutide",{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":786,"NA":788},{"trials":767,"activeCount":100},[],{"trials":769,"activeCount":100},[],{"trials":771,"activeCount":100},[],{"trials":773,"activeCount":137,"soonestReadout":778},[774],{"nctId":775,"briefTitle":776,"status":227,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":785},"NCT06937060","Effect of Semaglutide in Patients With Psoriasis and Obesity",[91],"2026-07-31","2027-01-31","2025-03-20",14,[783,784],"Psoriasis (PsO)","Obesity and Overweight",[764],{"trials":787,"activeCount":100},[],{"trials":789,"activeCount":100},[],{"intervention":791,"totalTrials":137,"cells":792},"LingZhi",{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":799,"PHASE4":812,"NA":814},{"trials":794,"activeCount":100},[],{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":100},[],{"trials":800,"activeCount":137,"soonestReadout":805},[801],{"nctId":802,"briefTitle":803,"status":382,"phases":804,"primaryCompletion":805,"completion":229,"start":806,"enrollment":807,"conditions":808,"interventions":811},"NCT06739720","RCT of Efficacy and Safety of CP003 on CFS\u002FME or Post-COVID Fatigue",[90,91],"2026-06-30","2025-01-02",130,[809,810],"Chronic Fatigue Syndrome (CFS)","Post-COVID ME\u002FCFS",[791],{"trials":813,"activeCount":100},[],{"trials":815,"activeCount":100},[],{"intervention":817,"totalTrials":137,"cells":818},"Prednisolone 30 mg",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":825,"PHASE4":838,"NA":840},{"trials":820,"activeCount":100},[],{"trials":822,"activeCount":100},[],{"trials":824,"activeCount":100},[],{"trials":826,"activeCount":137,"soonestReadout":831},[827],{"nctId":828,"briefTitle":829,"status":227,"phases":830,"primaryCompletion":831,"completion":832,"start":833,"enrollment":834,"conditions":835,"interventions":837},"NCT06472219","PREDICATE Trial For Respiratory Tract Infections",[91],"2027-12-08","2028-12-08","2024-12-23",1300,[836],"Respiratory Tract Infections",[817],{"trials":839,"activeCount":100},[],{"trials":841,"activeCount":100},[],{"intervention":843,"totalTrials":137,"cells":844},"0.5% standard bupivacaine only",{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":851,"PHASE4":869,"NA":871},{"trials":846,"activeCount":100},[],{"trials":848,"activeCount":100},[],{"trials":850,"activeCount":100},[],{"trials":852,"activeCount":137,"soonestReadout":857},[853],{"nctId":854,"briefTitle":855,"status":227,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":866},"NCT06740214","Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty",[91],"2027-06-30","2028-06-30","2025-09-04",177,[417,862,863,864,865],"Analgesic Effect","Total Knee Arthroplasty","Liposomal Bupivacaine","Dose Response Relationship, Drug",[843,867,868],"1.33% liposomal bupivacaine with 0.5% standard bupivacaine","1.33% liposomal bupivacaine only",{"trials":870,"activeCount":100},[],{"trials":872,"activeCount":100},[],{"intervention":867,"totalTrials":137,"cells":874},{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":887,"NA":889},{"trials":876,"activeCount":100},[],{"trials":878,"activeCount":100},[],{"trials":880,"activeCount":100},[],{"trials":882,"activeCount":137,"soonestReadout":857},[883],{"nctId":854,"briefTitle":855,"status":227,"phases":884,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":885,"interventions":886},[91],[417,862,863,864,865],[843,867,868],{"trials":888,"activeCount":100},[],{"trials":890,"activeCount":100},[],{"intervention":868,"totalTrials":137,"cells":892},{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":905,"NA":907},{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":100},[],{"trials":900,"activeCount":137,"soonestReadout":857},[901],{"nctId":854,"briefTitle":855,"status":227,"phases":902,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":903,"interventions":904},[91],[417,862,863,864,865],[843,867,868],{"trials":906,"activeCount":100},[],{"trials":908,"activeCount":100},[],{"intervention":910,"totalTrials":137,"cells":911},"3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion",{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":930,"NA":932},{"trials":913,"activeCount":100},[],{"trials":915,"activeCount":100},[],{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":137,"soonestReadout":858},[920],{"nctId":921,"briefTitle":922,"status":227,"phases":923,"primaryCompletion":858,"completion":358,"start":924,"enrollment":925,"conditions":926,"interventions":928},"NCT06903884","3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis",[91],"2026-02-09",94,[927],"Vernal Keratoconjunctivitis",[910,929],"0.1% Cyclosporin A cationic ophthalmic emulsion",{"trials":931,"activeCount":100},[],{"trials":933,"activeCount":100},[],{"intervention":929,"totalTrials":137,"cells":935},{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":948,"NA":950},{"trials":937,"activeCount":100},[],{"trials":939,"activeCount":100},[],{"trials":941,"activeCount":100},[],{"trials":943,"activeCount":137,"soonestReadout":858},[944],{"nctId":921,"briefTitle":922,"status":227,"phases":945,"primaryCompletion":858,"completion":358,"start":924,"enrollment":925,"conditions":946,"interventions":947},[91],[927],[910,929],{"trials":949,"activeCount":100},[],{"trials":951,"activeCount":100},[],{"intervention":47,"totalTrials":137,"cells":953},{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":972,"NA":974},{"trials":955,"activeCount":100},[],{"trials":957,"activeCount":100},[],{"trials":959,"activeCount":100},[],{"trials":961,"activeCount":137,"soonestReadout":46},[962],{"nctId":44,"briefTitle":45,"status":227,"phases":963,"primaryCompletion":46,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":968},[91],"2026-05-30","2019-09-01",784,[614],[47,969,970,971],"FET: Decapeptyl","IVF: hCG and normal saline","FET: Normal Saline",{"trials":973,"activeCount":100},[],{"trials":975,"activeCount":100},[],{"intervention":969,"totalTrials":137,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":990,"NA":992},{"trials":979,"activeCount":100},[],{"trials":981,"activeCount":100},[],{"trials":983,"activeCount":100},[],{"trials":985,"activeCount":137,"soonestReadout":46},[986],{"nctId":44,"briefTitle":45,"status":227,"phases":987,"primaryCompletion":46,"completion":964,"start":965,"enrollment":966,"conditions":988,"interventions":989},[91],[614],[47,969,970,971],{"trials":991,"activeCount":100},[],{"trials":993,"activeCount":100},[],{"intervention":970,"totalTrials":137,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1008,"NA":1010},{"trials":997,"activeCount":100},[],{"trials":999,"activeCount":100},[],{"trials":1001,"activeCount":100},[],{"trials":1003,"activeCount":137,"soonestReadout":46},[1004],{"nctId":44,"briefTitle":45,"status":227,"phases":1005,"primaryCompletion":46,"completion":964,"start":965,"enrollment":966,"conditions":1006,"interventions":1007},[91],[614],[47,969,970,971],{"trials":1009,"activeCount":100},[],{"trials":1011,"activeCount":100},[],{"intervention":971,"totalTrials":137,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1026,"NA":1028},{"trials":1015,"activeCount":100},[],{"trials":1017,"activeCount":100},[],{"trials":1019,"activeCount":100},[],{"trials":1021,"activeCount":137,"soonestReadout":46},[1022],{"nctId":44,"briefTitle":45,"status":227,"phases":1023,"primaryCompletion":46,"completion":964,"start":965,"enrollment":966,"conditions":1024,"interventions":1025},[91],[614],[47,969,970,971],{"trials":1027,"activeCount":100},[],{"trials":1029,"activeCount":100},[],{"intervention":740,"totalTrials":151,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1044,"NA":1046},{"trials":1033,"activeCount":100},[],{"trials":1035,"activeCount":100},[],{"trials":1037,"activeCount":100},[],{"trials":1039,"activeCount":137,"soonestReadout":732},[1040],{"nctId":729,"briefTitle":730,"status":227,"phases":1041,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":1042,"interventions":1043},[91],[737],[718,739,740],{"trials":1045,"activeCount":100},[],{"trials":1047,"activeCount":100},[1048],{"nctId":1049,"briefTitle":1050,"status":112,"phases":1051,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1056},"NCT02517463","Ulipristal Emergency Contraception Used Before or After Ovulation",[],"2014-04","2011-05",700,[737],[1057],"Ulipristal acetate",{"intervention":52,"totalTrials":492,"cells":1059},{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1105,"PHASE4":1107,"NA":1109},{"trials":1061,"activeCount":100},[],{"trials":1063,"activeCount":100},[],{"trials":1065,"activeCount":151,"soonestReadout":51},[1066,1079,1088,1097],{"nctId":1067,"briefTitle":1068,"status":164,"phases":1069,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1076},"NCT04447612","Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma",[90],"2023-12-31","2024-12-31","2020-06-01",118,[1075],"Nasopharyngeal Carcinoma",[52,1077,1078],"Cisplatin","Gemcitabine",{"nctId":1080,"briefTitle":1081,"status":164,"phases":1082,"primaryCompletion":1070,"completion":1071,"start":1083,"enrollment":1084,"conditions":1085,"interventions":1087},"NCT04913480","SBRT and Durvalumab for Inoperable\u002FUnresectable Hepatocellular Carcinoma",[90],"2020-10-15",37,[1086],"Hepatocellular Carcinoma",[52],{"nctId":1089,"briefTitle":1090,"status":227,"phases":1091,"primaryCompletion":81,"completion":805,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1095},"NCT05809869","Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma",[90],"2023-02-15",25,[1086],[52,1096],"Tremelimumab",{"nctId":49,"briefTitle":50,"status":227,"phases":1098,"primaryCompletion":51,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1104},[90],"2026-12-01","2020-12-01",33,[1103],"HCC",[52,1096],{"trials":1106,"activeCount":100},[],{"trials":1108,"activeCount":100},[],{"trials":1110,"activeCount":100},[],{"intervention":1112,"totalTrials":151,"cells":1113},"Carboplatin plus Paclitaxel",{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":151,"soonestReadout":81},[1120,1131],{"nctId":1121,"briefTitle":1122,"status":227,"phases":1123,"primaryCompletion":358,"completion":358,"start":1124,"enrollment":1125,"conditions":1126,"interventions":1130},"NCT07023484","Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer",[90],"2025-05-22",126,[1127,1128,1129],"Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma",[1112],{"nctId":1132,"briefTitle":1133,"status":227,"phases":1134,"primaryCompletion":81,"completion":81,"start":1135,"enrollment":26,"conditions":1136,"interventions":1138},"NCT07022535","Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer",[90],"2024-05-28",[1127,1128,1137],"Peritoneal Cancer",[1112],{"trials":1140,"activeCount":100},[],{"trials":1142,"activeCount":100},[],{"trials":1144,"activeCount":100},[],{"intervention":1146,"totalTrials":151,"cells":1147},"Silver diamine fluoride gel",{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1152,"PHASE3":1176,"PHASE4":1178,"NA":1180},{"trials":1149,"activeCount":100},[],{"trials":1151,"activeCount":100},[],{"trials":1153,"activeCount":151,"soonestReadout":1169},[1154,1165],{"nctId":1155,"briefTitle":1156,"status":124,"phases":1157,"primaryCompletion":1158,"completion":358,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1163},"NCT07455604","Preventing Early Childhood Caries With a Silver Diamine Fluoride Gel",[90],"2028-08-31","2026-01-01",1500,[1162],"Early Childhood Caries (ECC)",[1146,1164],"Sodium Fluoride varnish",{"nctId":1166,"briefTitle":1167,"status":124,"phases":1168,"primaryCompletion":1169,"completion":126,"start":1170,"enrollment":1171,"conditions":1172,"interventions":1174},"NCT06241261","Arresting Early Childhood Caries With a Silver Diamine Fluoride Gel",[90],"2027-08-31","2024-01-01",630,[1173],"Early Childhood Caries",[1146,1175],"Silver diamine fluoride solution",{"trials":1177,"activeCount":100},[],{"trials":1179,"activeCount":100},[],{"trials":1181,"activeCount":100},[],{"intervention":1096,"totalTrials":151,"cells":1183},{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1185,"activeCount":100},[],{"trials":1187,"activeCount":100},[],{"trials":1189,"activeCount":151,"soonestReadout":51},[1190,1194],{"nctId":1089,"briefTitle":1090,"status":227,"phases":1191,"primaryCompletion":81,"completion":805,"start":1092,"enrollment":1093,"conditions":1192,"interventions":1193},[90],[1086],[52,1096],{"nctId":49,"briefTitle":50,"status":227,"phases":1195,"primaryCompletion":51,"completion":1099,"start":1100,"enrollment":1101,"conditions":1196,"interventions":1197},[90],[1103],[52,1096],{"trials":1199,"activeCount":100},[],{"trials":1201,"activeCount":100},[],{"trials":1203,"activeCount":100},[],{"intervention":1077,"totalTrials":492,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1227,"PHASE4":1245,"NA":1263},{"trials":1207,"activeCount":100},[],{"trials":1209,"activeCount":100},[],{"trials":1211,"activeCount":137,"soonestReadout":126},[1212,1216],{"nctId":1067,"briefTitle":1068,"status":164,"phases":1213,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1214,"interventions":1215},[90],[1075],[52,1077,1078],{"nctId":1217,"briefTitle":1218,"status":382,"phases":1219,"primaryCompletion":126,"completion":858,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1225},"NCT07129772","Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma",[90],"2025-11-01",53,[1223,1224],"Nasopharyngeal Cancer Recurrent","Nasopharyngeal Cancinoma (NPC)",[1078,1077,1226],"PEMBROLIZUMAB",{"trials":1228,"activeCount":100},[1229],{"nctId":1230,"briefTitle":1231,"status":164,"phases":1232,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1241},"NCT03623087","SIMPLE Chemotherapy for NK Lymphoma\u002FLeukaemia",[91],"2020-03-14","2020-06-30","2017-07-01",68,[1238,1239,1240],"Non-Hodgkin's Lymphoma, Relapsed","Non-Hodgkin T-cell Lymphoma","Natural Killer\u002FT-Cell Lymphoma, Nasal and Nasal-Type",[1077,1078,1242,1243,1244],"Etoposide","Dexamethasone","L-asparaginase",{"trials":1246,"activeCount":100},[1247],{"nctId":1248,"briefTitle":1249,"status":164,"phases":1250,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":1255,"interventions":1257},"NCT03071822","Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed\u002FRefractory Peripheral T Cell Lymphomas",[92],"2021-07-31","2022-02-28","2017-02-24",50,[1256],"Peripheral T Cell Lymphoma",[1258,1259,1260,1244,1261,1262],"cisplatin","ifosfamide","gemcitabine","etoposide","dexamethasone",{"trials":1264,"activeCount":100},[],{"intervention":1078,"totalTrials":492,"cells":1266},{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1281,"PHASE4":1287,"NA":1293},{"trials":1268,"activeCount":100},[],{"trials":1270,"activeCount":100},[],{"trials":1272,"activeCount":137,"soonestReadout":126},[1273,1277],{"nctId":1067,"briefTitle":1068,"status":164,"phases":1274,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1275,"interventions":1276},[90],[1075],[52,1077,1078],{"nctId":1217,"briefTitle":1218,"status":382,"phases":1278,"primaryCompletion":126,"completion":858,"start":1220,"enrollment":1221,"conditions":1279,"interventions":1280},[90],[1223,1224],[1078,1077,1226],{"trials":1282,"activeCount":100},[1283],{"nctId":1230,"briefTitle":1231,"status":164,"phases":1284,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1236,"conditions":1285,"interventions":1286},[91],[1238,1239,1240],[1077,1078,1242,1243,1244],{"trials":1288,"activeCount":100},[1289],{"nctId":1248,"briefTitle":1249,"status":164,"phases":1290,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":1291,"interventions":1292},[92],[1256],[1258,1259,1260,1244,1261,1262],{"trials":1294,"activeCount":100},[],{"intervention":1164,"totalTrials":151,"cells":1296},{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1307,"PHASE4":1321,"NA":1323},{"trials":1298,"activeCount":100},[],{"trials":1300,"activeCount":100},[],{"trials":1302,"activeCount":137,"soonestReadout":1158},[1303],{"nctId":1155,"briefTitle":1156,"status":124,"phases":1304,"primaryCompletion":1158,"completion":358,"start":1159,"enrollment":1160,"conditions":1305,"interventions":1306},[90],[1162],[1146,1164],{"trials":1308,"activeCount":100},[1309],{"nctId":1310,"briefTitle":1311,"status":164,"phases":1312,"primaryCompletion":1313,"completion":1313,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1318},"NCT05084001","Silver Diamine Fluoride in Preventing Occlusal Caries in Primary Teeth",[90,91],"2023-07-31","2020-03-01",769,[1317],"Dental Caries in Children",[1319,1320],"silver diamine fluoride","sodium fluoride varnish",{"trials":1322,"activeCount":100},[],{"trials":1324,"activeCount":100},[],{"intervention":1326,"totalTrials":151,"cells":1327},"Ropeginterferon alfa-2b",{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1356,"PHASE4":1358,"NA":1360},{"trials":1329,"activeCount":100},[],{"trials":1331,"activeCount":100},[],{"trials":1333,"activeCount":137,"soonestReadout":683},[1334,1346],{"nctId":1335,"briefTitle":1336,"status":227,"phases":1337,"primaryCompletion":683,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1345},"NCT06770842","Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis",[90],"2027-12","2025-03-01",20,[1342,1343,1344],"Primary Myelofibrosis (PMF)","Post Polycythemia Myelofibrosis (PPV MF)","Post Essential Thrombocythaemia Myelofibrosis (PET-MF)",[1326],{"nctId":1347,"briefTitle":1348,"status":164,"phases":1349,"primaryCompletion":1350,"completion":81,"start":1351,"enrollment":1254,"conditions":1352,"interventions":1355},"NCT04988815","Ropeginterferon Alfa 2b for Early Myelofibrosis",[90],"2025-07-31","2021-09-01",[1353,1354],"Primary Myelofibrosis, Prefibrotic Stage","Myelofibrosis",[1326],{"trials":1357,"activeCount":100},[],{"trials":1359,"activeCount":100},[],{"trials":1361,"activeCount":100},[],{"intervention":1363,"totalTrials":151,"cells":1364},"pembrolizumab",{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1386,"PHASE4":1388,"NA":1390},{"trials":1366,"activeCount":100},[],{"trials":1368,"activeCount":100},[],{"trials":1370,"activeCount":137,"soonestReadout":126},[1371,1382],{"nctId":1372,"briefTitle":1373,"status":164,"phases":1374,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1101,"conditions":1378,"interventions":1381},"NCT03021057","Pembrolizumab for T\u002FNK-cell lymphomasNK-cell Lymphomas",[90],"2020-06","2020-12","2016-12-01",[1379,1380],"T-Cell Lymphoma","NK-Cell Lymphoma",[1363],{"nctId":1217,"briefTitle":1218,"status":382,"phases":1383,"primaryCompletion":126,"completion":858,"start":1220,"enrollment":1221,"conditions":1384,"interventions":1385},[90],[1223,1224],[1078,1077,1226],{"trials":1387,"activeCount":100},[],{"trials":1389,"activeCount":100},[],{"trials":1391,"activeCount":100},[],{"intervention":1393,"totalTrials":151,"cells":1394},"Oral Arsenic Trioxide Formulation",{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1415,"PHASE4":1417,"NA":1419},{"trials":1396,"activeCount":100},[],{"trials":1398,"activeCount":100},[],{"trials":1400,"activeCount":137,"soonestReadout":81},[1401,1408],{"nctId":1402,"briefTitle":1403,"status":227,"phases":1404,"primaryCompletion":81,"completion":805,"start":116,"enrollment":635,"conditions":1405,"interventions":1407},"NCT04687176","Frontline Oral Arsenic Trioxide for APL",[90],[1406],"Acute Promyelocytic Leukemia",[1393],{"nctId":1409,"briefTitle":1410,"status":164,"phases":1411,"primaryCompletion":1070,"completion":1071,"start":116,"enrollment":1254,"conditions":1412,"interventions":1414},"NCT04689815","Oral Arsenic Trioxide for NPM1-mutated AML",[90],[1413],"NPMc+ AML",[1393],{"trials":1416,"activeCount":100},[],{"trials":1418,"activeCount":100},[],{"trials":1420,"activeCount":100},[],{"intervention":1422,"totalTrials":137,"cells":1423},"Osimertinib plus platinum doublet chemotherapy",{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1425,"activeCount":100},[],{"trials":1427,"activeCount":100},[],{"trials":1429,"activeCount":137,"soonestReadout":126},[1430],{"nctId":1431,"briefTitle":1432,"status":382,"phases":1433,"primaryCompletion":126,"completion":126,"start":1434,"enrollment":1435,"conditions":1436,"interventions":1438},"NCT06918782","Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma",[90],"2025-05-01",47,[1437],"Lung Cancer (NSCLC)",[1422],{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":100},[],{"trials":1444,"activeCount":100},[],{"intervention":1446,"totalTrials":137,"cells":1447},"Oral arsenic trioxide",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1468,"PHASE4":1470,"NA":1472},{"trials":1449,"activeCount":100},[],{"trials":1451,"activeCount":100},[],{"trials":1453,"activeCount":137,"soonestReadout":1458},[1454],{"nctId":1455,"briefTitle":1456,"status":227,"phases":1457,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":386,"conditions":1461,"interventions":1467},"NCT06778187","Oral-ATO for TP53-mutated Myeloid Malignancies",[90],"2027-02","2028-02","2025-02-07",[1462,1463,1464,1465,1466],"Acute Myeloid Leukemia","Myelodysplastic Neoplasm","Chronic Myelomonocytic Leukemia","TP53 Gene Mutation","Arsenic Trioxide",[1446],{"trials":1469,"activeCount":100},[],{"trials":1471,"activeCount":100},[],{"trials":1473,"activeCount":100},[],{"intervention":1475,"totalTrials":137,"cells":1476},"Pressured Intraperitoneal Aerosol Chemotherapy",{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1492,"PHASE4":1494,"NA":1496},{"trials":1478,"activeCount":100},[],{"trials":1480,"activeCount":100},[],{"trials":1482,"activeCount":137,"soonestReadout":1487},[1483],{"nctId":1484,"briefTitle":1485,"status":227,"phases":1486,"primaryCompletion":1487,"completion":1169,"start":1488,"enrollment":709,"conditions":1489,"interventions":1491},"NCT06367270","The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies",[90],"2026-08-31","2023-09-01",[1490],"Peritoneal Metastases",[1475],{"trials":1493,"activeCount":100},[],{"trials":1495,"activeCount":100},[],{"trials":1497,"activeCount":100},[],{"intervention":1499,"totalTrials":137,"cells":1500},"Asciminib add-on",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1524,"PHASE4":1526,"NA":1528},{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":137,"soonestReadout":1511},[1507],{"nctId":1508,"briefTitle":1509,"status":382,"phases":1510,"primaryCompletion":1511,"completion":1512,"start":1513,"enrollment":1514,"conditions":1515,"interventions":1520},"NCT07493408","Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",[90],"2035-12-31","2037-12-31","2026-03-30",45,[1516,1517,1518,1519],"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)","Blastic Transformation of Chronic Myeloid Leukemia","Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","Haematopoietic Stem Cell Transplant, Allogeneic",[1499,1521,1522,1523],"Imatinib","Dasatinib","Nilotinib",{"trials":1525,"activeCount":100},[],{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[],{"intervention":1521,"totalTrials":137,"cells":1531},{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1533,"activeCount":100},[],{"trials":1535,"activeCount":100},[],{"trials":1537,"activeCount":137,"soonestReadout":1511},[1538],{"nctId":1508,"briefTitle":1509,"status":382,"phases":1539,"primaryCompletion":1511,"completion":1512,"start":1513,"enrollment":1514,"conditions":1540,"interventions":1541},[90],[1516,1517,1518,1519],[1499,1521,1522,1523],{"trials":1543,"activeCount":100},[],{"trials":1545,"activeCount":100},[],{"trials":1547,"activeCount":100},[],{"intervention":1522,"totalTrials":137,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1551,"activeCount":100},[],{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":137,"soonestReadout":1511},[1556],{"nctId":1508,"briefTitle":1509,"status":382,"phases":1557,"primaryCompletion":1511,"completion":1512,"start":1513,"enrollment":1514,"conditions":1558,"interventions":1559},[90],[1516,1517,1518,1519],[1499,1521,1522,1523],{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":100},[],{"intervention":1523,"totalTrials":137,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1569,"activeCount":100},[],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":137,"soonestReadout":1511},[1574],{"nctId":1508,"briefTitle":1509,"status":382,"phases":1575,"primaryCompletion":1511,"completion":1512,"start":1513,"enrollment":1514,"conditions":1576,"interventions":1577},[90],[1516,1517,1518,1519],[1499,1521,1522,1523],{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[],{"intervention":1585,"totalTrials":137,"cells":1586},"Dapagliflozin 10mg Tab",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1588,"activeCount":100},[],{"trials":1590,"activeCount":100},[],{"trials":1592,"activeCount":137,"soonestReadout":229},[1593],{"nctId":1594,"briefTitle":1595,"status":227,"phases":1596,"primaryCompletion":229,"completion":229,"start":1597,"enrollment":1598,"conditions":1599,"interventions":1602},"NCT06155604","SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease",[90],"2023-01-04",150,[1600,1601],"Lupus Nephritis","Chronic Kidney Diseases",[1585,1603],"Standard maintenance therapy",{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[],{"trials":1609,"activeCount":100},[],{"intervention":1603,"totalTrials":137,"cells":1611},{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1616,"PHASE3":1622,"PHASE4":1624,"NA":1626},{"trials":1613,"activeCount":100},[],{"trials":1615,"activeCount":100},[],{"trials":1617,"activeCount":137,"soonestReadout":229},[1618],{"nctId":1594,"briefTitle":1595,"status":227,"phases":1619,"primaryCompletion":229,"completion":229,"start":1597,"enrollment":1598,"conditions":1620,"interventions":1621},[90],[1600,1601],[1585,1603],{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[],{"intervention":1629,"totalTrials":137,"cells":1630},"Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine",{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1647,"PHASE4":1649,"NA":1651},{"trials":1632,"activeCount":100},[],{"trials":1634,"activeCount":100},[],{"trials":1636,"activeCount":137,"soonestReadout":1641},[1637],{"nctId":1638,"briefTitle":1639,"status":227,"phases":1640,"primaryCompletion":1641,"completion":1487,"start":1642,"enrollment":1643,"conditions":1644,"interventions":1646},"NCT06314087","Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)",[90],"2026-08-16","2024-01-31",154,[1645],"Advanced Tumors",[1629],{"trials":1648,"activeCount":100},[],{"trials":1650,"activeCount":100},[],{"trials":1652,"activeCount":100},[],{"intervention":1175,"totalTrials":137,"cells":1654},{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1656,"activeCount":100},[],{"trials":1658,"activeCount":100},[],{"trials":1660,"activeCount":137,"soonestReadout":1169},[1661],{"nctId":1166,"briefTitle":1167,"status":124,"phases":1662,"primaryCompletion":1169,"completion":126,"start":1170,"enrollment":1171,"conditions":1663,"interventions":1664},[90],[1173],[1146,1175],{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":100},[],{"trials":1670,"activeCount":100},[],{"intervention":1672,"totalTrials":137,"cells":1673},"Rituximab",{"EARLY_PHASE1":1674,"PHASE1":1676,"PHASE2":1678,"PHASE3":1688,"PHASE4":1690,"NA":1692},{"trials":1675,"activeCount":100},[],{"trials":1677,"activeCount":100},[],{"trials":1679,"activeCount":137,"soonestReadout":81},[1680],{"nctId":1681,"briefTitle":1682,"status":124,"phases":1683,"primaryCompletion":81,"completion":805,"start":1684,"enrollment":1340,"conditions":1685,"interventions":1687},"NCT04400994","IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus",[90],"2020-06-20",[1686],"Pemphigus",[1672],{"trials":1689,"activeCount":100},[],{"trials":1691,"activeCount":100},[],{"trials":1693,"activeCount":100},[],{"intervention":1695,"totalTrials":137,"cells":1696},"Bifidobacterium probiotics supplementation",{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1709,"PHASE3":1711,"PHASE4":1713,"NA":1715},{"trials":1698,"activeCount":100},[],{"trials":1700,"activeCount":137,"soonestReadout":1705},[1701],{"nctId":1702,"briefTitle":1703,"status":382,"phases":1704,"primaryCompletion":1705,"completion":1705,"start":1706,"enrollment":386,"conditions":1707,"interventions":1708},"NCT07206303","The Effects of Bifidobacterium-based Probiotics in Reducing Blood Pressure in Middle-aged Chinese With Hypertension",[89],"2027-05","2026-05",[30],[1695],{"trials":1710,"activeCount":100},[],{"trials":1712,"activeCount":100},[],{"trials":1714,"activeCount":100},[],{"trials":1716,"activeCount":100},[],{"intervention":1718,"totalTrials":151,"cells":1719},"Folic Acid 5 MG",{"EARLY_PHASE1":1720,"PHASE1":1740,"PHASE2":1742,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1721,"activeCount":151,"soonestReadout":1736},[1722,1732],{"nctId":1723,"briefTitle":1724,"status":382,"phases":1725,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":1728,"conditions":1729,"interventions":1731},"NCT07377071","Folate Treatment to Reduce Death Risk in the Year After Infection-Related Acute Kidney Injury",[88],"2029-03-31","2026-04-01",382,[1730],"Infection-Associated Acute Kidney Injury",[1718],{"nctId":1733,"briefTitle":1734,"status":382,"phases":1735,"primaryCompletion":1736,"completion":183,"start":440,"enrollment":415,"conditions":1737,"interventions":1739},"NCT07013136","Feasibility Test of Folic Acid on Acute Kidney Injury",[88],"2027-03-31",[1738],"Acute Kidney Injury",[1718],{"trials":1741,"activeCount":100},[],{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":100},[],{"trials":1749,"activeCount":100},[],{"intervention":1751,"totalTrials":151,"cells":1752},"Metformin",{"EARLY_PHASE1":1753,"PHASE1":1764,"PHASE2":1766,"PHASE3":1768,"PHASE4":1784,"NA":1786},{"trials":1754,"activeCount":137,"soonestReadout":1759},[1755],{"nctId":1756,"briefTitle":1757,"status":382,"phases":1758,"primaryCompletion":1759,"completion":1760,"start":440,"enrollment":635,"conditions":1761,"interventions":1763},"NCT07065591","Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight\u002FObesity",[88],"2028-04-17","2028-07-17",[1762],"Osteoarthritis (OA) of the Knee",[1751],{"trials":1765,"activeCount":100},[],{"trials":1767,"activeCount":100},[],{"trials":1769,"activeCount":100},[1770],{"nctId":1771,"briefTitle":1772,"status":164,"phases":1773,"primaryCompletion":1774,"completion":1774,"start":1775,"enrollment":1776,"conditions":1777,"interventions":1783},"NCT05412056","Metformin to Prevent Preterm Birth in Twin Pregnancy",[90,91],"2025-06","2022-06",790,[605,1778,1779,1780,1781,1751,1782],"Premature Obstetric Labor","Twin; Complicating Pregnancy","Pregnancy Complications","Pregnancy Preterm","Drug Effect",[1751],{"trials":1785,"activeCount":100},[],{"trials":1787,"activeCount":100},[],{"intervention":1789,"totalTrials":137,"cells":1790},"Glucagon-like peptide-1 receptor agonists",{"EARLY_PHASE1":1791,"PHASE1":1803,"PHASE2":1805,"PHASE3":1807,"PHASE4":1809,"NA":1811},{"trials":1792,"activeCount":137,"soonestReadout":1797},[1793],{"nctId":1794,"briefTitle":1795,"status":382,"phases":1796,"primaryCompletion":1797,"completion":1798,"start":1799,"enrollment":1800,"conditions":1801,"interventions":1802},"NCT06807970","Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist",[88],"2027-07-01","2028-07-01","2025-09-01",54,[1762],[1789],{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":100},[],{"trials":1808,"activeCount":100},[],{"trials":1810,"activeCount":100},[],{"trials":1812,"activeCount":100},[],{"intervention":1814,"totalTrials":1815,"cells":1816},"Letrozole",6,{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1832,"PHASE4":1844,"NA":1846},{"trials":1818,"activeCount":100},[],{"trials":1820,"activeCount":100},[],{"trials":1822,"activeCount":100},[1823],{"nctId":1824,"briefTitle":1825,"status":112,"phases":1826,"primaryCompletion":1827,"completion":1828,"start":1829,"enrollment":1340,"conditions":1830,"interventions":1831},"NCT02457312","The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues",[90],"2013-05","2013-12","2013-03",[594],[1814],{"trials":1833,"activeCount":100},[1834],{"nctId":1835,"briefTitle":1836,"status":112,"phases":1837,"primaryCompletion":1838,"completion":1839,"start":1840,"enrollment":1841,"conditions":1842,"interventions":1843},"NCT02912988","Letrozole in Stimulated IVF Cycles",[91],"2022-04-30","2023-04-30","2018-03-01",900,[614],[1814],{"trials":1845,"activeCount":100},[],{"trials":1847,"activeCount":151,"soonestReadout":229},[1848,1857,1868,1879],{"nctId":1849,"briefTitle":1850,"status":227,"phases":1851,"primaryCompletion":229,"completion":857,"start":1852,"enrollment":1853,"conditions":1854,"interventions":1856},"NCT05487092","Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy",[93],"2022-12-01",194,[1855],"Endometriotic Cyst of Ovary",[1814],{"nctId":1858,"briefTitle":1859,"status":164,"phases":1860,"primaryCompletion":1861,"completion":1861,"start":1862,"enrollment":1254,"conditions":1863,"interventions":1865},"NCT01475318","Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy",[93],"2012-06","2011-10",[1864],"Complete Abortion",[1866,1814,1867],"mifepristone","Misoprostol",{"nctId":1869,"briefTitle":1870,"status":164,"phases":1871,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":1874,"conditions":1875,"interventions":1877},"NCT02647424","A Comparison of Letrozole and Clomifene Citrate",[93],"2017-12","2015-12",40,[1876,614],"Polycystic Ovarian Syndrome",[1814,1878],"Clomiphene",{"nctId":1880,"briefTitle":1881,"status":382,"phases":1882,"primaryCompletion":1883,"completion":1884,"start":1885,"enrollment":1886,"conditions":1887,"interventions":1889},"NCT06733727","Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage",[93],"2027-12-05","2028-06-05","2024-12-06",884,[1888],"Silent Miscarriage",[1814,1890],"Mifepristone",{"intervention":1892,"totalTrials":96,"cells":1893},"Nicotine Replacement Therapy",{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1898,"PHASE3":1900,"PHASE4":1902,"NA":1904},{"trials":1895,"activeCount":100},[],{"trials":1897,"activeCount":100},[],{"trials":1899,"activeCount":100},[],{"trials":1901,"activeCount":100},[],{"trials":1903,"activeCount":100},[],{"trials":1905,"activeCount":151,"soonestReadout":1927},[1906,1914,1923],{"nctId":1907,"briefTitle":1908,"status":112,"phases":1909,"primaryCompletion":1910,"completion":1910,"start":1911,"enrollment":20,"conditions":1912,"interventions":1913},"NCT02935231","PMCAN for Smokers at Smoking Hotspots",[93],"2016-11-30","2016-09-01",[16],[1892],{"nctId":1915,"briefTitle":1916,"status":227,"phases":1917,"primaryCompletion":1736,"completion":183,"start":1918,"enrollment":1919,"conditions":1920,"interventions":1922},"NCT06127589","The \"Quit-for-Kids\" Project: to Increase Abstinence and Protect Children From Tobacco Smoke Exposure",[93],"2024-02-05",1200,[16,1921],"Second Hand Tobacco Smoke",[1892],{"nctId":1924,"briefTitle":1925,"status":227,"phases":1926,"primaryCompletion":1927,"completion":1927,"start":1928,"enrollment":1929,"conditions":1930,"interventions":1931},"NCT06931054","Combination of Acupuncture, Auricular Acupressure and Nicotine Replacement Therapy for Smoking Cessation",[93],"2026-10-30","2025-05-05",270,[25],[1932],"Nicotine Replacement therapy",{"intervention":62,"totalTrials":96,"cells":1934},{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1941,"PHASE4":1943,"NA":1945},{"trials":1936,"activeCount":100},[],{"trials":1938,"activeCount":100},[],{"trials":1940,"activeCount":100},[],{"trials":1942,"activeCount":100},[],{"trials":1944,"activeCount":100},[],{"trials":1946,"activeCount":137,"soonestReadout":61},[1947,1952,1962],{"nctId":59,"briefTitle":60,"status":124,"phases":1948,"primaryCompletion":61,"completion":229,"start":1949,"enrollment":1800,"conditions":1950,"interventions":1951},[],"2021-06-01",[130],[62],{"nctId":1953,"briefTitle":1954,"status":112,"phases":1955,"primaryCompletion":1956,"completion":1956,"start":1957,"enrollment":1254,"conditions":1958,"interventions":1960},"NCT01013272","Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load",[93],"2010-07","2007-06",[1959],"Hepatitis B, Chronic",[62,1961],"Lamivudine",{"nctId":1963,"briefTitle":1964,"status":164,"phases":1965,"primaryCompletion":1070,"completion":1070,"start":1966,"enrollment":635,"conditions":1967,"interventions":1970},"NCT04199819","Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc)",[93],"2022-01-01",[1968,1969],"Occult Hepatitis B","Liver Transplant; Complications",[1971],"entecavir",{"intervention":1973,"totalTrials":151,"cells":1974},"Mailed nicotine replacement therapy",{"EARLY_PHASE1":1975,"PHASE1":1977,"PHASE2":1979,"PHASE3":1981,"PHASE4":1983,"NA":1985},{"trials":1976,"activeCount":100},[],{"trials":1978,"activeCount":100},[],{"trials":1980,"activeCount":100},[],{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[],{"trials":1986,"activeCount":137,"soonestReadout":2000},[1987,1996],{"nctId":1988,"briefTitle":1989,"status":164,"phases":1990,"primaryCompletion":1991,"completion":1991,"start":1992,"enrollment":1993,"conditions":1994,"interventions":1995},"NCT04772521","Smoking Cessation Programme in Workplaces in Hong Kong (Phase Ⅴ)",[93],"2023-12-30","2021-04-15",300,[16],[1973],{"nctId":1997,"briefTitle":1998,"status":227,"phases":1999,"primaryCompletion":2000,"completion":2001,"start":2002,"enrollment":2003,"conditions":2004,"interventions":2005},"NCT06932718","Smoking Cessation Programme in Workplaces in Hong Kong (Phase ⅤII)",[93],"2026-12-20","2027-04-30","2025-03-18",328,[16],[1973],{"intervention":1866,"totalTrials":151,"cells":2007},{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2009,"activeCount":100},[],{"trials":2011,"activeCount":100},[],{"trials":2013,"activeCount":100},[],{"trials":2015,"activeCount":100},[],{"trials":2017,"activeCount":100},[],{"trials":2019,"activeCount":137,"soonestReadout":1883},[2020,2024],{"nctId":1858,"briefTitle":1859,"status":164,"phases":2021,"primaryCompletion":1861,"completion":1861,"start":1862,"enrollment":1254,"conditions":2022,"interventions":2023},[93],[1864],[1866,1814,1867],{"nctId":1880,"briefTitle":1881,"status":382,"phases":2025,"primaryCompletion":1883,"completion":1884,"start":1885,"enrollment":1886,"conditions":2026,"interventions":2027},[93],[1888],[1814,1890],{"intervention":2029,"totalTrials":151,"cells":2030},"Fluoride varnish",{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2051,"PHASE4":2053,"NA":2055},{"trials":2032,"activeCount":100},[],{"trials":2034,"activeCount":100},[],{"trials":2036,"activeCount":100},[2037],{"nctId":2038,"briefTitle":2039,"status":164,"phases":2040,"primaryCompletion":2041,"completion":2042,"start":2043,"enrollment":169,"conditions":2044,"interventions":2048},"NCT04342858","Prospective Randomized Controlled Trial for Prevention of Demineralization During Fixed Orthodontic Treatment",[90],"2021-03-30","2021-07-30","2017-09-15",[2045,2046,2047],"Demineralization, Tooth","Caries,Dental","White Spot Lesion",[2049,2050],"Fluoride Varnish","Fluoride Varnish with tricalcium phosphate",{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":137,"soonestReadout":2061},[2057],{"nctId":2058,"briefTitle":2059,"status":124,"phases":2060,"primaryCompletion":2061,"completion":1338,"start":2062,"enrollment":2063,"conditions":2064,"interventions":2067},"NCT06131957","Root Caries Prevention Using Fluoride Varnish Fortified With SBGC",[93],"2027-01","2024-01-15",540,[2065,2066],"Dental Caries of Root Surface","Root Caries",[2068,2029],"Fluoride varnish with SBGC",{"intervention":2070,"totalTrials":151,"cells":2071},"Tranexamic Acid",{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2076,"PHASE3":2078,"PHASE4":2080,"NA":2093},{"trials":2073,"activeCount":100},[],{"trials":2075,"activeCount":100},[],{"trials":2077,"activeCount":100},[],{"trials":2079,"activeCount":100},[],{"trials":2081,"activeCount":100},[2082],{"nctId":2083,"briefTitle":2084,"status":164,"phases":2085,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2092},"NCT04290884","Tranexamic Acid in Chinese Elderly Patients With Intertrochanteric Fracture RCT",[92],"2020-02-14","2020-05","2018-05-23",120,[2091],"Fracture of Femur",[2070],{"trials":2094,"activeCount":137,"soonestReadout":857},[2095],{"nctId":2096,"briefTitle":2097,"status":227,"phases":2098,"primaryCompletion":857,"completion":126,"start":1159,"enrollment":2099,"conditions":2100,"interventions":2102},"NCT07365150","Precision Use of TXA in Intracerebral Hemorrhage",[93],70,[2101],"Intracerebral Hemorrhage",[2070],{"intervention":57,"totalTrials":137,"cells":2104},{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2111,"PHASE4":2113,"NA":2115},{"trials":2106,"activeCount":100},[],{"trials":2108,"activeCount":100},[],{"trials":2110,"activeCount":100},[],{"trials":2112,"activeCount":100},[],{"trials":2114,"activeCount":100},[],{"trials":2116,"activeCount":137,"soonestReadout":56},[2117],{"nctId":54,"briefTitle":55,"status":227,"phases":2118,"primaryCompletion":56,"completion":229,"start":2119,"enrollment":2120,"conditions":2121,"interventions":2126},[93],"2024-01-18",3772,[2122,30,2123,2124,2125],"Diabetes Mellitus, Type 2","Chronic Disease","Disease Management","Primary Healthcare",[57],{"intervention":2128,"totalTrials":137,"cells":2129},"Vitamin D",{"EARLY_PHASE1":2130,"PHASE1":2132,"PHASE2":2134,"PHASE3":2136,"PHASE4":2138,"NA":2140},{"trials":2131,"activeCount":100},[],{"trials":2133,"activeCount":100},[],{"trials":2135,"activeCount":100},[],{"trials":2137,"activeCount":100},[],{"trials":2139,"activeCount":100},[],{"trials":2141,"activeCount":137,"soonestReadout":1169},[2142],{"nctId":2143,"briefTitle":2144,"status":227,"phases":2145,"primaryCompletion":1169,"completion":2146,"start":2147,"enrollment":1874,"conditions":2148,"interventions":2149},"NCT07458815","Vitamin D for Acute Intracerebral Hemorrhage",[93],"2028-02-28","2026-03-01",[2101],[2128],{"intervention":2151,"totalTrials":137,"cells":2152},"Fecal microbiota transplant",{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2161,"NA":2163},{"trials":2154,"activeCount":100},[],{"trials":2156,"activeCount":100},[],{"trials":2158,"activeCount":100},[],{"trials":2160,"activeCount":100},[],{"trials":2162,"activeCount":100},[],{"trials":2164,"activeCount":137,"soonestReadout":126},[2165],{"nctId":2166,"briefTitle":2167,"status":382,"phases":2168,"primaryCompletion":126,"completion":858,"start":2169,"enrollment":2170,"conditions":2171,"interventions":2174},"NCT05981430","Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae",[93],"2026-11-01",80,[2172,2173],"Carbapenem-Resistant Enterobacteriaceae Infection","Fecal Microbiota Transplantation",[2151,2175],"Sham fecal microbiota transplant",{"intervention":2175,"totalTrials":137,"cells":2177},{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2184,"PHASE4":2186,"NA":2188},{"trials":2179,"activeCount":100},[],{"trials":2181,"activeCount":100},[],{"trials":2183,"activeCount":100},[],{"trials":2185,"activeCount":100},[],{"trials":2187,"activeCount":100},[],{"trials":2189,"activeCount":137,"soonestReadout":126},[2190],{"nctId":2166,"briefTitle":2167,"status":382,"phases":2191,"primaryCompletion":126,"completion":858,"start":2169,"enrollment":2170,"conditions":2192,"interventions":2193},[93],[2172,2173],[2151,2175],{"intervention":82,"totalTrials":137,"cells":2195},{"EARLY_PHASE1":2196,"PHASE1":2198,"PHASE2":2200,"PHASE3":2202,"PHASE4":2204,"NA":2206},{"trials":2197,"activeCount":100},[],{"trials":2199,"activeCount":100},[],{"trials":2201,"activeCount":100},[],{"trials":2203,"activeCount":100},[],{"trials":2205,"activeCount":100},[],{"trials":2207,"activeCount":137,"soonestReadout":81},[2208],{"nctId":79,"briefTitle":80,"status":227,"phases":2209,"primaryCompletion":81,"completion":2210,"start":2211,"enrollment":441,"conditions":2212,"interventions":2215},[93],"2026-02-28","2023-11-06",[2213,2214],"Urinary Tract Infections","Urinary Tract Infection Lower Acute",[82],{"intervention":2217,"totalTrials":137,"cells":2218},"ctDNA mutations and methylation with SPOTMAS Lung assays",{"EARLY_PHASE1":2219,"PHASE1":2221,"PHASE2":2223,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2220,"activeCount":100},[],{"trials":2222,"activeCount":100},[],{"trials":2224,"activeCount":100},[],{"trials":2226,"activeCount":100},[],{"trials":2228,"activeCount":100},[],{"trials":2230,"activeCount":137,"soonestReadout":2235},[2231],{"nctId":2232,"briefTitle":2233,"status":382,"phases":2234,"primaryCompletion":2235,"completion":2236,"start":2237,"enrollment":441,"conditions":2238,"interventions":2242},"NCT07615556","Circulating Tumor DNA Mutations and Methylation Status as Biomarkers for Early Detection of Lung Cancer in Patients With Suspicious Lung Nodules",[],"2028-06","2028-12","2026-06",[2239,2240,2241],"Suspicious Lung Nodules (> 0.5 - 30mm in Longest Diameter, Non-calcified)","Suspicious Lung Nodules, With SUV More Than 1","Early Detection of Lung Cancer",[2217],{"intervention":2244,"totalTrials":137,"cells":2245},"Exforge HCT® or Three Individual drug amlodipine + valsartan + hydrochlorothiazide",{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2256},{"trials":2247,"activeCount":100},[],{"trials":2249,"activeCount":100},[],{"trials":2251,"activeCount":100},[],{"trials":2253,"activeCount":100},[],{"trials":2255,"activeCount":100},[],{"trials":2257,"activeCount":137,"soonestReadout":2262},[2258],{"nctId":2259,"briefTitle":2260,"status":227,"phases":2261,"primaryCompletion":2262,"completion":2263,"start":2147,"enrollment":2264,"conditions":2265,"interventions":2266},"NCT07458880","Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control",[93],"2029-09-30","2030-06-30",140,[2101],[2244],{"intervention":86,"totalTrials":137,"cells":2268},{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2270,"activeCount":100},[],{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"trials":2276,"activeCount":100},[],{"trials":2278,"activeCount":100},[],{"trials":2280,"activeCount":137,"soonestReadout":81},[2281],{"nctId":84,"briefTitle":85,"status":124,"phases":2282,"primaryCompletion":81,"completion":229,"start":1092,"enrollment":709,"conditions":2283,"interventions":2285},[],[2284],"Non-small Cell Lung Cancer",[86],{"intervention":2068,"totalTrials":137,"cells":2287},{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2296,"NA":2298},{"trials":2289,"activeCount":100},[],{"trials":2291,"activeCount":100},[],{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":100},[],{"trials":2297,"activeCount":100},[],{"trials":2299,"activeCount":137,"soonestReadout":2061},[2300],{"nctId":2058,"briefTitle":2059,"status":124,"phases":2301,"primaryCompletion":2061,"completion":1338,"start":2062,"enrollment":2063,"conditions":2302,"interventions":2303},[93],[2065,2066],[2068,2029],{"intervention":2305,"totalTrials":137,"cells":2306},"Vericiguat",{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2308,"activeCount":100},[],{"trials":2310,"activeCount":100},[],{"trials":2312,"activeCount":100},[],{"trials":2314,"activeCount":100},[],{"trials":2316,"activeCount":100},[],{"trials":2318,"activeCount":137,"soonestReadout":1169},[2319],{"nctId":2320,"briefTitle":2321,"status":227,"phases":2322,"primaryCompletion":1169,"completion":1169,"start":46,"enrollment":925,"conditions":2323,"interventions":2325},"NCT06239974","Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)",[93],[2324],"Chest Pain",[2305],{"intervention":2327,"totalTrials":137,"cells":2328},"Vancomycin powder",{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2335,"PHASE4":2337,"NA":2339},{"trials":2330,"activeCount":100},[],{"trials":2332,"activeCount":100},[],{"trials":2334,"activeCount":100},[],{"trials":2336,"activeCount":100},[],{"trials":2338,"activeCount":100},[],{"trials":2340,"activeCount":137,"soonestReadout":1736},[2341],{"nctId":2342,"briefTitle":2343,"status":124,"phases":2344,"primaryCompletion":1736,"completion":857,"start":508,"enrollment":2345,"conditions":2346,"interventions":2351},"NCT03839914","Evaluating the Efficacy and Safety of Intra-wound Vancomycin Powder in High Risk Patients",[93],76,[2347,2348,2349,2350],"Spinal Deformity","Trauma","Spinal Tumor","Surgical Site Infection",[2327],{"intervention":2353,"totalTrials":137,"cells":2354},"Teriparatide",{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2359,"PHASE3":2361,"PHASE4":2363,"NA":2365},{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":100},[],{"trials":2360,"activeCount":100},[],{"trials":2362,"activeCount":100},[],{"trials":2364,"activeCount":100},[],{"trials":2366,"activeCount":137,"soonestReadout":2371},[2367],{"nctId":2368,"briefTitle":2369,"status":124,"phases":2370,"primaryCompletion":2371,"completion":805,"start":2372,"enrollment":2373,"conditions":2374,"interventions":2377},"NCT03770338","Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery",[93],"2026-03-31","2019-03-01",192,[2375,2376],"Osteoporosis","Fusion of Spine, Lumbar Region",[2353],{"intervention":2379,"totalTrials":137,"cells":2380},"MMF-MMF",{"EARLY_PHASE1":2381,"PHASE1":2383,"PHASE2":2385,"PHASE3":2387,"PHASE4":2389,"NA":2391},{"trials":2382,"activeCount":100},[],{"trials":2384,"activeCount":100},[],{"trials":2386,"activeCount":100},[],{"trials":2388,"activeCount":100},[],{"trials":2390,"activeCount":100},[],{"trials":2392,"activeCount":137,"soonestReadout":358},[2393],{"nctId":2394,"briefTitle":2395,"status":227,"phases":2396,"primaryCompletion":358,"completion":358,"start":2397,"enrollment":1254,"conditions":2398,"interventions":2399},"NCT02954939","The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis",[93],"2017-03-01",[1600],[2379,2400],"CTX-AZA",{"intervention":2400,"totalTrials":137,"cells":2402},{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2407,"PHASE3":2409,"PHASE4":2411,"NA":2413},{"trials":2404,"activeCount":100},[],{"trials":2406,"activeCount":100},[],{"trials":2408,"activeCount":100},[],{"trials":2410,"activeCount":100},[],{"trials":2412,"activeCount":100},[],{"trials":2414,"activeCount":137,"soonestReadout":358},[2415],{"nctId":2394,"briefTitle":2395,"status":227,"phases":2416,"primaryCompletion":358,"completion":358,"start":2397,"enrollment":1254,"conditions":2417,"interventions":2418},[93],[1600],[2379,2400],{"intervention":2420,"totalTrials":137,"cells":2421},"Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar",{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2423,"activeCount":100},[],{"trials":2425,"activeCount":100},[],{"trials":2427,"activeCount":100},[],{"trials":2429,"activeCount":100},[],{"trials":2431,"activeCount":100},[],{"trials":2433,"activeCount":137,"soonestReadout":229},[2434],{"nctId":2435,"briefTitle":2436,"status":227,"phases":2437,"primaryCompletion":229,"completion":229,"start":2438,"enrollment":26,"conditions":2439,"interventions":2441},"NCT06292286","Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer",[93],"2023-11-01",[2440],"Recurrent Ovarian Carcinoma",[2420,2442],"Bevacizumab or biosimilar",{"intervention":2442,"totalTrials":137,"cells":2444},{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2446,"activeCount":100},[],{"trials":2448,"activeCount":100},[],{"trials":2450,"activeCount":100},[],{"trials":2452,"activeCount":100},[],{"trials":2454,"activeCount":100},[],{"trials":2456,"activeCount":137,"soonestReadout":229},[2457],{"nctId":2435,"briefTitle":2436,"status":227,"phases":2458,"primaryCompletion":229,"completion":229,"start":2438,"enrollment":26,"conditions":2459,"interventions":2460},[93],[2440],[2420,2442],{"intervention":2462,"totalTrials":1815,"cells":2463},"Dexmedetomidine",{"EARLY_PHASE1":2464,"PHASE1":2466,"PHASE2":2468,"PHASE3":2470,"PHASE4":2519,"NA":2530},{"trials":2465,"activeCount":100},[],{"trials":2467,"activeCount":100},[],{"trials":2469,"activeCount":100},[],{"trials":2471,"activeCount":100},[2472,2482,2490,2500,2510],{"nctId":2473,"briefTitle":2474,"status":112,"phases":2475,"primaryCompletion":2476,"completion":2477,"start":2478,"enrollment":635,"conditions":2479,"interventions":2480},"NCT01353456","Multimodal Analgesic Using Morphine and COX-2 With or Without Dexmedetomidine for Colorectal Surgery",[91],"2010-03","2010-09","2008-05",[417],[2462,2481],"Normal Saline",{"nctId":2483,"briefTitle":2484,"status":112,"phases":2485,"primaryCompletion":1828,"completion":1828,"start":1827,"enrollment":2486,"conditions":2487,"interventions":2489},"NCT03323593","Pharmacokinetics of Different Mode Administration of Intranasal Dexmedetomidine",[91],8,[2488,2462],"Bioavailability",[2462],{"nctId":2491,"briefTitle":2492,"status":164,"phases":2493,"primaryCompletion":2494,"completion":2495,"start":2496,"enrollment":1340,"conditions":2497,"interventions":2498},"NCT05615727","Intranasal Dexmedetomidine and Zolpidem for Treatment of Primary Insomnia",[91],"2023-09","2024-09","2022-09-01",[19],[2462,2499],"Zolpidem",{"nctId":2501,"briefTitle":2502,"status":112,"phases":2503,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":2506,"conditions":2507,"interventions":2509},"NCT01065701","Comparison of Two Doses of Intranasal Dexmedetomidine as Premedication in Children",[91],"2010-08","2009-07",104,[2508],"Patient Between 1-8 Years Old Undergoing Elective Surgery at Queen Mary Hospital",[2462],{"nctId":2511,"briefTitle":2512,"status":112,"phases":2513,"primaryCompletion":2476,"completion":2514,"start":2515,"enrollment":1254,"conditions":2516,"interventions":2518},"NCT01887184","Sedation Using Intranasal Dexmedetomidine in Upper Gastrointestinal Endoscopy",[91],"2010-04","2009-01",[2517],"Gastrointestinal Disease",[2462],{"trials":2520,"activeCount":100},[2521],{"nctId":2522,"briefTitle":2523,"status":164,"phases":2524,"primaryCompletion":2525,"completion":2525,"start":2526,"enrollment":2264,"conditions":2527,"interventions":2529},"NCT02459509","A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children",[92],"2016-05","2015-06",[2528],"Anxiety, Separation",[2462],{"trials":2531,"activeCount":100},[],{"intervention":1243,"totalTrials":2533,"cells":2534},5,{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2541,"PHASE4":2558,"NA":2586},{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"trials":2540,"activeCount":100},[],{"trials":2542,"activeCount":100},[2543,2554],{"nctId":2544,"briefTitle":2545,"status":112,"phases":2546,"primaryCompletion":2547,"completion":2548,"start":2549,"enrollment":1598,"conditions":2550,"interventions":2552},"NCT02021240","Ketamine in Post-operative Dental Pain and Recovery",[91],"2015-09-18","2016-04-18","2014-02-10",[2551],"Post-operative Pain",[2553,1243,2481],"Ketamine",{"nctId":1230,"briefTitle":1231,"status":164,"phases":2555,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1236,"conditions":2556,"interventions":2557},[91],[1238,1239,1240],[1077,1078,1242,1243,1244],{"trials":2559,"activeCount":100},[2560,2564,2575],{"nctId":1248,"briefTitle":1249,"status":164,"phases":2561,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":2562,"interventions":2563},[92],[1256],[1258,1259,1260,1244,1261,1262],{"nctId":2565,"briefTitle":2566,"status":164,"phases":2567,"primaryCompletion":2568,"completion":116,"start":2569,"enrollment":2570,"conditions":2571,"interventions":2573},"NCT03901768","Effects of Combined Topical and Systemic Steroid Administrations on Better Early Postoperative Pain Management in Total Knee Arthroplasty",[92],"2020-01-01","2018-04-26",180,[2572],"Total Knee Replacement",[1243,2574,662],"Triamcinolone",{"nctId":2576,"briefTitle":2577,"status":112,"phases":2578,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":2583,"interventions":2585},"NCT02767882","Dexamethasone in Pain Control After Total Knee Replacement",[92],"2019-01-31","2020-12-31","2016-05-01",138,[2584],"Acute Pain",[1243,575],{"trials":2587,"activeCount":100},[],{"intervention":2481,"totalTrials":492,"cells":2589},{"EARLY_PHASE1":2590,"PHASE1":2592,"PHASE2":2594,"PHASE3":2596,"PHASE4":2617,"NA":2629},{"trials":2591,"activeCount":100},[],{"trials":2593,"activeCount":100},[],{"trials":2595,"activeCount":100},[],{"trials":2597,"activeCount":100},[2598,2602,2613],{"nctId":2473,"briefTitle":2474,"status":112,"phases":2599,"primaryCompletion":2476,"completion":2477,"start":2478,"enrollment":635,"conditions":2600,"interventions":2601},[91],[417],[2462,2481],{"nctId":2603,"briefTitle":2604,"status":112,"phases":2605,"primaryCompletion":2606,"completion":2607,"start":2608,"enrollment":635,"conditions":2609,"interventions":2611},"NCT02329457","VZV Vaccine for Hematopoietic Stem Cell Transplantation",[90,91],"2019-09","2019-10","2014-12",[2610],"Varicella Zoster Infection",[2612,2481],"Zostavax",{"nctId":2544,"briefTitle":2545,"status":112,"phases":2614,"primaryCompletion":2547,"completion":2548,"start":2549,"enrollment":1598,"conditions":2615,"interventions":2616},[91],[2551],[2553,1243,2481],{"trials":2618,"activeCount":100},[2619],{"nctId":2620,"briefTitle":2621,"status":112,"phases":2622,"primaryCompletion":1828,"completion":1828,"start":2623,"enrollment":2624,"conditions":2625,"interventions":2626},"NCT01501214","Use of Atosiban in in Vitro Fertilization (IVF) Treatment",[92],"2011-12",800,[614],[2627,2628],"Atosiban","Normal saline",{"trials":2630,"activeCount":100},[],{"intervention":662,"totalTrials":96,"cells":2632},{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2645,"NA":2660},{"trials":2634,"activeCount":100},[],{"trials":2636,"activeCount":100},[],{"trials":2638,"activeCount":100},[],{"trials":2640,"activeCount":100},[2641],{"nctId":650,"briefTitle":651,"status":112,"phases":2642,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":2643,"interventions":2644},[90,91],[658,659,660],[72,662,663],{"trials":2646,"activeCount":100},[2647,2656],{"nctId":2648,"briefTitle":2649,"status":2650,"phases":2651,"primaryCompletion":414,"completion":46,"start":2652,"enrollment":635,"conditions":2653,"interventions":2654},"NCT03824847","Immunomodulatory Effect of Macrolides in Naturally Occurring Influenza Virus Infections in the Community","SUSPENDED",[92],"2023-06-01",[561],[2655,662],"Clarithromycin 250 MG",{"nctId":2565,"briefTitle":2566,"status":164,"phases":2657,"primaryCompletion":2568,"completion":116,"start":2569,"enrollment":2570,"conditions":2658,"interventions":2659},[92],[2572],[1243,2574,662],{"trials":2661,"activeCount":100},[],{"intervention":2663,"totalTrials":151,"cells":2664},"telbivudine",{"EARLY_PHASE1":2665,"PHASE1":2667,"PHASE2":2669,"PHASE3":2682,"PHASE4":2684,"NA":2696},{"trials":2666,"activeCount":100},[],{"trials":2668,"activeCount":100},[],{"trials":2670,"activeCount":100},[2671],{"nctId":2672,"briefTitle":2673,"status":112,"phases":2674,"primaryCompletion":2675,"completion":2476,"start":2676,"enrollment":36,"conditions":2677,"interventions":2679},"NCT00804622","Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)",[90],"2009-06","2008-12",[2678],"Chronic Hepatitis B",[2663,2680,2681],"tenofovir disproxil fumarate","telbivudine plus tenofovir disproxil fumarate",{"trials":2683,"activeCount":100},[],{"trials":2685,"activeCount":100},[2686],{"nctId":2687,"briefTitle":2688,"status":112,"phases":2689,"primaryCompletion":2690,"completion":590,"start":2691,"enrollment":2692,"conditions":2693,"interventions":2694},"NCT03778567","Renoprotective Effects of Telbivudine in Chronic Hepatitis B",[92],"2016-06-16","2013-08-01",31,[1959,1601],[2695],"Telbivudine",{"trials":2697,"activeCount":100},[],{"intervention":2699,"totalTrials":151,"cells":2700},"Aliskiren",{"EARLY_PHASE1":2701,"PHASE1":2703,"PHASE2":2705,"PHASE3":2707,"PHASE4":2709,"NA":2727},{"trials":2702,"activeCount":100},[],{"trials":2704,"activeCount":100},[],{"trials":2706,"activeCount":100},[],{"trials":2708,"activeCount":100},[],{"trials":2710,"activeCount":100},[2711,2720],{"nctId":2712,"briefTitle":2713,"status":112,"phases":2714,"primaryCompletion":2715,"completion":2715,"start":2505,"enrollment":2170,"conditions":2716,"interventions":2718},"NCT01150201","Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease",[92],"2014-08",[2717],"Kidney Disease",[2699,2719],"Losartan",{"nctId":2721,"briefTitle":2722,"status":112,"phases":2723,"primaryCompletion":569,"completion":569,"start":2505,"enrollment":1093,"conditions":2724,"interventions":2726},"NCT00922311","Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade",[92],[2725],"IgA Nephropathy",[2699],{"trials":2728,"activeCount":100},[],{"intervention":1244,"totalTrials":151,"cells":2730},{"EARLY_PHASE1":2731,"PHASE1":2733,"PHASE2":2735,"PHASE3":2737,"PHASE4":2743,"NA":2749},{"trials":2732,"activeCount":100},[],{"trials":2734,"activeCount":100},[],{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":100},[2739],{"nctId":1230,"briefTitle":1231,"status":164,"phases":2740,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1236,"conditions":2741,"interventions":2742},[91],[1238,1239,1240],[1077,1078,1242,1243,1244],{"trials":2744,"activeCount":100},[2745],{"nctId":1248,"briefTitle":1249,"status":164,"phases":2746,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":2747,"interventions":2748},[92],[1256],[1258,1259,1260,1244,1261,1262],{"trials":2750,"activeCount":100},[],{"intervention":1261,"totalTrials":151,"cells":2752},{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2765,"NA":2771},{"trials":2754,"activeCount":100},[],{"trials":2756,"activeCount":100},[],{"trials":2758,"activeCount":100},[],{"trials":2760,"activeCount":100},[2761],{"nctId":1230,"briefTitle":1231,"status":164,"phases":2762,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1236,"conditions":2763,"interventions":2764},[91],[1238,1239,1240],[1077,1078,1242,1243,1244],{"trials":2766,"activeCount":100},[2767],{"nctId":1248,"briefTitle":1249,"status":164,"phases":2768,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":2769,"interventions":2770},[92],[1256],[1258,1259,1260,1244,1261,1262],{"trials":2772,"activeCount":100},[],{"intervention":2774,"totalTrials":151,"cells":2775},"Mycophenolate mofetil",{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2782,"PHASE4":2793,"NA":2807},{"trials":2777,"activeCount":100},[],{"trials":2779,"activeCount":100},[],{"trials":2781,"activeCount":100},[],{"trials":2783,"activeCount":100},[2784],{"nctId":2785,"briefTitle":2786,"status":112,"phases":2787,"primaryCompletion":2788,"completion":2788,"start":2789,"enrollment":807,"conditions":2790,"interventions":2791},"NCT02630628","Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis",[91],"2024-12-27","2015-12-05",[1600],[2792,2774],"Tacrolimus",{"trials":2794,"activeCount":100},[2795],{"nctId":2796,"briefTitle":2797,"status":112,"phases":2798,"primaryCompletion":2799,"completion":2800,"start":2801,"enrollment":1874,"conditions":2802,"interventions":2804},"NCT00863252","Mycophenolate Mofetil for IgA Nephropathy",[92],"2004-06","2009-03","2002-03",[2803],"IGA Nephropathy",[2805,2806],"mycophenolate mofetil","angiotensin blockade",{"trials":2808,"activeCount":100},[],{"intervention":2810,"totalTrials":151,"cells":2811},"Bevacizumab",{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2816,"PHASE3":2833,"PHASE4":2835,"NA":2846},{"trials":2813,"activeCount":100},[],{"trials":2815,"activeCount":100},[],{"trials":2817,"activeCount":100},[2818],{"nctId":2819,"briefTitle":2820,"status":164,"phases":2821,"primaryCompletion":2822,"completion":2823,"start":2824,"enrollment":1874,"conditions":2825,"interventions":2829},"NCT03647956","Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors",[90],"2019-12-31","2020-04-03","2018-10-01",[2826,2827,2828],"NSCLC Stage IIIB","NSCLC Stage IV","EGFR Activating Mutation",[2830,2810,2831,2832],"Atezolizumab","Carboplatin","Pemetrexed",{"trials":2834,"activeCount":100},[],{"trials":2836,"activeCount":100},[2837],{"nctId":2838,"briefTitle":2839,"status":164,"phases":2840,"primaryCompletion":2841,"completion":1872,"start":2526,"enrollment":709,"conditions":2842,"interventions":2844},"NCT02462304","To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema",[92],"2017-06",[2843],"Diabetic Macula Edema",[2845,2810],"ranibizumab",{"trials":2847,"activeCount":100},[],{"intervention":2849,"totalTrials":151,"cells":2850},"CoronaVac",{"EARLY_PHASE1":2851,"PHASE1":2853,"PHASE2":2855,"PHASE3":2869,"PHASE4":2871,"NA":2883},{"trials":2852,"activeCount":100},[],{"trials":2854,"activeCount":100},[],{"trials":2856,"activeCount":100},[2857],{"nctId":2858,"briefTitle":2859,"status":164,"phases":2860,"primaryCompletion":2861,"completion":2861,"start":2862,"enrollment":2863,"conditions":2864,"interventions":2866},"NCT04800133","Covid-19 Vaccination in Adolescents and Children",[90],"2025-03-31","2021-05-08",1018,[2865],"Covid19",[2867,2849,2868],"Tozinameran","CoronaVac, intradermal",{"trials":2870,"activeCount":100},[],{"trials":2872,"activeCount":100},[2873],{"nctId":2874,"briefTitle":2875,"status":112,"phases":2876,"primaryCompletion":1071,"completion":81,"start":2877,"enrollment":2878,"conditions":2879,"interventions":2881},"NCT05057169","Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)",[92],"2021-11-18",451,[2880],"COVID-19 Vaccination",[2882,2849],"BNT162b2",{"trials":2884,"activeCount":100},[],{"intervention":513,"totalTrials":151,"cells":2886},{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2893,"PHASE4":2899,"NA":2905},{"trials":2888,"activeCount":100},[],{"trials":2890,"activeCount":100},[],{"trials":2892,"activeCount":100},[],{"trials":2894,"activeCount":100},[2895],{"nctId":503,"briefTitle":504,"status":164,"phases":2896,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":2897,"interventions":2898},[91],[511],[419,513],{"trials":2900,"activeCount":100},[2901],{"nctId":517,"briefTitle":518,"status":112,"phases":2902,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":2903,"interventions":2904},[92],[511],[419,513],{"trials":2906,"activeCount":100},[],{"intervention":2882,"totalTrials":151,"cells":2908},{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2913,"PHASE3":2915,"PHASE4":2917,"NA":2932},{"trials":2910,"activeCount":100},[],{"trials":2912,"activeCount":100},[],{"trials":2914,"activeCount":100},[],{"trials":2916,"activeCount":100},[],{"trials":2918,"activeCount":100},[2919,2928],{"nctId":2920,"briefTitle":2921,"status":112,"phases":2922,"primaryCompletion":2923,"completion":1071,"start":2924,"enrollment":1993,"conditions":2925,"interventions":2927},"NCT05057182","Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)",[92],"2024-03-31","2021-10-18",[2926],"COVID 19 Vaccine",[2882],{"nctId":2874,"briefTitle":2875,"status":112,"phases":2929,"primaryCompletion":1071,"completion":81,"start":2877,"enrollment":2878,"conditions":2930,"interventions":2931},[92],[2880],[2882,2849],{"trials":2933,"activeCount":100},[],{"intervention":2935,"totalTrials":137,"cells":2936},"Intanza",{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2943,"PHASE4":2945,"NA":2956},{"trials":2938,"activeCount":100},[],{"trials":2940,"activeCount":100},[],{"trials":2942,"activeCount":100},[],{"trials":2944,"activeCount":100},[],{"trials":2946,"activeCount":100},[2947],{"nctId":2948,"briefTitle":2949,"status":164,"phases":2950,"primaryCompletion":2951,"completion":2526,"start":2952,"enrollment":635,"conditions":2953,"interventions":2954},"NCT01967368","Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults",[92],"2014-05","2013-10",[561],[2935,2955],"Vaxigrip",{"trials":2957,"activeCount":100},[],{"intervention":2955,"totalTrials":137,"cells":2959},{"EARLY_PHASE1":2960,"PHASE1":2962,"PHASE2":2964,"PHASE3":2966,"PHASE4":2968,"NA":2974},{"trials":2961,"activeCount":100},[],{"trials":2963,"activeCount":100},[],{"trials":2965,"activeCount":100},[],{"trials":2967,"activeCount":100},[],{"trials":2969,"activeCount":100},[2970],{"nctId":2948,"briefTitle":2949,"status":164,"phases":2971,"primaryCompletion":2951,"completion":2526,"start":2952,"enrollment":635,"conditions":2972,"interventions":2973},[92],[561],[2935,2955],{"trials":2975,"activeCount":100},[],{"intervention":2977,"totalTrials":137,"cells":2978},"Paracetamol",{"EARLY_PHASE1":2979,"PHASE1":2981,"PHASE2":2983,"PHASE3":2985,"PHASE4":2987,"NA":2998},{"trials":2980,"activeCount":100},[],{"trials":2982,"activeCount":100},[],{"trials":2984,"activeCount":100},[],{"trials":2986,"activeCount":100},[],{"trials":2988,"activeCount":100},[2989],{"nctId":2990,"briefTitle":2991,"status":112,"phases":2992,"primaryCompletion":2993,"completion":2993,"start":2994,"enrollment":1993,"conditions":2995,"interventions":2996},"NCT01891084","The Benefit and Harm of Fever Suppression by Antipyretics in Influenza",[92],"2018-12","2013-07",[468],[2977,2997],"Backup NSAID ibuprofen",{"trials":2999,"activeCount":100},[],{"intervention":2997,"totalTrials":137,"cells":3001},{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3008,"PHASE4":3010,"NA":3016},{"trials":3003,"activeCount":100},[],{"trials":3005,"activeCount":100},[],{"trials":3007,"activeCount":100},[],{"trials":3009,"activeCount":100},[],{"trials":3011,"activeCount":100},[3012],{"nctId":2990,"briefTitle":2991,"status":112,"phases":3013,"primaryCompletion":2993,"completion":2993,"start":2994,"enrollment":1993,"conditions":3014,"interventions":3015},[92],[468],[2977,2997],{"trials":3017,"activeCount":100},[],{"intervention":3019,"totalTrials":137,"cells":3020},"Standard inactivated influenza vaccine",{"EARLY_PHASE1":3021,"PHASE1":3023,"PHASE2":3025,"PHASE3":3027,"PHASE4":3029,"NA":3042},{"trials":3022,"activeCount":100},[],{"trials":3024,"activeCount":100},[],{"trials":3026,"activeCount":100},[],{"trials":3028,"activeCount":100},[],{"trials":3030,"activeCount":100},[3031],{"nctId":3032,"briefTitle":3033,"status":112,"phases":3034,"primaryCompletion":81,"completion":81,"start":3035,"enrollment":3036,"conditions":3037,"interventions":3038},"NCT03330132","Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong",[92],"2017-10-07",1861,[561],[3019,3039,3040,3041],"MF 59 adjuvanted inactivated influenza vaccine","High-dose inactivated influenza vaccine","Recombinant hemagglutinin inactivated influenza vaccine",{"trials":3043,"activeCount":100},[],{"intervention":3039,"totalTrials":137,"cells":3045},{"EARLY_PHASE1":3046,"PHASE1":3048,"PHASE2":3050,"PHASE3":3052,"PHASE4":3054,"NA":3060},{"trials":3047,"activeCount":100},[],{"trials":3049,"activeCount":100},[],{"trials":3051,"activeCount":100},[],{"trials":3053,"activeCount":100},[],{"trials":3055,"activeCount":100},[3056],{"nctId":3032,"briefTitle":3033,"status":112,"phases":3057,"primaryCompletion":81,"completion":81,"start":3035,"enrollment":3036,"conditions":3058,"interventions":3059},[92],[561],[3019,3039,3040,3041],{"trials":3061,"activeCount":100},[],{"intervention":3040,"totalTrials":137,"cells":3063},{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3078},{"trials":3065,"activeCount":100},[],{"trials":3067,"activeCount":100},[],{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[],{"trials":3073,"activeCount":100},[3074],{"nctId":3032,"briefTitle":3033,"status":112,"phases":3075,"primaryCompletion":81,"completion":81,"start":3035,"enrollment":3036,"conditions":3076,"interventions":3077},[92],[561],[3019,3039,3040,3041],{"trials":3079,"activeCount":100},[],{"intervention":3041,"totalTrials":137,"cells":3081},{"EARLY_PHASE1":3082,"PHASE1":3084,"PHASE2":3086,"PHASE3":3088,"PHASE4":3090,"NA":3096},{"trials":3083,"activeCount":100},[],{"trials":3085,"activeCount":100},[],{"trials":3087,"activeCount":100},[],{"trials":3089,"activeCount":100},[],{"trials":3091,"activeCount":100},[3092],{"nctId":3032,"briefTitle":3033,"status":112,"phases":3093,"primaryCompletion":81,"completion":81,"start":3035,"enrollment":3036,"conditions":3094,"interventions":3095},[92],[561],[3019,3039,3040,3041],{"trials":3097,"activeCount":100},[],{"intervention":3099,"totalTrials":137,"cells":3100},"7-valent pneumococcal conjugated vaccine",{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3105,"PHASE3":3107,"PHASE4":3109,"NA":3119},{"trials":3102,"activeCount":100},[],{"trials":3104,"activeCount":100},[],{"trials":3106,"activeCount":100},[],{"trials":3108,"activeCount":100},[],{"trials":3110,"activeCount":100},[3111],{"nctId":3112,"briefTitle":3113,"status":112,"phases":3114,"primaryCompletion":569,"completion":569,"start":3115,"enrollment":635,"conditions":3116,"interventions":3118},"NCT02040402","Immunogenicity of 3+1 Versus 2+1 Schedule for PCV7",[92],"2009-02",[3117],"Infectious Disease",[3099,3099],{"trials":3120,"activeCount":100},[],{"intervention":2719,"totalTrials":137,"cells":3122},{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3129,"PHASE4":3131,"NA":3137},{"trials":3124,"activeCount":100},[],{"trials":3126,"activeCount":100},[],{"trials":3128,"activeCount":100},[],{"trials":3130,"activeCount":100},[],{"trials":3132,"activeCount":100},[3133],{"nctId":2712,"briefTitle":2713,"status":112,"phases":3134,"primaryCompletion":2715,"completion":2715,"start":2505,"enrollment":2170,"conditions":3135,"interventions":3136},[92],[2717],[2699,2719],{"trials":3138,"activeCount":100},[],{"intervention":3140,"totalTrials":137,"cells":3141},"Ketamine 0.5mg\u002Fkg",{"EARLY_PHASE1":3142,"PHASE1":3144,"PHASE2":3146,"PHASE3":3148,"PHASE4":3150,"NA":3163},{"trials":3143,"activeCount":100},[],{"trials":3145,"activeCount":100},[],{"trials":3147,"activeCount":100},[],{"trials":3149,"activeCount":100},[],{"trials":3151,"activeCount":100},[3152],{"nctId":3153,"briefTitle":3154,"status":2650,"phases":3155,"primaryCompletion":3156,"completion":3156,"start":3157,"enrollment":3158,"conditions":3159,"interventions":3161},"NCT02729805","Intraoperative Ketamine on Chronic Pain After Mastectomy",[92],"2024-06","2015-08-18",135,[3160],"Chronic Pain",[575,3140,3162],"Ketamine 0.75mg\u002Fkg",{"trials":3164,"activeCount":100},[],{"intervention":3162,"totalTrials":137,"cells":3166},{"EARLY_PHASE1":3167,"PHASE1":3169,"PHASE2":3171,"PHASE3":3173,"PHASE4":3175,"NA":3181},{"trials":3168,"activeCount":100},[],{"trials":3170,"activeCount":100},[],{"trials":3172,"activeCount":100},[],{"trials":3174,"activeCount":100},[],{"trials":3176,"activeCount":100},[3177],{"nctId":3153,"briefTitle":3154,"status":2650,"phases":3178,"primaryCompletion":3156,"completion":3156,"start":3157,"enrollment":3158,"conditions":3179,"interventions":3180},[92],[3160],[575,3140,3162],{"trials":3182,"activeCount":100},[],{"intervention":1259,"totalTrials":137,"cells":3184},{"EARLY_PHASE1":3185,"PHASE1":3187,"PHASE2":3189,"PHASE3":3191,"PHASE4":3193,"NA":3199},{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":100},[],{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[3195],{"nctId":1248,"briefTitle":1249,"status":164,"phases":3196,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":3197,"interventions":3198},[92],[1256],[1258,1259,1260,1244,1261,1262],{"trials":3200,"activeCount":100},[],{"intervention":3202,"totalTrials":137,"cells":3203},"FluBlok",{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3208,"PHASE3":3210,"PHASE4":3212,"NA":3222},{"trials":3205,"activeCount":100},[],{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":100},[],{"trials":3211,"activeCount":100},[],{"trials":3213,"activeCount":100},[3214],{"nctId":3215,"briefTitle":3216,"status":112,"phases":3217,"primaryCompletion":81,"completion":81,"start":3218,"enrollment":3219,"conditions":3220,"interventions":3221},"NCT04576377","Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures",[92],"2020-10-05",977,[561],[3202],{"trials":3223,"activeCount":100},[],{"intervention":3225,"totalTrials":137,"cells":3226},"98% dehydrated alcohol",{"EARLY_PHASE1":3227,"PHASE1":3229,"PHASE2":3231,"PHASE3":3233,"PHASE4":3235,"NA":3249},{"trials":3228,"activeCount":100},[],{"trials":3230,"activeCount":100},[],{"trials":3232,"activeCount":100},[],{"trials":3234,"activeCount":100},[],{"trials":3236,"activeCount":100},[3237],{"nctId":3238,"briefTitle":3239,"status":164,"phases":3240,"primaryCompletion":1642,"completion":1642,"start":3241,"enrollment":1800,"conditions":3242,"interventions":3248},"NCT04809935","EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy",[92],"2020-09-21",[3243,3244,3245,3246,3247],"Cancer of Pancreas","Pancreatic Neoplasms","Pain","Cancer-Associated Pain","Pain Management",[3225],{"trials":3250,"activeCount":100},[],{"intervention":3252,"totalTrials":137,"cells":3253},"Cook double-balloon catheter",{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3258,"PHASE3":3260,"PHASE4":3262,"NA":3275},{"trials":3255,"activeCount":100},[],{"trials":3257,"activeCount":100},[],{"trials":3259,"activeCount":100},[],{"trials":3261,"activeCount":100},[],{"trials":3263,"activeCount":100},[3264],{"nctId":3265,"briefTitle":3266,"status":164,"phases":3267,"primaryCompletion":3268,"completion":3269,"start":3270,"enrollment":3271,"conditions":3272,"interventions":3274},"NCT06438081","Comparison Between Propess and Cook Double-balloon Catheter for Cervical Priming",[92],"2025-06-01","2025-12-01","2024-06-01",28,[3273],"Delivery Problem",[3252],{"trials":3276,"activeCount":100},[],{"intervention":2806,"totalTrials":137,"cells":3278},{"EARLY_PHASE1":3279,"PHASE1":3281,"PHASE2":3283,"PHASE3":3285,"PHASE4":3287,"NA":3293},{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[],{"trials":3284,"activeCount":100},[],{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":100},[3289],{"nctId":2796,"briefTitle":2797,"status":112,"phases":3290,"primaryCompletion":2799,"completion":2800,"start":2801,"enrollment":1874,"conditions":3291,"interventions":3292},[92],[2803],[2805,2806],{"trials":3294,"activeCount":100},[],{"intervention":3296,"totalTrials":137,"cells":3297},"Quetiapine",{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3302,"PHASE3":3304,"PHASE4":3306,"NA":3316},{"trials":3299,"activeCount":100},[],{"trials":3301,"activeCount":100},[],{"trials":3303,"activeCount":100},[],{"trials":3305,"activeCount":100},[],{"trials":3307,"activeCount":100},[3308],{"nctId":3309,"briefTitle":3310,"status":112,"phases":3311,"completion":1957,"start":3312,"enrollment":3313,"conditions":3314,"interventions":3315},"NCT00334035","Antipsychotic Therapy and First Episode",[92],"2003-08",169,[658],[3296],{"trials":3317,"activeCount":100},[],{"intervention":3319,"totalTrials":137,"cells":3320},"Simvastatin 10mg",{"EARLY_PHASE1":3321,"PHASE1":3323,"PHASE2":3325,"PHASE3":3327,"PHASE4":3329,"NA":3341},{"trials":3322,"activeCount":100},[],{"trials":3324,"activeCount":100},[],{"trials":3326,"activeCount":100},[],{"trials":3328,"activeCount":100},[],{"trials":3330,"activeCount":100},[3331],{"nctId":3332,"briefTitle":3333,"status":164,"phases":3334,"primaryCompletion":1071,"completion":3335,"start":3336,"enrollment":3337,"conditions":3338,"interventions":3339},"NCT05613400","Statin and Bone Health",[92],"2025-06-30","2022-04-13",240,[2122],[3319,3340],"Ezetimibe 10mg",{"trials":3342,"activeCount":100},[],{"intervention":3340,"totalTrials":137,"cells":3344},{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3349,"PHASE3":3351,"PHASE4":3353,"NA":3359},{"trials":3346,"activeCount":100},[],{"trials":3348,"activeCount":100},[],{"trials":3350,"activeCount":100},[],{"trials":3352,"activeCount":100},[],{"trials":3354,"activeCount":100},[3355],{"nctId":3332,"briefTitle":3333,"status":164,"phases":3356,"primaryCompletion":1071,"completion":3335,"start":3336,"enrollment":3337,"conditions":3357,"interventions":3358},[92],[2122],[3319,3340],{"trials":3360,"activeCount":100},[],{"intervention":2845,"totalTrials":137,"cells":3362},{"EARLY_PHASE1":3363,"PHASE1":3365,"PHASE2":3367,"PHASE3":3369,"PHASE4":3371,"NA":3377},{"trials":3364,"activeCount":100},[],{"trials":3366,"activeCount":100},[],{"trials":3368,"activeCount":100},[],{"trials":3370,"activeCount":100},[],{"trials":3372,"activeCount":100},[3373],{"nctId":2838,"briefTitle":2839,"status":164,"phases":3374,"primaryCompletion":2841,"completion":1872,"start":2526,"enrollment":709,"conditions":3375,"interventions":3376},[92],[2843],[2845,2810],{"trials":3378,"activeCount":100},[],{"intervention":3380,"totalTrials":137,"cells":3381},"Rivaroxaban 2.5 MG Oral Tablet [Xarelto]",{"EARLY_PHASE1":3382,"PHASE1":3384,"PHASE2":3386,"PHASE3":3388,"PHASE4":3390,"NA":3401},{"trials":3383,"activeCount":100},[],{"trials":3385,"activeCount":100},[],{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[],{"trials":3391,"activeCount":100},[3392],{"nctId":3393,"briefTitle":3394,"status":112,"phases":3395,"primaryCompletion":3396,"completion":414,"start":3397,"enrollment":2264,"conditions":3398,"interventions":3400},"NCT06986369","Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases",[92],"2023-08-28","2021-05-04",[3399],"Atherosclerosis, Coronary",[3380],{"trials":3402,"activeCount":100},[],{"intervention":3404,"totalTrials":137,"cells":3405},"Myfortic plus low-dose steroid",{"EARLY_PHASE1":3406,"PHASE1":3408,"PHASE2":3410,"PHASE3":3412,"PHASE4":3414,"NA":3424},{"trials":3407,"activeCount":100},[],{"trials":3409,"activeCount":100},[],{"trials":3411,"activeCount":100},[],{"trials":3413,"activeCount":100},[],{"trials":3415,"activeCount":100},[3416],{"nctId":3417,"briefTitle":3418,"status":112,"phases":3419,"primaryCompletion":2841,"completion":2841,"start":2477,"enrollment":1340,"conditions":3420,"interventions":3422},"NCT01185197","Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study",[92],[3421],"Nephrosis, Lipoid",[3404,3423],"Prednisolone",{"trials":3425,"activeCount":100},[],{"intervention":3423,"totalTrials":137,"cells":3427},{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3434,"PHASE4":3436,"NA":3442},{"trials":3429,"activeCount":100},[],{"trials":3431,"activeCount":100},[],{"trials":3433,"activeCount":100},[],{"trials":3435,"activeCount":100},[],{"trials":3437,"activeCount":100},[3438],{"nctId":3417,"briefTitle":3418,"status":112,"phases":3439,"primaryCompletion":2841,"completion":2841,"start":2477,"enrollment":1340,"conditions":3440,"interventions":3441},[92],[3421],[3404,3423],{"trials":3443,"activeCount":100},[],{"intervention":2627,"totalTrials":137,"cells":3445},{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3452,"PHASE4":3454,"NA":3460},{"trials":3447,"activeCount":100},[],{"trials":3449,"activeCount":100},[],{"trials":3451,"activeCount":100},[],{"trials":3453,"activeCount":100},[],{"trials":3455,"activeCount":100},[3456],{"nctId":2620,"briefTitle":2621,"status":112,"phases":3457,"primaryCompletion":1828,"completion":1828,"start":2623,"enrollment":2624,"conditions":3458,"interventions":3459},[92],[614],[2627,2628],{"trials":3461,"activeCount":100},[],{"intervention":2655,"totalTrials":137,"cells":3463},{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3470,"PHASE4":3472,"NA":3478},{"trials":3465,"activeCount":100},[],{"trials":3467,"activeCount":100},[],{"trials":3469,"activeCount":100},[],{"trials":3471,"activeCount":100},[],{"trials":3473,"activeCount":100},[3474],{"nctId":2648,"briefTitle":2649,"status":2650,"phases":3475,"primaryCompletion":414,"completion":46,"start":2652,"enrollment":635,"conditions":3476,"interventions":3477},[92],[561],[2655,662],{"trials":3479,"activeCount":100},[],{"intervention":3481,"totalTrials":137,"cells":3482},"Clopidogrel",{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3487,"PHASE3":3489,"PHASE4":3491,"NA":3504},{"trials":3484,"activeCount":100},[],{"trials":3486,"activeCount":100},[],{"trials":3488,"activeCount":100},[],{"trials":3490,"activeCount":100},[],{"trials":3492,"activeCount":100},[3493],{"nctId":3494,"briefTitle":3495,"status":112,"phases":3496,"primaryCompletion":3497,"completion":3497,"start":3498,"enrollment":3499,"conditions":3500,"interventions":3502},"NCT01994941","Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome",[92],"2015-08","2013-08",133,[3501],"Acute Coronary Syndrome",[3481,3503],"Ticagrelor",{"trials":3505,"activeCount":100},[],{"intervention":3503,"totalTrials":137,"cells":3507},{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3512,"PHASE3":3514,"PHASE4":3516,"NA":3522},{"trials":3509,"activeCount":100},[],{"trials":3511,"activeCount":100},[],{"trials":3513,"activeCount":100},[],{"trials":3515,"activeCount":100},[],{"trials":3517,"activeCount":100},[3518],{"nctId":3494,"briefTitle":3495,"status":112,"phases":3519,"primaryCompletion":3497,"completion":3497,"start":3498,"enrollment":3499,"conditions":3520,"interventions":3521},[92],[3501],[3481,3503],{"trials":3523,"activeCount":100},[],{"intervention":3525,"totalTrials":137,"cells":3526},"Olanzapine oro-dispersible 5Mg Tab",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3533,"PHASE4":3535,"NA":3550},{"trials":3528,"activeCount":100},[],{"trials":3530,"activeCount":100},[],{"trials":3532,"activeCount":100},[],{"trials":3534,"activeCount":100},[],{"trials":3536,"activeCount":100},[3537],{"nctId":3538,"briefTitle":3539,"status":3540,"phases":3541,"primaryCompletion":3542,"completion":3542,"start":168,"enrollment":3543,"conditions":3544,"interventions":3547},"NCT03246620","Oral Olanzapine Versus Haloperidol or Diazepam","TERMINATED",[92],"2018-06-01",12,[3545,3546],"Acute Agitation","Behavioural Emergency",[3525,3548,3549],"Haloperidol 2Mg encapsulated Tab","Diazepam 2Mg encapsulated Tab",{"trials":3551,"activeCount":100},[],{"intervention":3548,"totalTrials":137,"cells":3553},{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3558,"PHASE3":3560,"PHASE4":3562,"NA":3568},{"trials":3555,"activeCount":100},[],{"trials":3557,"activeCount":100},[],{"trials":3559,"activeCount":100},[],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[3564],{"nctId":3538,"briefTitle":3539,"status":3540,"phases":3565,"primaryCompletion":3542,"completion":3542,"start":168,"enrollment":3543,"conditions":3566,"interventions":3567},[92],[3545,3546],[3525,3548,3549],{"trials":3569,"activeCount":100},[],{"intervention":3549,"totalTrials":137,"cells":3571},{"EARLY_PHASE1":3572,"PHASE1":3574,"PHASE2":3576,"PHASE3":3578,"PHASE4":3580,"NA":3586},{"trials":3573,"activeCount":100},[],{"trials":3575,"activeCount":100},[],{"trials":3577,"activeCount":100},[],{"trials":3579,"activeCount":100},[],{"trials":3581,"activeCount":100},[3582],{"nctId":3538,"briefTitle":3539,"status":3540,"phases":3583,"primaryCompletion":3542,"completion":3542,"start":168,"enrollment":3543,"conditions":3584,"interventions":3585},[92],[3545,3546],[3525,3548,3549],{"trials":3587,"activeCount":100},[],{"intervention":3589,"totalTrials":137,"cells":3590},"Cinacalcet",{"EARLY_PHASE1":3591,"PHASE1":3593,"PHASE2":3595,"PHASE3":3597,"PHASE4":3599,"NA":3613},{"trials":3592,"activeCount":100},[],{"trials":3594,"activeCount":100},[],{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[3601],{"nctId":3602,"briefTitle":3603,"status":112,"phases":3604,"primaryCompletion":3605,"completion":3605,"start":3606,"enrollment":3607,"conditions":3608,"interventions":3612},"NCT01447368","Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients",[92],"2017-05-22","2010-05-10",67,[3609,3610,3611],"Kidney Failure","Secondary Hyperparathyroidism","Vascular Diseases",[3589],{"trials":3614,"activeCount":100},[],{"intervention":3616,"totalTrials":137,"cells":3617},"Botulinum Toxin Type A 100Unit\u002FVial",{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3622,"PHASE3":3624,"PHASE4":3626,"NA":3641},{"trials":3619,"activeCount":100},[],{"trials":3621,"activeCount":100},[],{"trials":3623,"activeCount":100},[],{"trials":3625,"activeCount":100},[],{"trials":3627,"activeCount":100},[3628],{"nctId":3629,"briefTitle":3630,"status":112,"phases":3631,"primaryCompletion":3632,"completion":3633,"start":3634,"enrollment":635,"conditions":3635,"interventions":3639},"NCT03508882","Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm",[92],"2017-10-31","2019-02-20","2015-07-01",[3636,3637,3638],"Blepharospasm","Hemifacial Spasm","Botulinum Toxins, Type A",[3616,3640],"Saline Solution for",{"trials":3642,"activeCount":100},[],{"intervention":3640,"totalTrials":137,"cells":3644},{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3651,"PHASE4":3653,"NA":3659},{"trials":3646,"activeCount":100},[],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[],{"trials":3654,"activeCount":100},[3655],{"nctId":3629,"briefTitle":3630,"status":112,"phases":3656,"primaryCompletion":3632,"completion":3633,"start":3634,"enrollment":635,"conditions":3657,"interventions":3658},[92],[3636,3637,3638],[3616,3640],{"trials":3660,"activeCount":100},[],{"intervention":2574,"totalTrials":137,"cells":3662},{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3667,"PHASE3":3669,"PHASE4":3671,"NA":3677},{"trials":3664,"activeCount":100},[],{"trials":3666,"activeCount":100},[],{"trials":3668,"activeCount":100},[],{"trials":3670,"activeCount":100},[],{"trials":3672,"activeCount":100},[3673],{"nctId":2565,"briefTitle":2566,"status":164,"phases":3674,"primaryCompletion":2568,"completion":116,"start":2569,"enrollment":2570,"conditions":3675,"interventions":3676},[92],[2572],[1243,2574,662],{"trials":3678,"activeCount":100},[],{"intervention":3680,"totalTrials":137,"cells":3681},"Ticagrelor 60 mg",{"EARLY_PHASE1":3682,"PHASE1":3684,"PHASE2":3686,"PHASE3":3688,"PHASE4":3690,"NA":3701},{"trials":3683,"activeCount":100},[],{"trials":3685,"activeCount":100},[],{"trials":3687,"activeCount":100},[],{"trials":3689,"activeCount":100},[],{"trials":3691,"activeCount":100},[3692],{"nctId":3693,"briefTitle":3694,"status":112,"phases":3695,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":441,"conditions":3698,"interventions":3699},"NCT03881943","Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of ACS",[92],"2018-12-21","2017-01",[3501],[3680,3700],"Aspirin 100 MG Oral Tablet, Enteric Coated",{"trials":3702,"activeCount":100},[],{"intervention":3700,"totalTrials":137,"cells":3704},{"EARLY_PHASE1":3705,"PHASE1":3707,"PHASE2":3709,"PHASE3":3711,"PHASE4":3713,"NA":3719},{"trials":3706,"activeCount":100},[],{"trials":3708,"activeCount":100},[],{"trials":3710,"activeCount":100},[],{"trials":3712,"activeCount":100},[],{"trials":3714,"activeCount":100},[3715],{"nctId":3693,"briefTitle":3694,"status":112,"phases":3716,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":441,"conditions":3717,"interventions":3718},[92],[3501],[3680,3700],{"trials":3720,"activeCount":100},[],{"intervention":3722,"totalTrials":137,"cells":3723},"Trivalent live attenuated seasonal influenza vaccine",{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3728,"PHASE3":3730,"PHASE4":3732,"NA":3746},{"trials":3725,"activeCount":100},[],{"trials":3727,"activeCount":100},[],{"trials":3729,"activeCount":100},[],{"trials":3731,"activeCount":100},[],{"trials":3733,"activeCount":100},[3734],{"nctId":3735,"briefTitle":3736,"status":112,"phases":3737,"primaryCompletion":3738,"completion":3738,"start":3739,"enrollment":3740,"conditions":3741,"interventions":3744},"NCT00981513","Direct and Indirect Benefits of Influenza Vaccination in Schools and Households",[92],"2010-11","2009-09",6300,[573,3742,3743],"Influenza-like Illness","Acute Respiratory Infection",[3722,3745,575],"Monovalent live attenuated pandemic influenza vaccine",{"trials":3747,"activeCount":100},[],{"intervention":3745,"totalTrials":137,"cells":3749},{"EARLY_PHASE1":3750,"PHASE1":3752,"PHASE2":3754,"PHASE3":3756,"PHASE4":3758,"NA":3764},{"trials":3751,"activeCount":100},[],{"trials":3753,"activeCount":100},[],{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[3760],{"nctId":3735,"briefTitle":3736,"status":112,"phases":3761,"primaryCompletion":3738,"completion":3738,"start":3739,"enrollment":3740,"conditions":3762,"interventions":3763},[92],[573,3742,3743],[3722,3745,575],{"trials":3765,"activeCount":100},[],{"intervention":3767,"totalTrials":137,"cells":3768},"Dienogest",{"EARLY_PHASE1":3769,"PHASE1":3771,"PHASE2":3773,"PHASE3":3775,"PHASE4":3777,"NA":3791},{"trials":3770,"activeCount":100},[],{"trials":3772,"activeCount":100},[],{"trials":3774,"activeCount":100},[],{"trials":3776,"activeCount":100},[],{"trials":3778,"activeCount":100},[3779],{"nctId":3780,"briefTitle":3781,"status":164,"phases":3782,"primaryCompletion":3783,"completion":3784,"start":3785,"enrollment":3786,"conditions":3787,"interventions":3789},"NCT02385448","Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery",[92],"2017-02","2019-02","2015-02",144,[3788],"Endometriosis",[3767,3790],"Microgynon",{"trials":3792,"activeCount":100},[],{"intervention":3790,"totalTrials":137,"cells":3794},{"EARLY_PHASE1":3795,"PHASE1":3797,"PHASE2":3799,"PHASE3":3801,"PHASE4":3803,"NA":3809},{"trials":3796,"activeCount":100},[],{"trials":3798,"activeCount":100},[],{"trials":3800,"activeCount":100},[],{"trials":3802,"activeCount":100},[],{"trials":3804,"activeCount":100},[3805],{"nctId":3780,"briefTitle":3781,"status":164,"phases":3806,"primaryCompletion":3783,"completion":3784,"start":3785,"enrollment":3786,"conditions":3807,"interventions":3808},[92],[3788],[3767,3790],{"trials":3810,"activeCount":100},[],{"intervention":3812,"totalTrials":137,"cells":3813},"Zoledronate",{"EARLY_PHASE1":3814,"PHASE1":3816,"PHASE2":3818,"PHASE3":3820,"PHASE4":3822,"NA":3835},{"trials":3815,"activeCount":100},[],{"trials":3817,"activeCount":100},[],{"trials":3819,"activeCount":100},[],{"trials":3821,"activeCount":100},[],{"trials":3823,"activeCount":100},[3824],{"nctId":3825,"briefTitle":3826,"status":164,"phases":3827,"primaryCompletion":3828,"completion":1774,"start":3829,"enrollment":3830,"conditions":3831,"interventions":3834},"NCT05743179","The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients",[92],"2025-05","2022-12-05",2692,[3832,3833],"Hip Fractures","Pneumonia",[3812],{"trials":3836,"activeCount":100},[],{"intervention":3838,"totalTrials":137,"cells":3839},"Alcohol",{"EARLY_PHASE1":3840,"PHASE1":3842,"PHASE2":3844,"PHASE3":3846,"PHASE4":3848,"NA":3858},{"trials":3841,"activeCount":100},[],{"trials":3843,"activeCount":100},[],{"trials":3845,"activeCount":100},[],{"trials":3847,"activeCount":100},[],{"trials":3849,"activeCount":100},[3850],{"nctId":3851,"briefTitle":3852,"status":164,"phases":3853,"primaryCompletion":1642,"completion":2861,"start":3854,"enrollment":1800,"conditions":3855,"interventions":3857},"NCT04801082","Endoscopic Ultrasound Guided Coeliac Plexus Neurolysis for Cancer Pain",[92],"2021-03",[3856,3247],"Malignancy",[3838],{"trials":3859,"activeCount":100},[],{"intervention":3861,"totalTrials":137,"cells":3862},"Jing Fang Bai Du san",{"EARLY_PHASE1":3863,"PHASE1":3865,"PHASE2":3867,"PHASE3":3869,"PHASE4":3871,"NA":3883},{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[],{"trials":3868,"activeCount":100},[],{"trials":3870,"activeCount":100},[],{"trials":3872,"activeCount":100},[3873],{"nctId":3874,"briefTitle":3875,"status":112,"phases":3876,"primaryCompletion":1957,"completion":1957,"start":3877,"enrollment":3878,"conditions":3879,"interventions":3881},"NCT00887172","Trial of Chinese Herbal Medicine in the Treatment of Upper Respiratory Tract Infections (URTIs)",[92],"2005-06",327,[3880],"Acute Upper Respiratory Tract Infections",[3861,3882],"Ying Qiao san",{"trials":3884,"activeCount":100},[],{"intervention":3882,"totalTrials":137,"cells":3886},{"EARLY_PHASE1":3887,"PHASE1":3889,"PHASE2":3891,"PHASE3":3893,"PHASE4":3895,"NA":3901},{"trials":3888,"activeCount":100},[],{"trials":3890,"activeCount":100},[],{"trials":3892,"activeCount":100},[],{"trials":3894,"activeCount":100},[],{"trials":3896,"activeCount":100},[3897],{"nctId":3874,"briefTitle":3875,"status":112,"phases":3898,"primaryCompletion":1957,"completion":1957,"start":3877,"enrollment":3878,"conditions":3899,"interventions":3900},[92],[3880],[3861,3882],{"trials":3902,"activeCount":100},[],{"intervention":3904,"totalTrials":137,"cells":3905},"Remifentanil",{"EARLY_PHASE1":3906,"PHASE1":3908,"PHASE2":3910,"PHASE3":3912,"PHASE4":3914,"NA":3924},{"trials":3907,"activeCount":100},[],{"trials":3909,"activeCount":100},[],{"trials":3911,"activeCount":100},[],{"trials":3913,"activeCount":100},[],{"trials":3915,"activeCount":100},[3916],{"nctId":3917,"briefTitle":3918,"status":112,"phases":3919,"primaryCompletion":3497,"completion":3497,"start":3785,"enrollment":635,"conditions":3920,"interventions":3922},"NCT02287181","A Phase IV Study Investigating the Effects of Remifentanil Concentrations on Propofol Requirements for Loss of Consciousness, Response to Painful Stimuli, Bispectral Index and Associated Haemodynamic Changes",[92],[3921],"Induction of Anaesthesia",[3904,3923],"Propofol",{"trials":3925,"activeCount":100},[],{"intervention":3927,"totalTrials":137,"cells":3928},"tramadol\u002Facetaminophen",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3950},{"trials":3930,"activeCount":100},[],{"trials":3932,"activeCount":100},[],{"trials":3934,"activeCount":100},[],{"trials":3936,"activeCount":100},[],{"trials":3938,"activeCount":100},[3939],{"nctId":3940,"briefTitle":3941,"status":112,"phases":3942,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":709,"conditions":3946,"interventions":3948},"NCT00942565","Adjuvant Analgesic Effects of Low Dose Tramadol\u002FAcetaminophen Combination After Open Gynaecological Surgery",[92],"2008-10","2012-12","2007-04",[3947],"Postoperative Pain",[3927,3949],"acetaminophen",{"trials":3951,"activeCount":100},[],{"intervention":3949,"totalTrials":137,"cells":3953},{"EARLY_PHASE1":3954,"PHASE1":3956,"PHASE2":3958,"PHASE3":3960,"PHASE4":3962,"NA":3968},{"trials":3955,"activeCount":100},[],{"trials":3957,"activeCount":100},[],{"trials":3959,"activeCount":100},[],{"trials":3961,"activeCount":100},[],{"trials":3963,"activeCount":100},[3964],{"nctId":3940,"briefTitle":3941,"status":112,"phases":3965,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":709,"conditions":3966,"interventions":3967},[92],[3947],[3927,3949],{"trials":3969,"activeCount":100},[],{"intervention":3971,"totalTrials":137,"cells":3972},"Brolucizumab",{"EARLY_PHASE1":3973,"PHASE1":3975,"PHASE2":3977,"PHASE3":3979,"PHASE4":3981,"NA":3994},{"trials":3974,"activeCount":100},[],{"trials":3976,"activeCount":100},[],{"trials":3978,"activeCount":100},[],{"trials":3980,"activeCount":100},[],{"trials":3982,"activeCount":100},[3983],{"nctId":3984,"briefTitle":3985,"status":112,"phases":3986,"primaryCompletion":3987,"completion":3988,"start":3989,"enrollment":386,"conditions":3990,"interventions":3992},"NCT05710471","Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E",[92],"2023-07-25","2023-08-30","2022-07-25",[3991],"Age-Related Macular Degeneration",[3971,3993],"Aflibercept",{"trials":3995,"activeCount":100},[],{"intervention":3993,"totalTrials":137,"cells":3997},{"EARLY_PHASE1":3998,"PHASE1":4000,"PHASE2":4002,"PHASE3":4004,"PHASE4":4006,"NA":4012},{"trials":3999,"activeCount":100},[],{"trials":4001,"activeCount":100},[],{"trials":4003,"activeCount":100},[],{"trials":4005,"activeCount":100},[],{"trials":4007,"activeCount":100},[4008],{"nctId":3984,"briefTitle":3985,"status":112,"phases":4009,"primaryCompletion":3987,"completion":3988,"start":3989,"enrollment":386,"conditions":4010,"interventions":4011},[92],[3991],[3971,3993],{"trials":4013,"activeCount":100},[],{"intervention":4015,"totalTrials":137,"cells":4016},"Meropenem",{"EARLY_PHASE1":4017,"PHASE1":4019,"PHASE2":4021,"PHASE3":4023,"PHASE4":4025,"NA":4040},{"trials":4018,"activeCount":100},[],{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[],{"trials":4024,"activeCount":100},[],{"trials":4026,"activeCount":100},[4027],{"nctId":4028,"briefTitle":4029,"status":164,"phases":4030,"primaryCompletion":4031,"completion":3335,"start":4032,"enrollment":4033,"conditions":4034,"interventions":4036},"NCT05393505","Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection",[92],"2025-03-14","2022-10-24",344,[4035],"Neutropenic Fever",[4015,4037,4038,4039],"Levofloxacin","Amoxicillin Clavulanate","Antibiotic",{"trials":4041,"activeCount":100},[],{"intervention":4037,"totalTrials":137,"cells":4043},{"EARLY_PHASE1":4044,"PHASE1":4046,"PHASE2":4048,"PHASE3":4050,"PHASE4":4052,"NA":4058},{"trials":4045,"activeCount":100},[],{"trials":4047,"activeCount":100},[],{"trials":4049,"activeCount":100},[],{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[4054],{"nctId":4028,"briefTitle":4029,"status":164,"phases":4055,"primaryCompletion":4031,"completion":3335,"start":4032,"enrollment":4033,"conditions":4056,"interventions":4057},[92],[4035],[4015,4037,4038,4039],{"trials":4059,"activeCount":100},[],{"intervention":4038,"totalTrials":137,"cells":4061},{"EARLY_PHASE1":4062,"PHASE1":4064,"PHASE2":4066,"PHASE3":4068,"PHASE4":4070,"NA":4076},{"trials":4063,"activeCount":100},[],{"trials":4065,"activeCount":100},[],{"trials":4067,"activeCount":100},[],{"trials":4069,"activeCount":100},[],{"trials":4071,"activeCount":100},[4072],{"nctId":4028,"briefTitle":4029,"status":164,"phases":4073,"primaryCompletion":4031,"completion":3335,"start":4032,"enrollment":4033,"conditions":4074,"interventions":4075},[92],[4035],[4015,4037,4038,4039],{"trials":4077,"activeCount":100},[],{"intervention":4039,"totalTrials":137,"cells":4079},{"EARLY_PHASE1":4080,"PHASE1":4082,"PHASE2":4084,"PHASE3":4086,"PHASE4":4088,"NA":4094},{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[],{"trials":4085,"activeCount":100},[],{"trials":4087,"activeCount":100},[],{"trials":4089,"activeCount":100},[4090],{"nctId":4028,"briefTitle":4029,"status":164,"phases":4091,"primaryCompletion":4031,"completion":3335,"start":4032,"enrollment":4033,"conditions":4092,"interventions":4093},[92],[4035],[4015,4037,4038,4039],{"trials":4095,"activeCount":100},[],{"intervention":4097,"totalTrials":137,"cells":4098},"Olanzapine",{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4103,"PHASE3":4105,"PHASE4":4107,"NA":4119},{"trials":4100,"activeCount":100},[],{"trials":4102,"activeCount":100},[],{"trials":4104,"activeCount":100},[],{"trials":4106,"activeCount":100},[],{"trials":4108,"activeCount":100},[4109],{"nctId":4110,"briefTitle":4111,"status":3540,"phases":4112,"primaryCompletion":2606,"completion":2606,"start":2608,"enrollment":4113,"conditions":4114,"interventions":4116},"NCT02380118","IM Olanzapine Versus Haloperidol or Midazolam",[92],167,[4115],"Acute Agitation, Behavioural Emergency",[4097,4117,4118],"Haloperidol","Midazolam",{"trials":4120,"activeCount":100},[],{"intervention":4117,"totalTrials":137,"cells":4122},{"EARLY_PHASE1":4123,"PHASE1":4125,"PHASE2":4127,"PHASE3":4129,"PHASE4":4131,"NA":4137},{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[],{"trials":4128,"activeCount":100},[],{"trials":4130,"activeCount":100},[],{"trials":4132,"activeCount":100},[4133],{"nctId":4110,"briefTitle":4111,"status":3540,"phases":4134,"primaryCompletion":2606,"completion":2606,"start":2608,"enrollment":4113,"conditions":4135,"interventions":4136},[92],[4115],[4097,4117,4118],{"trials":4138,"activeCount":100},[],{"intervention":4118,"totalTrials":137,"cells":4140},{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4147,"PHASE4":4149,"NA":4155},{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[],{"trials":4146,"activeCount":100},[],{"trials":4148,"activeCount":100},[],{"trials":4150,"activeCount":100},[4151],{"nctId":4110,"briefTitle":4111,"status":3540,"phases":4152,"primaryCompletion":2606,"completion":2606,"start":2608,"enrollment":4113,"conditions":4153,"interventions":4154},[92],[4115],[4097,4117,4118],{"trials":4156,"activeCount":100},[],{"intervention":390,"totalTrials":137,"cells":4158},{"EARLY_PHASE1":4159,"PHASE1":4161,"PHASE2":4163,"PHASE3":4165,"PHASE4":4167,"NA":4180},{"trials":4160,"activeCount":100},[],{"trials":4162,"activeCount":100},[],{"trials":4164,"activeCount":100},[],{"trials":4166,"activeCount":100},[],{"trials":4168,"activeCount":100},[4169],{"nctId":4170,"briefTitle":4171,"status":164,"phases":4172,"primaryCompletion":4173,"completion":4174,"start":4175,"enrollment":386,"conditions":4176,"interventions":4179},"NCT04200586","The Effects of SGLTi on Diabetic Cardiomyopathy",[92],"2021-03-04","2021-09-30","2020-04-09",[4177,4178],"Type2 Diabetes","Heart Failure With Reduced Ejection Fraction",[390],{"trials":4181,"activeCount":100},[],{"intervention":4183,"totalTrials":137,"cells":4184},"Valsartan 80 mg",{"EARLY_PHASE1":4185,"PHASE1":4187,"PHASE2":4189,"PHASE3":4191,"PHASE4":4193,"NA":4204},{"trials":4186,"activeCount":100},[],{"trials":4188,"activeCount":100},[],{"trials":4190,"activeCount":100},[],{"trials":4192,"activeCount":100},[],{"trials":4194,"activeCount":100},[4195],{"nctId":4196,"briefTitle":4197,"status":164,"phases":4198,"primaryCompletion":4199,"completion":4199,"start":4200,"enrollment":2170,"conditions":4201,"interventions":4203},"NCT05269615","Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II",[92],"2024-09-30","2023-03-20",[4202],"Exercise Physiology",[4183],{"trials":4205,"activeCount":100},[],{"intervention":4207,"totalTrials":137,"cells":4208},"Intravenous Paricalcitol",{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4215,"PHASE4":4217,"NA":4228},{"trials":4210,"activeCount":100},[],{"trials":4212,"activeCount":100},[],{"trials":4214,"activeCount":100},[],{"trials":4216,"activeCount":100},[],{"trials":4218,"activeCount":100},[4219],{"nctId":4220,"briefTitle":4221,"status":164,"phases":4222,"primaryCompletion":1872,"completion":4223,"start":4224,"enrollment":386,"conditions":4225,"interventions":4227},"NCT03023748","Intravenous Paricalcitol in Chronic Hemodialysis Patients",[92],"2018-01","2011-09",[4226,3610],"Endstage Renal Disease",[4207],{"trials":4229,"activeCount":100},[],{"intervention":4231,"totalTrials":137,"cells":4232},"Lidocaine",{"EARLY_PHASE1":4233,"PHASE1":4235,"PHASE2":4237,"PHASE3":4239,"PHASE4":4241,"NA":4253},{"trials":4234,"activeCount":100},[],{"trials":4236,"activeCount":100},[],{"trials":4238,"activeCount":100},[],{"trials":4240,"activeCount":100},[],{"trials":4242,"activeCount":100},[4243],{"nctId":4244,"briefTitle":4245,"status":112,"phases":4246,"primaryCompletion":4247,"completion":4248,"start":4249,"enrollment":4250,"conditions":4251,"interventions":4252},"NCT03597776","Intravenous Lidocaine in Total Knee Replacement",[92],"2020-09-10","2020-09-14","2019-01-03",62,[2584],[4231,575],{"trials":4254,"activeCount":100},[],{"intervention":4256,"totalTrials":137,"cells":4257},"Bupivacaine Injection [Marcaine]",{"EARLY_PHASE1":4258,"PHASE1":4260,"PHASE2":4262,"PHASE3":4264,"PHASE4":4266,"NA":4278},{"trials":4259,"activeCount":100},[],{"trials":4261,"activeCount":100},[],{"trials":4263,"activeCount":100},[],{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[4268],{"nctId":4269,"briefTitle":4270,"status":112,"phases":4271,"primaryCompletion":4272,"completion":4273,"start":4274,"enrollment":2170,"conditions":4275,"interventions":4276},"NCT05118399","Analgesic Effect of Liposomal Bupivacaine",[92],"2022-12-08","2023-03-08","2021-11-15",[2584],[4256,4277],"Bupivacaine Liposome 13.3 MG\u002FML [Exparel]",{"trials":4279,"activeCount":100},[],{"intervention":4277,"totalTrials":137,"cells":4281},{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4288,"PHASE4":4290,"NA":4296},{"trials":4283,"activeCount":100},[],{"trials":4285,"activeCount":100},[],{"trials":4287,"activeCount":100},[],{"trials":4289,"activeCount":100},[],{"trials":4291,"activeCount":100},[4292],{"nctId":4269,"briefTitle":4270,"status":112,"phases":4293,"primaryCompletion":4272,"completion":4273,"start":4274,"enrollment":2170,"conditions":4294,"interventions":4295},[92],[2584],[4256,4277],{"trials":4297,"activeCount":100},[],{"intervention":4299,"totalTrials":137,"cells":4300},"desmopressin",{"EARLY_PHASE1":4301,"PHASE1":4303,"PHASE2":4305,"PHASE3":4307,"PHASE4":4309,"NA":4320},{"trials":4302,"activeCount":100},[],{"trials":4304,"activeCount":100},[],{"trials":4306,"activeCount":100},[],{"trials":4308,"activeCount":100},[],{"trials":4310,"activeCount":100},[4311],{"nctId":4312,"briefTitle":4313,"status":164,"phases":4314,"primaryCompletion":569,"completion":4315,"start":2675,"enrollment":4316,"conditions":4317,"interventions":4319},"NCT00902057","Desmopressin for Bleeding Related to Low Body Temperature",[92],"2011-06",48,[4318],"Hypothermia Induced Impairment of Primary Haemostasis",[4299,4299,4299],{"trials":4321,"activeCount":100},[],{"intervention":4323,"totalTrials":137,"cells":4324},"Dapagliflozin 10 mg",{"EARLY_PHASE1":4325,"PHASE1":4327,"PHASE2":4329,"PHASE3":4331,"PHASE4":4333,"NA":4345},{"trials":4326,"activeCount":100},[],{"trials":4328,"activeCount":100},[],{"trials":4330,"activeCount":100},[],{"trials":4332,"activeCount":100},[],{"trials":4334,"activeCount":100},[4335],{"nctId":4336,"briefTitle":4337,"status":112,"phases":4338,"primaryCompletion":4339,"completion":4339,"start":4340,"enrollment":709,"conditions":4341,"interventions":4343},"NCT03959501","Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy",[92],"2020-10-16","2017-08-16",[146,4342],"Ketonemia",[4323,4344],"Sitagliptin 100mg",{"trials":4346,"activeCount":100},[],{"intervention":4344,"totalTrials":137,"cells":4348},{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4353,"PHASE3":4355,"PHASE4":4357,"NA":4363},{"trials":4350,"activeCount":100},[],{"trials":4352,"activeCount":100},[],{"trials":4354,"activeCount":100},[],{"trials":4356,"activeCount":100},[],{"trials":4358,"activeCount":100},[4359],{"nctId":4336,"briefTitle":4337,"status":112,"phases":4360,"primaryCompletion":4339,"completion":4339,"start":4340,"enrollment":709,"conditions":4361,"interventions":4362},[92],[146,4342],[4323,4344],{"trials":4364,"activeCount":100},[],{"intervention":4366,"totalTrials":137,"cells":4367},"Dexamethasone 4mg",{"EARLY_PHASE1":4368,"PHASE1":4370,"PHASE2":4372,"PHASE3":4374,"PHASE4":4376,"NA":4387},{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"trials":4377,"activeCount":100},[4378],{"nctId":4379,"briefTitle":4380,"status":164,"phases":4381,"primaryCompletion":4382,"completion":4383,"start":4384,"enrollment":2099,"conditions":4385,"interventions":4386},"NCT05129085","Transforaminal Epidural Platelet Rich Plasma Versus Epidural Steroid Injection for Lumbosacral Radicular Pain",[92],"2024-03","2024-12","2021-03-01",[3160],[4366],{"trials":4388,"activeCount":100},[],{"intervention":4390,"totalTrials":151,"cells":4391},"silver diammine fluoride",{"EARLY_PHASE1":4392,"PHASE1":4394,"PHASE2":4396,"PHASE3":4398,"PHASE4":4418,"NA":4420},{"trials":4393,"activeCount":100},[],{"trials":4395,"activeCount":100},[],{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":100},[4400,4410],{"nctId":4401,"briefTitle":4402,"status":112,"phases":4403,"primaryCompletion":4404,"completion":4404,"start":4405,"enrollment":4406,"conditions":4407,"interventions":4409},"NCT02360124","Preventing and Arresting Dental Root Surface Caries in Community-dwelling Older Adults",[90,91],"2015-04","2012-01",323,[4408],"Dental Caries",[4390],{"nctId":4411,"briefTitle":4412,"status":112,"phases":4413,"primaryCompletion":1873,"completion":1873,"start":4414,"enrollment":4415,"conditions":4416,"interventions":4417},"NCT02742142","Fluoride Application on Preventing and Arresting Root Caries in Fluoridated and Non-fluoridated Areas",[90,91],"2012-10",534,[4408],[4390],{"trials":4419,"activeCount":100},[],{"trials":4421,"activeCount":100},[],{"intervention":4423,"totalTrials":137,"cells":4424},"Aripiprazole",{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4429,"PHASE3":4431,"PHASE4":4449,"NA":4451},{"trials":4426,"activeCount":100},[],{"trials":4428,"activeCount":100},[],{"trials":4430,"activeCount":100},[],{"trials":4432,"activeCount":100},[4433],{"nctId":4434,"briefTitle":4435,"status":112,"phases":4436,"primaryCompletion":4437,"completion":4438,"start":4439,"enrollment":4440,"conditions":4441,"interventions":4447},"NCT03485417","Substance Misuse To Psychosis for Stimulants",[90,91],"2024-05-31","2025-05-31","2019-06-01",165,[4442,4443,4444,4445,4446],"Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis)","Schizophrenia and Related Disorders","Stimulant Dependence","Stimulant Abuse","Pharmacotherapy",[4423,4448],"Paliperidone",{"trials":4450,"activeCount":100},[],{"trials":4452,"activeCount":100},[],{"intervention":4448,"totalTrials":137,"cells":4454},{"EARLY_PHASE1":4455,"PHASE1":4457,"PHASE2":4459,"PHASE3":4461,"PHASE4":4467,"NA":4469},{"trials":4456,"activeCount":100},[],{"trials":4458,"activeCount":100},[],{"trials":4460,"activeCount":100},[],{"trials":4462,"activeCount":100},[4463],{"nctId":4434,"briefTitle":4435,"status":112,"phases":4464,"primaryCompletion":4437,"completion":4438,"start":4439,"enrollment":4440,"conditions":4465,"interventions":4466},[90,91],[4442,4443,4444,4445,4446],[4423,4448],{"trials":4468,"activeCount":100},[],{"trials":4470,"activeCount":100},[],{"intervention":4472,"totalTrials":137,"cells":4473},"Astragalus Powder",{"EARLY_PHASE1":4474,"PHASE1":4476,"PHASE2":4478,"PHASE3":4480,"PHASE4":4493,"NA":4495},{"trials":4475,"activeCount":100},[],{"trials":4477,"activeCount":100},[],{"trials":4479,"activeCount":100},[],{"trials":4481,"activeCount":100},[4482],{"nctId":4483,"briefTitle":4484,"status":164,"phases":4485,"primaryCompletion":4486,"completion":4487,"start":4488,"enrollment":1073,"conditions":4489,"interventions":4492},"NCT03535935","Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease",[90,91],"2022-06-30","2022-12-31","2018-07-01",[4490,4491],"Diabetic Nephropathies","Diabetic Kidney Disease",[4472],{"trials":4494,"activeCount":100},[],{"trials":4496,"activeCount":100},[],{"intervention":175,"totalTrials":137,"cells":4498},{"EARLY_PHASE1":4499,"PHASE1":4501,"PHASE2":4503,"PHASE3":4505,"PHASE4":4511,"NA":4513},{"trials":4500,"activeCount":100},[],{"trials":4502,"activeCount":100},[],{"trials":4504,"activeCount":100},[],{"trials":4506,"activeCount":100},[4507],{"nctId":162,"briefTitle":163,"status":164,"phases":4508,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":4509,"interventions":4510},[91],[171,172,173],[150,175],{"trials":4512,"activeCount":100},[],{"trials":4514,"activeCount":100},[],{"intervention":4516,"totalTrials":137,"cells":4517},"Bupivacaine Liposome 13.3 Milligrams\u002FMilliliter [Exparel]",{"EARLY_PHASE1":4518,"PHASE1":4520,"PHASE2":4522,"PHASE3":4524,"PHASE4":4536,"NA":4538},{"trials":4519,"activeCount":100},[],{"trials":4521,"activeCount":100},[],{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[4526],{"nctId":4527,"briefTitle":4528,"status":112,"phases":4529,"primaryCompletion":4530,"completion":4531,"start":41,"enrollment":4532,"conditions":4533,"interventions":4534},"NCT06235606","Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine",[91],"2025-11-03","2026-02-05",96,[2584],[4516,4535],"Dexmedetomidine 0.5milligram",{"trials":4537,"activeCount":100},[],{"trials":4539,"activeCount":100},[],{"intervention":4535,"totalTrials":137,"cells":4541},{"EARLY_PHASE1":4542,"PHASE1":4544,"PHASE2":4546,"PHASE3":4548,"PHASE4":4554,"NA":4556},{"trials":4543,"activeCount":100},[],{"trials":4545,"activeCount":100},[],{"trials":4547,"activeCount":100},[],{"trials":4549,"activeCount":100},[4550],{"nctId":4527,"briefTitle":4528,"status":112,"phases":4551,"primaryCompletion":4530,"completion":4531,"start":41,"enrollment":4532,"conditions":4552,"interventions":4553},[91],[2584],[4516,4535],{"trials":4555,"activeCount":100},[],{"trials":4557,"activeCount":100},[],{"intervention":2499,"totalTrials":137,"cells":4559},{"EARLY_PHASE1":4560,"PHASE1":4562,"PHASE2":4564,"PHASE3":4566,"PHASE4":4572,"NA":4574},{"trials":4561,"activeCount":100},[],{"trials":4563,"activeCount":100},[],{"trials":4565,"activeCount":100},[],{"trials":4567,"activeCount":100},[4568],{"nctId":2491,"briefTitle":2492,"status":164,"phases":4569,"primaryCompletion":2494,"completion":2495,"start":2496,"enrollment":1340,"conditions":4570,"interventions":4571},[91],[19],[2462,2499],{"trials":4573,"activeCount":100},[],{"trials":4575,"activeCount":100},[],{"intervention":2792,"totalTrials":137,"cells":4577},{"EARLY_PHASE1":4578,"PHASE1":4580,"PHASE2":4582,"PHASE3":4584,"PHASE4":4590,"NA":4592},{"trials":4579,"activeCount":100},[],{"trials":4581,"activeCount":100},[],{"trials":4583,"activeCount":100},[],{"trials":4585,"activeCount":100},[4586],{"nctId":2785,"briefTitle":2786,"status":112,"phases":4587,"primaryCompletion":2788,"completion":2788,"start":2789,"enrollment":807,"conditions":4588,"interventions":4589},[91],[1600],[2792,2774],{"trials":4591,"activeCount":100},[],{"trials":4593,"activeCount":100},[],{"intervention":4595,"totalTrials":137,"cells":4596},"TSD",{"EARLY_PHASE1":4597,"PHASE1":4599,"PHASE2":4601,"PHASE3":4603,"PHASE4":4614,"NA":4616},{"trials":4598,"activeCount":100},[],{"trials":4600,"activeCount":100},[],{"trials":4602,"activeCount":100},[],{"trials":4604,"activeCount":100},[4605],{"nctId":4606,"briefTitle":4607,"status":112,"phases":4608,"primaryCompletion":4609,"completion":4610,"start":2951,"enrollment":523,"conditions":4611,"interventions":4613},"NCT02189083","Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids",[91],"2015-11","2016-02",[4612],"Leiomyoma",[4595],{"trials":4615,"activeCount":100},[],{"trials":4617,"activeCount":100},[],{"intervention":4619,"totalTrials":137,"cells":4620},"Intranasal dexmedetomidine",{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4625,"PHASE3":4627,"PHASE4":4636,"NA":4638},{"trials":4622,"activeCount":100},[],{"trials":4624,"activeCount":100},[],{"trials":4626,"activeCount":100},[],{"trials":4628,"activeCount":100},[4629],{"nctId":4630,"briefTitle":4631,"status":112,"phases":4632,"conditions":4633,"interventions":4635},"NCT01132794","A Study to Assess the Analgesia and Sedation Using Intranasal Dexmedetomidine in Third Molar Surgery Under Local Anaesthesia",[91],[3245,4634],"Sedation",[4619],{"trials":4637,"activeCount":100},[],{"trials":4639,"activeCount":100},[],{"intervention":2612,"totalTrials":137,"cells":4641},{"EARLY_PHASE1":4642,"PHASE1":4644,"PHASE2":4646,"PHASE3":4648,"PHASE4":4654,"NA":4656},{"trials":4643,"activeCount":100},[],{"trials":4645,"activeCount":100},[],{"trials":4647,"activeCount":100},[],{"trials":4649,"activeCount":100},[4650],{"nctId":2603,"briefTitle":2604,"status":112,"phases":4651,"primaryCompletion":2606,"completion":2607,"start":2608,"enrollment":635,"conditions":4652,"interventions":4653},[90,91],[2610],[2612,2481],{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"intervention":4659,"totalTrials":137,"cells":4660},"local dexmedetomidine",{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4665,"PHASE3":4667,"PHASE4":4681,"NA":4683},{"trials":4662,"activeCount":100},[],{"trials":4664,"activeCount":100},[],{"trials":4666,"activeCount":100},[],{"trials":4668,"activeCount":100},[4669],{"nctId":4670,"briefTitle":4671,"status":112,"phases":4672,"primaryCompletion":4673,"completion":4673,"start":4674,"enrollment":4675,"conditions":4676,"interventions":4678},"NCT00971178","Analgesic Effect of Peripheral Dexmedetomidine",[91],"2008-03","2006-02",105,[4677],"Third Molar Extraction",[4659,4679,4680],"Peripheral normal saline","IV dexmedetomidine",{"trials":4682,"activeCount":100},[],{"trials":4684,"activeCount":100},[],{"intervention":4679,"totalTrials":137,"cells":4686},{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4691,"PHASE3":4693,"PHASE4":4699,"NA":4701},{"trials":4688,"activeCount":100},[],{"trials":4690,"activeCount":100},[],{"trials":4692,"activeCount":100},[],{"trials":4694,"activeCount":100},[4695],{"nctId":4670,"briefTitle":4671,"status":112,"phases":4696,"primaryCompletion":4673,"completion":4673,"start":4674,"enrollment":4675,"conditions":4697,"interventions":4698},[91],[4677],[4659,4679,4680],{"trials":4700,"activeCount":100},[],{"trials":4702,"activeCount":100},[],{"intervention":4680,"totalTrials":137,"cells":4704},{"EARLY_PHASE1":4705,"PHASE1":4707,"PHASE2":4709,"PHASE3":4711,"PHASE4":4717,"NA":4719},{"trials":4706,"activeCount":100},[],{"trials":4708,"activeCount":100},[],{"trials":4710,"activeCount":100},[],{"trials":4712,"activeCount":100},[4713],{"nctId":4670,"briefTitle":4671,"status":112,"phases":4714,"primaryCompletion":4673,"completion":4673,"start":4674,"enrollment":4675,"conditions":4715,"interventions":4716},[91],[4677],[4659,4679,4680],{"trials":4718,"activeCount":100},[],{"trials":4720,"activeCount":100},[],{"intervention":2553,"totalTrials":137,"cells":4722},{"EARLY_PHASE1":4723,"PHASE1":4725,"PHASE2":4727,"PHASE3":4729,"PHASE4":4735,"NA":4737},{"trials":4724,"activeCount":100},[],{"trials":4726,"activeCount":100},[],{"trials":4728,"activeCount":100},[],{"trials":4730,"activeCount":100},[4731],{"nctId":2544,"briefTitle":2545,"status":112,"phases":4732,"primaryCompletion":2547,"completion":2548,"start":2549,"enrollment":1598,"conditions":4733,"interventions":4734},[91],[2551],[2553,1243,2481],{"trials":4736,"activeCount":100},[],{"trials":4738,"activeCount":100},[],{"intervention":4740,"totalTrials":137,"cells":4741},"Escitalopram",{"EARLY_PHASE1":4742,"PHASE1":4744,"PHASE2":4746,"PHASE3":4748,"PHASE4":4762,"NA":4764},{"trials":4743,"activeCount":100},[],{"trials":4745,"activeCount":100},[],{"trials":4747,"activeCount":100},[],{"trials":4749,"activeCount":100},[4750],{"nctId":4751,"briefTitle":4752,"status":112,"phases":4753,"primaryCompletion":4754,"completion":4755,"start":4756,"enrollment":4757,"conditions":4758,"interventions":4760},"NCT03909217","Treating Depression With Transcutaneous Electrical Cranial-auricular Acupoint Stimulation (TECAS).",[90,91],"2021-07-02","2021-12-02","2019-07-29",470,[4759],"Mild-to-moderate Depression",[4740,4761],"Insomnia medication",{"trials":4763,"activeCount":100},[],{"trials":4765,"activeCount":100},[],{"intervention":4761,"totalTrials":137,"cells":4767},{"EARLY_PHASE1":4768,"PHASE1":4770,"PHASE2":4772,"PHASE3":4774,"PHASE4":4780,"NA":4782},{"trials":4769,"activeCount":100},[],{"trials":4771,"activeCount":100},[],{"trials":4773,"activeCount":100},[],{"trials":4775,"activeCount":100},[4776],{"nctId":4751,"briefTitle":4752,"status":112,"phases":4777,"primaryCompletion":4754,"completion":4755,"start":4756,"enrollment":4757,"conditions":4778,"interventions":4779},[90,91],[4759],[4740,4761],{"trials":4781,"activeCount":100},[],{"trials":4783,"activeCount":100},[],{"intervention":4785,"totalTrials":137,"cells":4786},"Celecoxib",{"EARLY_PHASE1":4787,"PHASE1":4789,"PHASE2":4791,"PHASE3":4793,"PHASE4":4806,"NA":4808},{"trials":4788,"activeCount":100},[],{"trials":4790,"activeCount":100},[],{"trials":4792,"activeCount":100},[],{"trials":4794,"activeCount":100},[4795],{"nctId":4796,"briefTitle":4797,"status":112,"phases":4798,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":4803,"interventions":4804},"NCT02108366","Treatment of Severe Influenza A Infection",[91],"2018-03","2018-06","2014-03",107,[561],[4785,4805],"Oseltamivir",{"trials":4807,"activeCount":100},[],{"trials":4809,"activeCount":100},[],{"intervention":4805,"totalTrials":137,"cells":4811},{"EARLY_PHASE1":4812,"PHASE1":4814,"PHASE2":4816,"PHASE3":4818,"PHASE4":4824,"NA":4826},{"trials":4813,"activeCount":100},[],{"trials":4815,"activeCount":100},[],{"trials":4817,"activeCount":100},[],{"trials":4819,"activeCount":100},[4820],{"nctId":4796,"briefTitle":4797,"status":112,"phases":4821,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":4822,"interventions":4823},[91],[561],[4785,4805],{"trials":4825,"activeCount":100},[],{"trials":4827,"activeCount":100},[],{"intervention":4829,"totalTrials":137,"cells":4830},"25% AgNO3 solution followed by 5% NaF",{"EARLY_PHASE1":4831,"PHASE1":4833,"PHASE2":4835,"PHASE3":4837,"PHASE4":4849,"NA":4851},{"trials":4832,"activeCount":100},[],{"trials":4834,"activeCount":100},[],{"trials":4836,"activeCount":100},[],{"trials":4838,"activeCount":100},[4839],{"nctId":4840,"briefTitle":4841,"status":112,"phases":4842,"primaryCompletion":4843,"completion":4844,"start":168,"enrollment":4845,"conditions":4846,"interventions":4847},"NCT03423797","The Caries-arresting Effect of Incorporating fTCP to NaF Varnish Applied Following AgNO3 in Preschool Children",[91],"2020-05-01","2020-08-30",408,[1173],[4829,4848],"25% AgNO3 solution followed by 5% NaF with fTCP",{"trials":4850,"activeCount":100},[],{"trials":4852,"activeCount":100},[],{"intervention":4848,"totalTrials":137,"cells":4854},{"EARLY_PHASE1":4855,"PHASE1":4857,"PHASE2":4859,"PHASE3":4861,"PHASE4":4867,"NA":4869},{"trials":4856,"activeCount":100},[],{"trials":4858,"activeCount":100},[],{"trials":4860,"activeCount":100},[],{"trials":4862,"activeCount":100},[4863],{"nctId":4840,"briefTitle":4841,"status":112,"phases":4864,"primaryCompletion":4843,"completion":4844,"start":168,"enrollment":4845,"conditions":4865,"interventions":4866},[91],[1173],[4829,4848],{"trials":4868,"activeCount":100},[],{"trials":4870,"activeCount":100},[],{"intervention":4872,"totalTrials":137,"cells":4873},"Imiquimod + ID HBVv",{"EARLY_PHASE1":4874,"PHASE1":4876,"PHASE2":4878,"PHASE3":4880,"PHASE4":4894,"NA":4896},{"trials":4875,"activeCount":100},[],{"trials":4877,"activeCount":100},[],{"trials":4879,"activeCount":100},[],{"trials":4881,"activeCount":100},[4882],{"nctId":4883,"briefTitle":4884,"status":112,"phases":4885,"primaryCompletion":4886,"completion":4887,"start":4888,"enrollment":2089,"conditions":4889,"interventions":4891},"NCT03307902","ID HBV Vaccination With Imiquimod in OBI",[90,91],"2019-03-31","2019-07-31","2016-10-01",[4890],"Hepatitis B",[4872,4892,4893],"Aqueous + ID HBVv","Imiquimod + IM HBVv",{"trials":4895,"activeCount":100},[],{"trials":4897,"activeCount":100},[],{"intervention":4892,"totalTrials":137,"cells":4899},{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4904,"PHASE3":4906,"PHASE4":4912,"NA":4914},{"trials":4901,"activeCount":100},[],{"trials":4903,"activeCount":100},[],{"trials":4905,"activeCount":100},[],{"trials":4907,"activeCount":100},[4908],{"nctId":4883,"briefTitle":4884,"status":112,"phases":4909,"primaryCompletion":4886,"completion":4887,"start":4888,"enrollment":2089,"conditions":4910,"interventions":4911},[90,91],[4890],[4872,4892,4893],{"trials":4913,"activeCount":100},[],{"trials":4915,"activeCount":100},[],{"intervention":4893,"totalTrials":137,"cells":4917},{"EARLY_PHASE1":4918,"PHASE1":4920,"PHASE2":4922,"PHASE3":4924,"PHASE4":4930,"NA":4932},{"trials":4919,"activeCount":100},[],{"trials":4921,"activeCount":100},[],{"trials":4923,"activeCount":100},[],{"trials":4925,"activeCount":100},[4926],{"nctId":4883,"briefTitle":4884,"status":112,"phases":4927,"primaryCompletion":4886,"completion":4887,"start":4888,"enrollment":2089,"conditions":4928,"interventions":4929},[90,91],[4890],[4872,4892,4893],{"trials":4931,"activeCount":100},[],{"trials":4933,"activeCount":100},[],{"intervention":4935,"totalTrials":137,"cells":4936},"Imiquimod ointment",{"EARLY_PHASE1":4937,"PHASE1":4939,"PHASE2":4941,"PHASE3":4943,"PHASE4":4956,"NA":4958},{"trials":4938,"activeCount":100},[],{"trials":4940,"activeCount":100},[],{"trials":4942,"activeCount":100},[],{"trials":4944,"activeCount":100},[4945],{"nctId":4946,"briefTitle":4947,"status":112,"phases":4948,"primaryCompletion":4949,"completion":4949,"start":4801,"enrollment":144,"conditions":4950,"interventions":4952},"NCT02103023","Intradermal Influenza Vaccine in the Young",[91],"2014-11",[4951],"Influenza Viral Infections",[4935,4953,4954,4955],"Aqueous cream","Intradermal influenza vaccine","Intramuscular influenza vaccine",{"trials":4957,"activeCount":100},[],{"trials":4959,"activeCount":100},[],{"intervention":4954,"totalTrials":137,"cells":4961},{"EARLY_PHASE1":4962,"PHASE1":4964,"PHASE2":4966,"PHASE3":4968,"PHASE4":4974,"NA":4976},{"trials":4963,"activeCount":100},[],{"trials":4965,"activeCount":100},[],{"trials":4967,"activeCount":100},[],{"trials":4969,"activeCount":100},[4970],{"nctId":4946,"briefTitle":4947,"status":112,"phases":4971,"primaryCompletion":4949,"completion":4949,"start":4801,"enrollment":144,"conditions":4972,"interventions":4973},[91],[4951],[4935,4953,4954,4955],{"trials":4975,"activeCount":100},[],{"trials":4977,"activeCount":100},[],{"intervention":4955,"totalTrials":137,"cells":4979},{"EARLY_PHASE1":4980,"PHASE1":4982,"PHASE2":4984,"PHASE3":4986,"PHASE4":4992,"NA":4994},{"trials":4981,"activeCount":100},[],{"trials":4983,"activeCount":100},[],{"trials":4985,"activeCount":100},[],{"trials":4987,"activeCount":100},[4988],{"nctId":4946,"briefTitle":4947,"status":112,"phases":4989,"primaryCompletion":4949,"completion":4949,"start":4801,"enrollment":144,"conditions":4990,"interventions":4991},[91],[4951],[4935,4953,4954,4955],{"trials":4993,"activeCount":100},[],{"trials":4995,"activeCount":100},[],{"intervention":4997,"totalTrials":137,"cells":4998},"Intradermal hepatitis B vaccine with imiquimod",{"EARLY_PHASE1":4999,"PHASE1":5001,"PHASE2":5003,"PHASE3":5005,"PHASE4":5017,"NA":5019},{"trials":5000,"activeCount":100},[],{"trials":5002,"activeCount":100},[],{"trials":5004,"activeCount":100},[],{"trials":5006,"activeCount":100},[5007],{"nctId":5008,"briefTitle":5009,"status":112,"phases":5010,"primaryCompletion":653,"completion":5011,"start":5012,"enrollment":2506,"conditions":5013,"interventions":5015},"NCT04083157","Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients",[90,91],"2021-12-30","2019-08-12",[5014,4890],"Inflammatory Bowel Diseases",[4997,5016],"Intramuscular hepatitis B vaccine with aqueous cream",{"trials":5018,"activeCount":100},[],{"trials":5020,"activeCount":100},[],{"intervention":5016,"totalTrials":137,"cells":5022},{"EARLY_PHASE1":5023,"PHASE1":5025,"PHASE2":5027,"PHASE3":5029,"PHASE4":5035,"NA":5037},{"trials":5024,"activeCount":100},[],{"trials":5026,"activeCount":100},[],{"trials":5028,"activeCount":100},[],{"trials":5030,"activeCount":100},[5031],{"nctId":5008,"briefTitle":5009,"status":112,"phases":5032,"primaryCompletion":653,"completion":5011,"start":5012,"enrollment":2506,"conditions":5033,"interventions":5034},[90,91],[5014,4890],[4997,5016],{"trials":5036,"activeCount":100},[],{"trials":5038,"activeCount":100},[],{"intervention":5040,"totalTrials":137,"cells":5041},"Ibrutinib",{"EARLY_PHASE1":5042,"PHASE1":5044,"PHASE2":5046,"PHASE3":5048,"PHASE4":5064,"NA":5066},{"trials":5043,"activeCount":100},[],{"trials":5045,"activeCount":100},[],{"trials":5047,"activeCount":100},[],{"trials":5049,"activeCount":100},[5050],{"nctId":5051,"briefTitle":5052,"status":164,"phases":5053,"primaryCompletion":1376,"completion":5054,"start":5055,"enrollment":4250,"conditions":5056,"interventions":5063},"NCT02991638","Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers",[91],"2021-06","2016-11-01",[5057,5058,2678,5059,5060,5061,5062],"Chronic Lymphocytic Leukemia","Indolent B-cell Lymphomas","Lymphoma, Small Lymphocytic","Mantle-Cell Lymphoma","Waldenstrom's Macroglobulinaemia","Follicular Lymphoma",[5040],{"trials":5065,"activeCount":100},[],{"trials":5067,"activeCount":100},[],{"intervention":5069,"totalTrials":137,"cells":5070},"25% AgNO3 solution followed by 5% NaF varnish",{"EARLY_PHASE1":5071,"PHASE1":5073,"PHASE2":5075,"PHASE3":5077,"PHASE4":5088,"NA":5090},{"trials":5072,"activeCount":100},[],{"trials":5074,"activeCount":100},[],{"trials":5076,"activeCount":100},[],{"trials":5078,"activeCount":100},[5079],{"nctId":5080,"briefTitle":5081,"status":112,"phases":5082,"primaryCompletion":4800,"completion":4800,"start":5083,"enrollment":5084,"conditions":5085,"interventions":5086},"NCT02019160","Effectiveness of Dental Caries Arrest Treatment in Primary Teeth Using AgNO3 Followed by NaF Varnish",[91],"2014-09",1070,[1173],[5069,5087],"38% SDF solution followed by placebo varnish",{"trials":5089,"activeCount":100},[],{"trials":5091,"activeCount":100},[],{"intervention":5087,"totalTrials":137,"cells":5093},{"EARLY_PHASE1":5094,"PHASE1":5096,"PHASE2":5098,"PHASE3":5100,"PHASE4":5106,"NA":5108},{"trials":5095,"activeCount":100},[],{"trials":5097,"activeCount":100},[],{"trials":5099,"activeCount":100},[],{"trials":5101,"activeCount":100},[5102],{"nctId":5080,"briefTitle":5081,"status":112,"phases":5103,"primaryCompletion":4800,"completion":4800,"start":5083,"enrollment":5084,"conditions":5104,"interventions":5105},[91],[1173],[5069,5087],{"trials":5107,"activeCount":100},[],{"trials":5109,"activeCount":100},[],{"intervention":5111,"totalTrials":137,"cells":5112},"Semi-individualised Chinese Medicine treatment",{"EARLY_PHASE1":5113,"PHASE1":5115,"PHASE2":5117,"PHASE3":5119,"PHASE4":5131,"NA":5133},{"trials":5114,"activeCount":100},[],{"trials":5116,"activeCount":100},[],{"trials":5118,"activeCount":100},[],{"trials":5120,"activeCount":100},[5121],{"nctId":5122,"briefTitle":5123,"status":164,"phases":5124,"primaryCompletion":3854,"completion":5125,"start":5126,"enrollment":5127,"conditions":5128,"interventions":5129},"NCT02488252","Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy",[90,91],"2021-09","2015-07",148,[4490],[5111,5130],"Routine medical care",{"trials":5132,"activeCount":100},[],{"trials":5134,"activeCount":100},[],{"intervention":5130,"totalTrials":137,"cells":5136},{"EARLY_PHASE1":5137,"PHASE1":5139,"PHASE2":5141,"PHASE3":5143,"PHASE4":5149,"NA":5151},{"trials":5138,"activeCount":100},[],{"trials":5140,"activeCount":100},[],{"trials":5142,"activeCount":100},[],{"trials":5144,"activeCount":100},[5145],{"nctId":5122,"briefTitle":5123,"status":164,"phases":5146,"primaryCompletion":3854,"completion":5125,"start":5126,"enrollment":5127,"conditions":5147,"interventions":5148},[90,91],[4490],[5111,5130],{"trials":5150,"activeCount":100},[],{"trials":5152,"activeCount":100},[],{"intervention":5154,"totalTrials":137,"cells":5155},"Vaxigrip tetra",{"EARLY_PHASE1":5156,"PHASE1":5158,"PHASE2":5160,"PHASE3":5162,"PHASE4":5176,"NA":5178},{"trials":5157,"activeCount":100},[],{"trials":5159,"activeCount":100},[],{"trials":5161,"activeCount":100},[],{"trials":5163,"activeCount":100},[5164],{"nctId":5165,"briefTitle":5166,"status":164,"phases":5167,"primaryCompletion":5168,"completion":507,"start":5169,"enrollment":5170,"conditions":5171,"interventions":5172},"NCT04143451","Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients",[91],"2022-09-30","2019-10-23",4000,[468],[5154,5173,5174,5175],"Fluzone high-dose","Aldara 5% Topical Cream","Aqueous cream BP",{"trials":5177,"activeCount":100},[],{"trials":5179,"activeCount":100},[],{"intervention":5173,"totalTrials":137,"cells":5181},{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5186,"PHASE3":5188,"PHASE4":5194,"NA":5196},{"trials":5183,"activeCount":100},[],{"trials":5185,"activeCount":100},[],{"trials":5187,"activeCount":100},[],{"trials":5189,"activeCount":100},[5190],{"nctId":5165,"briefTitle":5166,"status":164,"phases":5191,"primaryCompletion":5168,"completion":507,"start":5169,"enrollment":5170,"conditions":5192,"interventions":5193},[91],[468],[5154,5173,5174,5175],{"trials":5195,"activeCount":100},[],{"trials":5197,"activeCount":100},[],{"intervention":5174,"totalTrials":137,"cells":5199},{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5206,"PHASE4":5212,"NA":5214},{"trials":5201,"activeCount":100},[],{"trials":5203,"activeCount":100},[],{"trials":5205,"activeCount":100},[],{"trials":5207,"activeCount":100},[5208],{"nctId":5165,"briefTitle":5166,"status":164,"phases":5209,"primaryCompletion":5168,"completion":507,"start":5169,"enrollment":5170,"conditions":5210,"interventions":5211},[91],[468],[5154,5173,5174,5175],{"trials":5213,"activeCount":100},[],{"trials":5215,"activeCount":100},[],{"intervention":5175,"totalTrials":137,"cells":5217},{"EARLY_PHASE1":5218,"PHASE1":5220,"PHASE2":5222,"PHASE3":5224,"PHASE4":5230,"NA":5232},{"trials":5219,"activeCount":100},[],{"trials":5221,"activeCount":100},[],{"trials":5223,"activeCount":100},[],{"trials":5225,"activeCount":100},[5226],{"nctId":5165,"briefTitle":5166,"status":164,"phases":5227,"primaryCompletion":5168,"completion":507,"start":5169,"enrollment":5170,"conditions":5228,"interventions":5229},[91],[468],[5154,5173,5174,5175],{"trials":5231,"activeCount":100},[],{"trials":5233,"activeCount":100},[],{"intervention":5235,"totalTrials":137,"cells":5236},"12% SDF",{"EARLY_PHASE1":5237,"PHASE1":5239,"PHASE2":5241,"PHASE3":5243,"PHASE4":5253,"NA":5255},{"trials":5238,"activeCount":100},[],{"trials":5240,"activeCount":100},[],{"trials":5242,"activeCount":100},[],{"trials":5244,"activeCount":100},[5245],{"nctId":5246,"briefTitle":5247,"status":112,"phases":5248,"primaryCompletion":591,"start":1829,"enrollment":5249,"conditions":5250,"interventions":5251},"NCT02385474","Effectiveness of SDF in Arresting Dental Caries in Preschool Children",[91],888,[1173],[5235,5252],"38% SDF",{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[],{"intervention":5252,"totalTrials":137,"cells":5258},{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5263,"PHASE3":5265,"PHASE4":5271,"NA":5273},{"trials":5260,"activeCount":100},[],{"trials":5262,"activeCount":100},[],{"trials":5264,"activeCount":100},[],{"trials":5266,"activeCount":100},[5267],{"nctId":5246,"briefTitle":5247,"status":112,"phases":5268,"primaryCompletion":591,"start":1829,"enrollment":5249,"conditions":5269,"interventions":5270},[91],[1173],[5235,5252],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[],{"intervention":5276,"totalTrials":137,"cells":5277},"Vortioxetine",{"EARLY_PHASE1":5278,"PHASE1":5280,"PHASE2":5282,"PHASE3":5284,"PHASE4":5298,"NA":5300},{"trials":5279,"activeCount":100},[],{"trials":5281,"activeCount":100},[],{"trials":5283,"activeCount":100},[],{"trials":5285,"activeCount":100},[5286],{"nctId":5287,"briefTitle":5288,"status":112,"phases":5289,"primaryCompletion":5290,"completion":1839,"start":5291,"enrollment":1084,"conditions":5292,"interventions":5297},"NCT03485274","Substance Misuse To Psychiatric Disorders for Cannabis",[90,91],"2023-02-28","2018-07-25",[5293,5294,5295,33,5296,4446],"Cannabis Use Disorder","Depressive State","Anxiety State","Anxiety Disorders",[5276],{"trials":5299,"activeCount":100},[],{"trials":5301,"activeCount":100},[],{"intervention":5303,"totalTrials":137,"cells":5304},"Intradermal HBVv with imiquimod",{"EARLY_PHASE1":5305,"PHASE1":5307,"PHASE2":5309,"PHASE3":5311,"PHASE4":5324,"NA":5326},{"trials":5306,"activeCount":100},[],{"trials":5308,"activeCount":100},[],{"trials":5310,"activeCount":100},[],{"trials":5312,"activeCount":100},[5313],{"nctId":5314,"briefTitle":5315,"status":112,"phases":5316,"primaryCompletion":2993,"completion":5317,"start":5318,"enrollment":925,"conditions":5319,"interventions":5321},"NCT02621112","HBV Vaccine in Renal Failure Patients",[90,91],"2019-03","2016-01",[5320],"Renal Failure",[5303,5322,5323],"Intradermal HBVv with aqueous cream","Intramuscular HBVv with aqueous cream",{"trials":5325,"activeCount":100},[],{"trials":5327,"activeCount":100},[],{"intervention":5322,"totalTrials":137,"cells":5329},{"EARLY_PHASE1":5330,"PHASE1":5332,"PHASE2":5334,"PHASE3":5336,"PHASE4":5342,"NA":5344},{"trials":5331,"activeCount":100},[],{"trials":5333,"activeCount":100},[],{"trials":5335,"activeCount":100},[],{"trials":5337,"activeCount":100},[5338],{"nctId":5314,"briefTitle":5315,"status":112,"phases":5339,"primaryCompletion":2993,"completion":5317,"start":5318,"enrollment":925,"conditions":5340,"interventions":5341},[90,91],[5320],[5303,5322,5323],{"trials":5343,"activeCount":100},[],{"trials":5345,"activeCount":100},[],{"intervention":5323,"totalTrials":137,"cells":5347},{"EARLY_PHASE1":5348,"PHASE1":5350,"PHASE2":5352,"PHASE3":5354,"PHASE4":5360,"NA":5362},{"trials":5349,"activeCount":100},[],{"trials":5351,"activeCount":100},[],{"trials":5353,"activeCount":100},[],{"trials":5355,"activeCount":100},[5356],{"nctId":5314,"briefTitle":5315,"status":112,"phases":5357,"primaryCompletion":2993,"completion":5317,"start":5318,"enrollment":925,"conditions":5358,"interventions":5359},[90,91],[5320],[5303,5322,5323],{"trials":5361,"activeCount":100},[],{"trials":5363,"activeCount":100},[],{"intervention":663,"totalTrials":137,"cells":5365},{"EARLY_PHASE1":5366,"PHASE1":5368,"PHASE2":5370,"PHASE3":5372,"PHASE4":5378,"NA":5380},{"trials":5367,"activeCount":100},[],{"trials":5369,"activeCount":100},[],{"trials":5371,"activeCount":100},[],{"trials":5373,"activeCount":100},[5374],{"nctId":650,"briefTitle":651,"status":112,"phases":5375,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":5376,"interventions":5377},[90,91],[658,659,660],[72,662,663],{"trials":5379,"activeCount":100},[],{"trials":5381,"activeCount":100},[],{"intervention":5383,"totalTrials":137,"cells":5384},"Rifaximin",{"EARLY_PHASE1":5385,"PHASE1":5387,"PHASE2":5389,"PHASE3":5391,"PHASE4":5403,"NA":5405},{"trials":5386,"activeCount":100},[],{"trials":5388,"activeCount":100},[],{"trials":5390,"activeCount":100},[],{"trials":5392,"activeCount":100},[5393],{"nctId":5394,"briefTitle":5395,"status":112,"phases":5396,"primaryCompletion":5397,"completion":5397,"start":5398,"enrollment":5399,"conditions":5400,"interventions":5402},"NCT01643083","Rifaximin for Functional Dyspepsia",[90,91],"2015-05","2013-01",95,[5401],"Functional Dyspepsia",[5383],{"trials":5404,"activeCount":100},[],{"trials":5406,"activeCount":100},[],{"intervention":5408,"totalTrials":2533,"cells":5409},"Interferon beta-1b",{"EARLY_PHASE1":5410,"PHASE1":5412,"PHASE2":5414,"PHASE3":5468,"PHASE4":5470,"NA":5472},{"trials":5411,"activeCount":100},[],{"trials":5413,"activeCount":100},[],{"trials":5415,"activeCount":100},[5416,5426,5439,5450,5458],{"nctId":5417,"briefTitle":5418,"status":164,"phases":5419,"primaryCompletion":5420,"completion":5421,"start":5422,"enrollment":4532,"conditions":5423,"interventions":5424},"NCT04494399","IFN Beta-1b and Ribavirin for Covid-19",[90],"2022-07-01","2022-08-01","2020-07-29",[2865],[5408,5425],"Ribavirin",{"nctId":5427,"briefTitle":5428,"status":112,"phases":5429,"primaryCompletion":5430,"completion":5431,"start":5432,"enrollment":5433,"conditions":5434,"interventions":5436},"NCT04276688","Lopinavir\u002F Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",[90],"2020-03-30","2020-03-31","2020-02-10",127,[5435],"Novel Coronavirus Infection",[5437,5425,5438],"Lopinavir\u002Fritonavir","Interferon Beta-1B",{"nctId":5440,"briefTitle":5441,"status":164,"phases":5442,"primaryCompletion":5443,"completion":4174,"start":5444,"enrollment":5445,"conditions":5446,"interventions":5448},"NCT04465695","Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19",[90],"2021-06-30","2020-07-14",81,[5447],"COVID-19",[5408,5449],"Clofazimine",{"nctId":5451,"briefTitle":5452,"status":164,"phases":5453,"primaryCompletion":1251,"completion":4174,"start":5454,"enrollment":635,"conditions":5455,"interventions":5456},"NCT04647695","IFN-beta 1b and Remdesivir for COVID19",[90],"2020-11-20",[2865],[5408,5457],"Remdesivir",{"nctId":5459,"briefTitle":5460,"status":112,"phases":5461,"primaryCompletion":5462,"completion":5463,"start":4175,"enrollment":709,"conditions":5464,"interventions":5466},"NCT04350281","Double Therapy With IFN-beta 1b and Hydroxychloroquine",[90],"2020-07-01","2020-07-07",[5465],"COVID",[5438,5467],"Hydroxychloroquine",{"trials":5469,"activeCount":100},[],{"trials":5471,"activeCount":100},[],{"trials":5473,"activeCount":100},[],{"intervention":5475,"totalTrials":2533,"cells":5476},"Oxaliplatin",{"EARLY_PHASE1":5477,"PHASE1":5479,"PHASE2":5481,"PHASE3":5530,"PHASE4":5532,"NA":5534},{"trials":5478,"activeCount":100},[],{"trials":5480,"activeCount":100},[],{"trials":5482,"activeCount":100},[5483,5493,5503,5511,5520],{"nctId":5484,"briefTitle":5485,"status":112,"phases":5486,"primaryCompletion":5487,"completion":5487,"start":1052,"enrollment":20,"conditions":5488,"interventions":5490},"NCT03146377","Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer",[90],"2016-12",[5489],"Colorectal Cancer",[5491,5475,5492],"Capecitabine","Irinotecan",{"nctId":5494,"briefTitle":5495,"status":164,"phases":5496,"primaryCompletion":5497,"start":5498,"enrollment":5499,"conditions":5500,"interventions":5502},"NCT00363831","Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma",[90],"2009-12","2006-07",42,[5501],"Nasopharyngeal Neoplasms",[5475],{"nctId":5504,"briefTitle":5505,"status":112,"phases":5506,"primaryCompletion":5487,"completion":5487,"start":5507,"enrollment":1084,"conditions":5508,"interventions":5510},"NCT01558869","Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma",[90],"2012-04",[5509],"Pancreatic Adenocarcinoma",[5491,5475,5492],{"nctId":5512,"briefTitle":5513,"status":112,"phases":5514,"primaryCompletion":5515,"completion":5515,"start":5516,"enrollment":36,"conditions":5517,"interventions":5518},"NCT03578874","SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC",[90],"2019-04-30","2016-06-20",[1086],[5519,5491,5475],"Sorafenib",{"nctId":5521,"briefTitle":5522,"status":112,"phases":5523,"primaryCompletion":5524,"completion":5524,"start":591,"enrollment":5525,"conditions":5526,"interventions":5529},"NCT02716766","Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)",[90],"2018-09",46,[5527,5528],"Carcinoma, Hepatocellular","Secondary",[5519,5491,5475],{"trials":5531,"activeCount":100},[],{"trials":5533,"activeCount":100},[],{"trials":5535,"activeCount":100},[],{"intervention":5491,"totalTrials":492,"cells":5537},{"EARLY_PHASE1":5538,"PHASE1":5540,"PHASE2":5542,"PHASE3":5560,"PHASE4":5562,"NA":5564},{"trials":5539,"activeCount":100},[],{"trials":5541,"activeCount":100},[],{"trials":5543,"activeCount":100},[5544,5548,5552,5556],{"nctId":5484,"briefTitle":5485,"status":112,"phases":5545,"primaryCompletion":5487,"completion":5487,"start":1052,"enrollment":20,"conditions":5546,"interventions":5547},[90],[5489],[5491,5475,5492],{"nctId":5504,"briefTitle":5505,"status":112,"phases":5549,"primaryCompletion":5487,"completion":5487,"start":5507,"enrollment":1084,"conditions":5550,"interventions":5551},[90],[5509],[5491,5475,5492],{"nctId":5512,"briefTitle":5513,"status":112,"phases":5553,"primaryCompletion":5515,"completion":5515,"start":5516,"enrollment":36,"conditions":5554,"interventions":5555},[90],[1086],[5519,5491,5475],{"nctId":5521,"briefTitle":5522,"status":112,"phases":5557,"primaryCompletion":5524,"completion":5524,"start":591,"enrollment":5525,"conditions":5558,"interventions":5559},[90],[5527,5528],[5519,5491,5475],{"trials":5561,"activeCount":100},[],{"trials":5563,"activeCount":100},[],{"trials":5565,"activeCount":100},[],{"intervention":5519,"totalTrials":96,"cells":5567},{"EARLY_PHASE1":5568,"PHASE1":5570,"PHASE2":5572,"PHASE3":5592,"PHASE4":5594,"NA":5596},{"trials":5569,"activeCount":100},[],{"trials":5571,"activeCount":100},[],{"trials":5573,"activeCount":100},[5574,5584,5588],{"nctId":5575,"briefTitle":5576,"status":112,"phases":5577,"primaryCompletion":5578,"completion":1314,"start":1235,"enrollment":2533,"conditions":5579,"interventions":5582},"NCT03170895","Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed\u002FRefractory AML Carrying FLT3-ITD",[90],"2020-02-01",[5580,5581],"AML","FLT3-ITD Mutation",[5519,5583],"Omacetaxine Mepesuccinate",{"nctId":5512,"briefTitle":5513,"status":112,"phases":5585,"primaryCompletion":5515,"completion":5515,"start":5516,"enrollment":36,"conditions":5586,"interventions":5587},[90],[1086],[5519,5491,5475],{"nctId":5521,"briefTitle":5522,"status":112,"phases":5589,"primaryCompletion":5524,"completion":5524,"start":591,"enrollment":5525,"conditions":5590,"interventions":5591},[90],[5527,5528],[5519,5491,5475],{"trials":5593,"activeCount":100},[],{"trials":5595,"activeCount":100},[],{"trials":5597,"activeCount":100},[],{"intervention":5425,"totalTrials":151,"cells":5599},{"EARLY_PHASE1":5600,"PHASE1":5602,"PHASE2":5604,"PHASE3":5614,"PHASE4":5616,"NA":5618},{"trials":5601,"activeCount":100},[],{"trials":5603,"activeCount":100},[],{"trials":5605,"activeCount":100},[5606,5610],{"nctId":5417,"briefTitle":5418,"status":164,"phases":5607,"primaryCompletion":5420,"completion":5421,"start":5422,"enrollment":4532,"conditions":5608,"interventions":5609},[90],[2865],[5408,5425],{"nctId":5427,"briefTitle":5428,"status":112,"phases":5611,"primaryCompletion":5430,"completion":5431,"start":5432,"enrollment":5433,"conditions":5612,"interventions":5613},[90],[5435],[5437,5425,5438],{"trials":5615,"activeCount":100},[],{"trials":5617,"activeCount":100},[],{"trials":5619,"activeCount":100},[],{"intervention":5492,"totalTrials":151,"cells":5621},{"EARLY_PHASE1":5622,"PHASE1":5624,"PHASE2":5626,"PHASE3":5636,"PHASE4":5638,"NA":5640},{"trials":5623,"activeCount":100},[],{"trials":5625,"activeCount":100},[],{"trials":5627,"activeCount":100},[5628,5632],{"nctId":5484,"briefTitle":5485,"status":112,"phases":5629,"primaryCompletion":5487,"completion":5487,"start":1052,"enrollment":20,"conditions":5630,"interventions":5631},[90],[5489],[5491,5475,5492],{"nctId":5504,"briefTitle":5505,"status":112,"phases":5633,"primaryCompletion":5487,"completion":5487,"start":5507,"enrollment":1084,"conditions":5634,"interventions":5635},[90],[5509],[5491,5475,5492],{"trials":5637,"activeCount":100},[],{"trials":5639,"activeCount":100},[],{"trials":5641,"activeCount":100},[],{"intervention":5583,"totalTrials":151,"cells":5643},{"EARLY_PHASE1":5644,"PHASE1":5646,"PHASE2":5648,"PHASE3":5663,"PHASE4":5665,"NA":5667},{"trials":5645,"activeCount":100},[],{"trials":5647,"activeCount":100},[],{"trials":5649,"activeCount":100},[5650,5659],{"nctId":5651,"briefTitle":5652,"status":164,"phases":5653,"primaryCompletion":143,"completion":5654,"start":5655,"enrollment":1874,"conditions":5656,"interventions":5657},"NCT03135054","Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD",[90],"2021-10-01","2017-10-01",[5580,5581],[5658,5583],"Quizartinib",{"nctId":5575,"briefTitle":5576,"status":112,"phases":5660,"primaryCompletion":5578,"completion":1314,"start":1235,"enrollment":2533,"conditions":5661,"interventions":5662},[90],[5580,5581],[5519,5583],{"trials":5664,"activeCount":100},[],{"trials":5666,"activeCount":100},[],{"trials":5668,"activeCount":100},[],{"intervention":2680,"totalTrials":137,"cells":5670},{"EARLY_PHASE1":5671,"PHASE1":5673,"PHASE2":5675,"PHASE3":5681,"PHASE4":5683,"NA":5685},{"trials":5672,"activeCount":100},[],{"trials":5674,"activeCount":100},[],{"trials":5676,"activeCount":100},[5677],{"nctId":2672,"briefTitle":2673,"status":112,"phases":5678,"primaryCompletion":2675,"completion":2476,"start":2676,"enrollment":36,"conditions":5679,"interventions":5680},[90],[2678],[2663,2680,2681],{"trials":5682,"activeCount":100},[],{"trials":5684,"activeCount":100},[],{"trials":5686,"activeCount":100},[],{"intervention":2681,"totalTrials":137,"cells":5688},{"EARLY_PHASE1":5689,"PHASE1":5691,"PHASE2":5693,"PHASE3":5699,"PHASE4":5701,"NA":5703},{"trials":5690,"activeCount":100},[],{"trials":5692,"activeCount":100},[],{"trials":5694,"activeCount":100},[5695],{"nctId":2672,"briefTitle":2673,"status":112,"phases":5696,"primaryCompletion":2675,"completion":2476,"start":2676,"enrollment":36,"conditions":5697,"interventions":5698},[90],[2678],[2663,2680,2681],{"trials":5700,"activeCount":100},[],{"trials":5702,"activeCount":100},[],{"trials":5704,"activeCount":100},[],{"intervention":5706,"totalTrials":137,"cells":5707},"DelNS1-2019-nCoV-RBD-OPT1",{"EARLY_PHASE1":5708,"PHASE1":5710,"PHASE2":5712,"PHASE3":5722,"PHASE4":5724,"NA":5726},{"trials":5709,"activeCount":100},[],{"trials":5711,"activeCount":100},[],{"trials":5713,"activeCount":100},[5714],{"nctId":5715,"briefTitle":5716,"status":164,"phases":5717,"primaryCompletion":5718,"completion":5718,"start":5719,"enrollment":1598,"conditions":5720,"interventions":5721},"NCT05200741","To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2",[90],"2024-02","2022-02-08",[2865],[5706],{"trials":5723,"activeCount":100},[],{"trials":5725,"activeCount":100},[],{"trials":5727,"activeCount":100},[],{"intervention":5729,"totalTrials":137,"cells":5730},"Cyclophosphamide",{"EARLY_PHASE1":5731,"PHASE1":5733,"PHASE2":5735,"PHASE3":5747,"PHASE4":5749,"NA":5751},{"trials":5732,"activeCount":100},[],{"trials":5734,"activeCount":100},[],{"trials":5736,"activeCount":100},[5737],{"nctId":5738,"briefTitle":5739,"status":112,"phases":5740,"primaryCompletion":1873,"completion":5741,"start":5742,"enrollment":259,"conditions":5743,"interventions":5746},"NCT02794077","Cyclophosphamide for Nasopharyngeal Carcinoma",[90],"2016-06","2008-01",[5744,5745],"Recurrent Nasopharyngeal Undifferentiated Carcinoma","Stage IV Nasopharyngeal Undifferentiated Carcinoma",[5729],{"trials":5748,"activeCount":100},[],{"trials":5750,"activeCount":100},[],{"trials":5752,"activeCount":100},[],{"intervention":5658,"totalTrials":137,"cells":5754},{"EARLY_PHASE1":5755,"PHASE1":5757,"PHASE2":5759,"PHASE3":5765,"PHASE4":5767,"NA":5769},{"trials":5756,"activeCount":100},[],{"trials":5758,"activeCount":100},[],{"trials":5760,"activeCount":100},[5761],{"nctId":5651,"briefTitle":5652,"status":164,"phases":5762,"primaryCompletion":143,"completion":5654,"start":5655,"enrollment":1874,"conditions":5763,"interventions":5764},[90],[5580,5581],[5658,5583],{"trials":5766,"activeCount":100},[],{"trials":5768,"activeCount":100},[],{"trials":5770,"activeCount":100},[],{"intervention":5772,"totalTrials":137,"cells":5773},"Roflumilast Oral",{"EARLY_PHASE1":5774,"PHASE1":5776,"PHASE2":5778,"PHASE3":5790,"PHASE4":5792,"NA":5794},{"trials":5775,"activeCount":100},[],{"trials":5777,"activeCount":100},[],{"trials":5779,"activeCount":100},[5780],{"nctId":5781,"briefTitle":5782,"status":112,"phases":5783,"primaryCompletion":5784,"completion":5785,"start":5786,"enrollment":5499,"conditions":5787,"interventions":5789},"NCT04322929","Roflumilast in Non-CF Bronchiectasis Study (2019)",[90],"2024-06-30","2024-11-30","2020-11-12",[5788],"Non-cystic Fibrosis Bronchiectasis",[5772],{"trials":5791,"activeCount":100},[],{"trials":5793,"activeCount":100},[],{"trials":5795,"activeCount":100},[],{"intervention":2830,"totalTrials":137,"cells":5797},{"EARLY_PHASE1":5798,"PHASE1":5800,"PHASE2":5802,"PHASE3":5808,"PHASE4":5810,"NA":5812},{"trials":5799,"activeCount":100},[],{"trials":5801,"activeCount":100},[],{"trials":5803,"activeCount":100},[5804],{"nctId":2819,"briefTitle":2820,"status":164,"phases":5805,"primaryCompletion":2822,"completion":2823,"start":2824,"enrollment":1874,"conditions":5806,"interventions":5807},[90],[2826,2827,2828],[2830,2810,2831,2832],{"trials":5809,"activeCount":100},[],{"trials":5811,"activeCount":100},[],{"trials":5813,"activeCount":100},[],{"intervention":2831,"totalTrials":137,"cells":5815},{"EARLY_PHASE1":5816,"PHASE1":5818,"PHASE2":5820,"PHASE3":5826,"PHASE4":5828,"NA":5830},{"trials":5817,"activeCount":100},[],{"trials":5819,"activeCount":100},[],{"trials":5821,"activeCount":100},[5822],{"nctId":2819,"briefTitle":2820,"status":164,"phases":5823,"primaryCompletion":2822,"completion":2823,"start":2824,"enrollment":1874,"conditions":5824,"interventions":5825},[90],[2826,2827,2828],[2830,2810,2831,2832],{"trials":5827,"activeCount":100},[],{"trials":5829,"activeCount":100},[],{"trials":5831,"activeCount":100},[],{"intervention":2832,"totalTrials":137,"cells":5833},{"EARLY_PHASE1":5834,"PHASE1":5836,"PHASE2":5838,"PHASE3":5844,"PHASE4":5846,"NA":5848},{"trials":5835,"activeCount":100},[],{"trials":5837,"activeCount":100},[],{"trials":5839,"activeCount":100},[5840],{"nctId":2819,"briefTitle":2820,"status":164,"phases":5841,"primaryCompletion":2822,"completion":2823,"start":2824,"enrollment":1874,"conditions":5842,"interventions":5843},[90],[2826,2827,2828],[2830,2810,2831,2832],{"trials":5845,"activeCount":100},[],{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[],{"intervention":5851,"totalTrials":137,"cells":5852},"Bintrafusp Alfa",{"EARLY_PHASE1":5853,"PHASE1":5855,"PHASE2":5857,"PHASE3":5871,"PHASE4":5873,"NA":5875},{"trials":5854,"activeCount":100},[],{"trials":5856,"activeCount":100},[],{"trials":5858,"activeCount":100},[5859],{"nctId":5860,"briefTitle":5861,"status":112,"phases":5862,"primaryCompletion":5168,"completion":5863,"start":5864,"enrollment":5865,"conditions":5866,"interventions":5870},"NCT04396886","Bintrafusp Alfa in Previously Treated Patients With R\u002FM Non-keratinizing NPC",[90],"2023-07-26","2020-02-27",38,[1075,5867,5868,5869],"Recurrent Carcinoma","Metastatic Cancer","Non-keratinizing Carinoma",[5851],{"trials":5872,"activeCount":100},[],{"trials":5874,"activeCount":100},[],{"trials":5876,"activeCount":100},[],{"intervention":5878,"totalTrials":137,"cells":5879},"Sorafenib with Capecitabine and Oxaliplatin",{"EARLY_PHASE1":5880,"PHASE1":5882,"PHASE2":5884,"PHASE3":5896,"PHASE4":5898,"NA":5900},{"trials":5881,"activeCount":100},[],{"trials":5883,"activeCount":100},[],{"trials":5885,"activeCount":100},[5886],{"nctId":5887,"briefTitle":5888,"status":164,"phases":5889,"primaryCompletion":2676,"completion":2676,"start":5890,"enrollment":5891,"conditions":5892,"interventions":5895},"NCT00752063","Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma",[90],"2007-09",52,[5893,5894],"Advanced Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma",[5878],{"trials":5897,"activeCount":100},[],{"trials":5899,"activeCount":100},[],{"trials":5901,"activeCount":100},[],{"intervention":5903,"totalTrials":137,"cells":5904},"Puerarin",{"EARLY_PHASE1":5905,"PHASE1":5907,"PHASE2":5909,"PHASE3":5921,"PHASE4":5923,"NA":5925},{"trials":5906,"activeCount":100},[],{"trials":5908,"activeCount":100},[],{"trials":5910,"activeCount":100},[5911],{"nctId":5912,"briefTitle":5913,"status":112,"phases":5914,"primaryCompletion":5915,"completion":5915,"start":5916,"enrollment":5917,"conditions":5918,"interventions":5920},"NCT03676296","Effect of Puerarin on Heart Health in Men",[90],"2021-04-17","2018-09-05",217,[5919],"Cardiovascular Disease Risk Factors",[5903],{"trials":5922,"activeCount":100},[],{"trials":5924,"activeCount":100},[],{"trials":5926,"activeCount":100},[],{"intervention":5437,"totalTrials":137,"cells":5928},{"EARLY_PHASE1":5929,"PHASE1":5931,"PHASE2":5933,"PHASE3":5939,"PHASE4":5941,"NA":5943},{"trials":5930,"activeCount":100},[],{"trials":5932,"activeCount":100},[],{"trials":5934,"activeCount":100},[5935],{"nctId":5427,"briefTitle":5428,"status":112,"phases":5936,"primaryCompletion":5430,"completion":5431,"start":5432,"enrollment":5433,"conditions":5937,"interventions":5938},[90],[5435],[5437,5425,5438],{"trials":5940,"activeCount":100},[],{"trials":5942,"activeCount":100},[],{"trials":5944,"activeCount":100},[],{"intervention":5946,"totalTrials":137,"cells":5947},"Bomedemstat",{"EARLY_PHASE1":5948,"PHASE1":5950,"PHASE2":5952,"PHASE3":5960,"PHASE4":5962,"NA":5964},{"trials":5949,"activeCount":100},[],{"trials":5951,"activeCount":100},[],{"trials":5953,"activeCount":100},[5954],{"nctId":5955,"briefTitle":5956,"status":164,"phases":5957,"primaryCompletion":1071,"completion":81,"start":1852,"enrollment":1874,"conditions":5958,"interventions":5959},"NCT05569538","Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis",[90],[1354],[5946],{"trials":5961,"activeCount":100},[],{"trials":5963,"activeCount":100},[],{"trials":5965,"activeCount":100},[],{"intervention":5967,"totalTrials":137,"cells":5968},"PGD granules",{"EARLY_PHASE1":5969,"PHASE1":5971,"PHASE2":5973,"PHASE3":5985,"PHASE4":5987,"NA":5989},{"trials":5970,"activeCount":100},[],{"trials":5972,"activeCount":100},[],{"trials":5974,"activeCount":100},[5975],{"nctId":5976,"briefTitle":5977,"status":112,"phases":5978,"primaryCompletion":1052,"completion":4949,"start":5398,"enrollment":5979,"conditions":5980,"interventions":5984},"NCT01852331","Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia",[90],103,[658,5981,5982,5983],"Schizophrenic Disorder","Hyperprolactinemia","Hyperprolactinaemia",[5967],{"trials":5986,"activeCount":100},[],{"trials":5988,"activeCount":100},[],{"trials":5990,"activeCount":100},[],{"intervention":2867,"totalTrials":137,"cells":5992},{"EARLY_PHASE1":5993,"PHASE1":5995,"PHASE2":5997,"PHASE3":6003,"PHASE4":6005,"NA":6007},{"trials":5994,"activeCount":100},[],{"trials":5996,"activeCount":100},[],{"trials":5998,"activeCount":100},[5999],{"nctId":2858,"briefTitle":2859,"status":164,"phases":6000,"primaryCompletion":2861,"completion":2861,"start":2862,"enrollment":2863,"conditions":6001,"interventions":6002},[90],[2865],[2867,2849,2868],{"trials":6004,"activeCount":100},[],{"trials":6006,"activeCount":100},[],{"trials":6008,"activeCount":100},[],{"intervention":2868,"totalTrials":137,"cells":6010},{"EARLY_PHASE1":6011,"PHASE1":6013,"PHASE2":6015,"PHASE3":6021,"PHASE4":6023,"NA":6025},{"trials":6012,"activeCount":100},[],{"trials":6014,"activeCount":100},[],{"trials":6016,"activeCount":100},[6017],{"nctId":2858,"briefTitle":2859,"status":164,"phases":6018,"primaryCompletion":2861,"completion":2861,"start":2862,"enrollment":2863,"conditions":6019,"interventions":6020},[90],[2865],[2867,2849,2868],{"trials":6022,"activeCount":100},[],{"trials":6024,"activeCount":100},[],{"trials":6026,"activeCount":100},[],{"intervention":5449,"totalTrials":137,"cells":6028},{"EARLY_PHASE1":6029,"PHASE1":6031,"PHASE2":6033,"PHASE3":6039,"PHASE4":6041,"NA":6043},{"trials":6030,"activeCount":100},[],{"trials":6032,"activeCount":100},[],{"trials":6034,"activeCount":100},[6035],{"nctId":5440,"briefTitle":5441,"status":164,"phases":6036,"primaryCompletion":5443,"completion":4174,"start":5444,"enrollment":5445,"conditions":6037,"interventions":6038},[90],[5447],[5408,5449],{"trials":6040,"activeCount":100},[],{"trials":6042,"activeCount":100},[],{"trials":6044,"activeCount":100},[],{"intervention":6046,"totalTrials":137,"cells":6047},"Talazoparib",{"EARLY_PHASE1":6048,"PHASE1":6050,"PHASE2":6052,"PHASE3":6066,"PHASE4":6068,"NA":6070},{"trials":6049,"activeCount":100},[],{"trials":6051,"activeCount":100},[],{"trials":6053,"activeCount":100},[6054],{"nctId":6055,"briefTitle":6056,"status":112,"phases":6057,"primaryCompletion":6058,"completion":6058,"start":116,"enrollment":1101,"conditions":6059,"interventions":6065},"NCT04740190","Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd",[90],"2023-12-14",[6060,6061,6062,6063,6064],"Recurrent Glioma","Recurrent Glioblastoma","Poly ADP Ribose Polymerase (PARP) Inhibitor","PTEN Gene Inactivation","IDH Mutation",[6046],{"trials":6067,"activeCount":100},[],{"trials":6069,"activeCount":100},[],{"trials":6071,"activeCount":100},[],{"intervention":5457,"totalTrials":137,"cells":6073},{"EARLY_PHASE1":6074,"PHASE1":6076,"PHASE2":6078,"PHASE3":6084,"PHASE4":6086,"NA":6088},{"trials":6075,"activeCount":100},[],{"trials":6077,"activeCount":100},[],{"trials":6079,"activeCount":100},[6080],{"nctId":5451,"briefTitle":5452,"status":164,"phases":6081,"primaryCompletion":1251,"completion":4174,"start":5454,"enrollment":635,"conditions":6082,"interventions":6083},[90],[2865],[5408,5457],{"trials":6085,"activeCount":100},[],{"trials":6087,"activeCount":100},[],{"trials":6089,"activeCount":100},[],{"intervention":6091,"totalTrials":137,"cells":6092},"Niraparib",{"EARLY_PHASE1":6093,"PHASE1":6095,"PHASE2":6097,"PHASE3":6106,"PHASE4":6108,"NA":6110},{"trials":6094,"activeCount":100},[],{"trials":6096,"activeCount":100},[],{"trials":6098,"activeCount":100},[6099],{"nctId":6100,"briefTitle":6101,"status":112,"phases":6102,"primaryCompletion":6103,"completion":6103,"start":4843,"enrollment":1340,"conditions":6104,"interventions":6105},"NCT04284852","Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting",[90],"2023-10-01",[1127],[6091],{"trials":6107,"activeCount":100},[],{"trials":6109,"activeCount":100},[],{"trials":6111,"activeCount":100},[],{"intervention":6113,"totalTrials":137,"cells":6114},"Sorafenib 200mg",{"EARLY_PHASE1":6115,"PHASE1":6117,"PHASE2":6119,"PHASE3":6129,"PHASE4":6131,"NA":6133},{"trials":6116,"activeCount":100},[],{"trials":6118,"activeCount":100},[],{"trials":6120,"activeCount":100},[6121],{"nctId":6122,"briefTitle":6123,"status":112,"phases":6124,"primaryCompletion":6125,"completion":1314,"start":6126,"enrollment":5525,"conditions":6127,"interventions":6128},"NCT03622541","Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD",[90],"2019-12-01","2010-11-15",[5581,5580],[6113],{"trials":6130,"activeCount":100},[],{"trials":6132,"activeCount":100},[],{"trials":6134,"activeCount":100},[],{"intervention":6136,"totalTrials":137,"cells":6137},"Interferon alpha-2b",{"EARLY_PHASE1":6138,"PHASE1":6140,"PHASE2":6142,"PHASE3":6152,"PHASE4":6154,"NA":6156},{"trials":6139,"activeCount":100},[],{"trials":6141,"activeCount":100},[],{"trials":6143,"activeCount":100},[6144],{"nctId":6145,"briefTitle":6146,"status":112,"phases":6147,"completion":6148,"start":6149,"enrollment":645,"conditions":6150,"interventions":6151},"NCT00234182","Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC",[89,90],"2004-12","2000-01",[1086],[6136],{"trials":6153,"activeCount":100},[],{"trials":6155,"activeCount":100},[],{"trials":6157,"activeCount":100},[],{"intervention":6159,"totalTrials":137,"cells":6160},"FFA, clarithromycin, oseltamivir",{"EARLY_PHASE1":6161,"PHASE1":6163,"PHASE2":6165,"PHASE3":6178,"PHASE4":6180,"NA":6182},{"trials":6162,"activeCount":100},[],{"trials":6164,"activeCount":100},[],{"trials":6166,"activeCount":100},[6167],{"nctId":6168,"briefTitle":6169,"status":164,"phases":6170,"primaryCompletion":6171,"completion":6172,"start":6173,"enrollment":441,"conditions":6174,"interventions":6176},"NCT03238612","Flufenamic Acid for Hospitalised Influenza Infection",[90],"2020-07-31","2020-10-31","2018-01-08",[6175],"Influenza A",[6159,6177],"Oseltamivir alone",{"trials":6179,"activeCount":100},[],{"trials":6181,"activeCount":100},[],{"trials":6183,"activeCount":100},[],{"intervention":6177,"totalTrials":137,"cells":6185},{"EARLY_PHASE1":6186,"PHASE1":6188,"PHASE2":6190,"PHASE3":6196,"PHASE4":6198,"NA":6200},{"trials":6187,"activeCount":100},[],{"trials":6189,"activeCount":100},[],{"trials":6191,"activeCount":100},[6192],{"nctId":6168,"briefTitle":6169,"status":164,"phases":6193,"primaryCompletion":6171,"completion":6172,"start":6173,"enrollment":441,"conditions":6194,"interventions":6195},[90],[6175],[6159,6177],{"trials":6197,"activeCount":100},[],{"trials":6199,"activeCount":100},[],{"trials":6201,"activeCount":100},[],{"intervention":6203,"totalTrials":137,"cells":6204},"Immune Checkpoint Inhibitor",{"EARLY_PHASE1":6205,"PHASE1":6207,"PHASE2":6209,"PHASE3":6218,"PHASE4":6220,"NA":6222},{"trials":6206,"activeCount":100},[],{"trials":6208,"activeCount":100},[],{"trials":6210,"activeCount":100},[6211],{"nctId":6212,"briefTitle":6213,"status":112,"phases":6214,"primaryCompletion":6215,"completion":5863,"start":2372,"enrollment":1101,"conditions":6216,"interventions":6217},"NCT03817736","Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy",[90],"2022-06-14",[1103],[6203],{"trials":6219,"activeCount":100},[],{"trials":6221,"activeCount":100},[],{"trials":6223,"activeCount":100},[],{"intervention":6225,"totalTrials":137,"cells":6226},"cisplatin, capecitabine",{"EARLY_PHASE1":6227,"PHASE1":6229,"PHASE2":6231,"PHASE3":6242,"PHASE4":6244,"NA":6246},{"trials":6228,"activeCount":100},[],{"trials":6230,"activeCount":100},[],{"trials":6232,"activeCount":100},[6233],{"nctId":6234,"briefTitle":6235,"status":112,"phases":6236,"primaryCompletion":6237,"completion":6237,"start":6238,"enrollment":6239,"conditions":6240,"interventions":6241},"NCT03427359","Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma",[90],"2017-12-31","2015-01-22",65,[1075],[6225],{"trials":6243,"activeCount":100},[],{"trials":6245,"activeCount":100},[],{"trials":6247,"activeCount":100},[],{"intervention":6249,"totalTrials":137,"cells":6250},"ID BNT162b2 vaccine",{"EARLY_PHASE1":6251,"PHASE1":6253,"PHASE2":6255,"PHASE3":6265,"PHASE4":6267,"NA":6269},{"trials":6252,"activeCount":100},[],{"trials":6254,"activeCount":100},[],{"trials":6256,"activeCount":100},[6257],{"nctId":6258,"briefTitle":6259,"status":164,"phases":6260,"primaryCompletion":507,"completion":115,"start":6261,"enrollment":807,"conditions":6262,"interventions":6263},"NCT05736913","Intradermal COVID-19 Vaccination in the Immunocompromised",[90],"2021-04-01",[5447],[6249,6264],"IM BNT162b2 vaccine",{"trials":6266,"activeCount":100},[],{"trials":6268,"activeCount":100},[],{"trials":6270,"activeCount":100},[],{"intervention":6264,"totalTrials":137,"cells":6272},{"EARLY_PHASE1":6273,"PHASE1":6275,"PHASE2":6277,"PHASE3":6283,"PHASE4":6285,"NA":6287},{"trials":6274,"activeCount":100},[],{"trials":6276,"activeCount":100},[],{"trials":6278,"activeCount":100},[6279],{"nctId":6258,"briefTitle":6259,"status":164,"phases":6280,"primaryCompletion":507,"completion":115,"start":6261,"enrollment":807,"conditions":6281,"interventions":6282},[90],[5447],[6249,6264],{"trials":6284,"activeCount":100},[],{"trials":6286,"activeCount":100},[],{"trials":6288,"activeCount":100},[],{"intervention":6290,"totalTrials":137,"cells":6291},"Oral Melatonin 10mg",{"EARLY_PHASE1":6292,"PHASE1":6294,"PHASE2":6296,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6293,"activeCount":100},[],{"trials":6295,"activeCount":100},[],{"trials":6297,"activeCount":100},[6298],{"nctId":6299,"briefTitle":6300,"status":164,"phases":6301,"primaryCompletion":6302,"completion":6303,"start":5741,"enrollment":1874,"conditions":6304,"interventions":6306},"NCT02889432","Effects of Oral Melatonin on Neurosensory Recovery Following Facial Osteotomies",[90],"2017-08","2017-09",[6305],"Dentofacial Deformities",[6290],{"trials":6308,"activeCount":100},[],{"trials":6310,"activeCount":100},[],{"trials":6312,"activeCount":100},[],{"intervention":6314,"totalTrials":137,"cells":6315},"TAS 102",{"EARLY_PHASE1":6316,"PHASE1":6318,"PHASE2":6320,"PHASE3":6330,"PHASE4":6332,"NA":6334},{"trials":6317,"activeCount":100},[],{"trials":6319,"activeCount":100},[],{"trials":6321,"activeCount":100},[6322],{"nctId":6323,"briefTitle":6324,"status":112,"phases":6325,"primaryCompletion":6326,"completion":1071,"start":4384,"enrollment":3271,"conditions":6327,"interventions":6329},"NCT04923529","TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma",[90],"2024-03-25",[6328],"Pancreas Cancer",[6314],{"trials":6331,"activeCount":100},[],{"trials":6333,"activeCount":100},[],{"trials":6335,"activeCount":100},[],{"intervention":6337,"totalTrials":137,"cells":6338},"Oral roflumilast",{"EARLY_PHASE1":6339,"PHASE1":6341,"PHASE2":6343,"PHASE3":6353,"PHASE4":6355,"NA":6357},{"trials":6340,"activeCount":100},[],{"trials":6342,"activeCount":100},[],{"trials":6344,"activeCount":100},[6345],{"nctId":6346,"briefTitle":6347,"status":112,"phases":6348,"primaryCompletion":6349,"completion":6349,"start":6350,"enrollment":1340,"conditions":6351,"interventions":6352},"NCT03428334","Roflumilast in Non-CF Bronchiectasis Study",[90],"2019-08-31","2018-05-10",[5788],[6337],{"trials":6354,"activeCount":100},[],{"trials":6356,"activeCount":100},[],{"trials":6358,"activeCount":100},[],{"intervention":6360,"totalTrials":137,"cells":6361},"Imatinib Mesylate",{"EARLY_PHASE1":6362,"PHASE1":6364,"PHASE2":6366,"PHASE3":6378,"PHASE4":6380,"NA":6382},{"trials":6363,"activeCount":100},[],{"trials":6365,"activeCount":100},[],{"trials":6367,"activeCount":100},[6368],{"nctId":6369,"briefTitle":6370,"status":164,"phases":6371,"primaryCompletion":6372,"completion":116,"start":6373,"enrollment":36,"conditions":6374,"interventions":6377},"NCT03241199","The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia",[90],"2020-06-13","2017-08-01",[6375,6376],"Chronic Myeloid Leukemia","Philadelphia Chromosome Positive CML",[6360],{"trials":6379,"activeCount":100},[],{"trials":6381,"activeCount":100},[],{"trials":6383,"activeCount":100},[],{"intervention":2050,"totalTrials":137,"cells":6385},{"EARLY_PHASE1":6386,"PHASE1":6388,"PHASE2":6390,"PHASE3":6396,"PHASE4":6398,"NA":6400},{"trials":6387,"activeCount":100},[],{"trials":6389,"activeCount":100},[],{"trials":6391,"activeCount":100},[6392],{"nctId":2038,"briefTitle":2039,"status":164,"phases":6393,"primaryCompletion":2041,"completion":2042,"start":2043,"enrollment":169,"conditions":6394,"interventions":6395},[90],[2045,2046,2047],[2049,2050],{"trials":6397,"activeCount":100},[],{"trials":6399,"activeCount":100},[],{"trials":6401,"activeCount":100},[],{"intervention":6403,"totalTrials":137,"cells":6404},"Yu-Ping-Feng formula",{"EARLY_PHASE1":6405,"PHASE1":6407,"PHASE2":6409,"PHASE3":6424,"PHASE4":6426,"NA":6428},{"trials":6406,"activeCount":100},[],{"trials":6408,"activeCount":100},[],{"trials":6410,"activeCount":100},[6411],{"nctId":6412,"briefTitle":6413,"status":164,"phases":6414,"primaryCompletion":6415,"completion":6415,"start":6416,"enrollment":6417,"conditions":6418,"interventions":6421},"NCT04668222","Changing Susceptible Body Constitution for COVID-19 Prevention by Chinese Medicine in Hong Kong Residents",[89,90],"2022-11-30","2021-04-30",480,[6419,6420],"COVID19","Herbal Medicine",[6403,6422,6423],"Xiang-Sha-Liu-Jun formula","Liu-Wei-Di-Huang formula",{"trials":6425,"activeCount":100},[],{"trials":6427,"activeCount":100},[],{"trials":6429,"activeCount":100},[],{"intervention":6422,"totalTrials":137,"cells":6431},{"EARLY_PHASE1":6432,"PHASE1":6434,"PHASE2":6436,"PHASE3":6442,"PHASE4":6444,"NA":6446},{"trials":6433,"activeCount":100},[],{"trials":6435,"activeCount":100},[],{"trials":6437,"activeCount":100},[6438],{"nctId":6412,"briefTitle":6413,"status":164,"phases":6439,"primaryCompletion":6415,"completion":6415,"start":6416,"enrollment":6417,"conditions":6440,"interventions":6441},[89,90],[6419,6420],[6403,6422,6423],{"trials":6443,"activeCount":100},[],{"trials":6445,"activeCount":100},[],{"trials":6447,"activeCount":100},[],{"intervention":6423,"totalTrials":137,"cells":6449},{"EARLY_PHASE1":6450,"PHASE1":6452,"PHASE2":6454,"PHASE3":6460,"PHASE4":6462,"NA":6464},{"trials":6451,"activeCount":100},[],{"trials":6453,"activeCount":100},[],{"trials":6455,"activeCount":100},[6456],{"nctId":6412,"briefTitle":6413,"status":164,"phases":6457,"primaryCompletion":6415,"completion":6415,"start":6416,"enrollment":6417,"conditions":6458,"interventions":6459},[89,90],[6419,6420],[6403,6422,6423],{"trials":6461,"activeCount":100},[],{"trials":6463,"activeCount":100},[],{"trials":6465,"activeCount":100},[],{"intervention":5467,"totalTrials":137,"cells":6467},{"EARLY_PHASE1":6468,"PHASE1":6470,"PHASE2":6472,"PHASE3":6478,"PHASE4":6480,"NA":6482},{"trials":6469,"activeCount":100},[],{"trials":6471,"activeCount":100},[],{"trials":6473,"activeCount":100},[6474],{"nctId":5459,"briefTitle":5460,"status":112,"phases":6475,"primaryCompletion":5462,"completion":5463,"start":4175,"enrollment":709,"conditions":6476,"interventions":6477},[90],[5465],[5438,5467],{"trials":6479,"activeCount":100},[],{"trials":6481,"activeCount":100},[],{"trials":6483,"activeCount":100},[],{"intervention":6485,"totalTrials":137,"cells":6486},"Afatinib",{"EARLY_PHASE1":6487,"PHASE1":6489,"PHASE2":6491,"PHASE3":6501,"PHASE4":6503,"NA":6505},{"trials":6488,"activeCount":100},[],{"trials":6490,"activeCount":100},[],{"trials":6492,"activeCount":100},[6493],{"nctId":6494,"briefTitle":6495,"status":112,"phases":6496,"primaryCompletion":5083,"completion":2608,"start":5398,"enrollment":1093,"conditions":6497,"interventions":6499},"NCT02625168","Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC",[90],[6498],"Lung Cancer",[6485,6500],"Erlotinib",{"trials":6502,"activeCount":100},[],{"trials":6504,"activeCount":100},[],{"trials":6506,"activeCount":100},[],{"intervention":6500,"totalTrials":137,"cells":6508},{"EARLY_PHASE1":6509,"PHASE1":6511,"PHASE2":6513,"PHASE3":6519,"PHASE4":6521,"NA":6523},{"trials":6510,"activeCount":100},[],{"trials":6512,"activeCount":100},[],{"trials":6514,"activeCount":100},[6515],{"nctId":6494,"briefTitle":6495,"status":112,"phases":6516,"primaryCompletion":5083,"completion":2608,"start":5398,"enrollment":1093,"conditions":6517,"interventions":6518},[90],[6498],[6485,6500],{"trials":6520,"activeCount":100},[],{"trials":6522,"activeCount":100},[],{"trials":6524,"activeCount":100},[],{"intervention":6526,"totalTrials":137,"cells":6527},"Nivolumab",{"EARLY_PHASE1":6528,"PHASE1":6530,"PHASE2":6532,"PHASE3":6543,"PHASE4":6545,"NA":6547},{"trials":6529,"activeCount":100},[],{"trials":6531,"activeCount":100},[],{"trials":6533,"activeCount":100},[6534],{"nctId":6535,"briefTitle":6536,"status":6537,"phases":6538,"primaryCompletion":6539,"completion":6540,"start":4800,"enrollment":100,"conditions":6541,"interventions":6542},"NCT03390738","Nivolumab as Treatment for Recurrent\u002FMetastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy","WITHDRAWN",[90],"2019-05","2019-06",[1075],[6526],{"trials":6544,"activeCount":100},[],{"trials":6546,"activeCount":100},[],{"trials":6548,"activeCount":100},[],{"intervention":6550,"totalTrials":137,"cells":6551},"Neurovit Forte",{"EARLY_PHASE1":6552,"PHASE1":6554,"PHASE2":6556,"PHASE3":6569,"PHASE4":6571,"NA":6573},{"trials":6553,"activeCount":100},[],{"trials":6555,"activeCount":100},[],{"trials":6557,"activeCount":100},[6558],{"nctId":6559,"briefTitle":6560,"status":112,"phases":6561,"primaryCompletion":5741,"completion":6562,"start":6563,"enrollment":6564,"conditions":6565,"interventions":6567},"NCT02794922","Effectiveness of Vitamin B in Reducing Temporomandibular Joint Disorder Pain",[90],"2017-07","2015-09",27,[6566],"Temporomandibular Joint Disorder",[6550,6568],"Corn Starch",{"trials":6570,"activeCount":100},[],{"trials":6572,"activeCount":100},[],{"trials":6574,"activeCount":100},[],{"intervention":6568,"totalTrials":137,"cells":6576},{"EARLY_PHASE1":6577,"PHASE1":6579,"PHASE2":6581,"PHASE3":6587,"PHASE4":6589,"NA":6591},{"trials":6578,"activeCount":100},[],{"trials":6580,"activeCount":100},[],{"trials":6582,"activeCount":100},[6583],{"nctId":6559,"briefTitle":6560,"status":112,"phases":6584,"primaryCompletion":5741,"completion":6562,"start":6563,"enrollment":6564,"conditions":6585,"interventions":6586},[90],[6566],[6550,6568],{"trials":6588,"activeCount":100},[],{"trials":6590,"activeCount":100},[],{"trials":6592,"activeCount":100},[],{"intervention":6594,"totalTrials":137,"cells":6595},"Clofarabine, AraC, mitoxantrone",{"EARLY_PHASE1":6596,"PHASE1":6598,"PHASE2":6600,"PHASE3":6611,"PHASE4":6613,"NA":6615},{"trials":6597,"activeCount":100},[],{"trials":6599,"activeCount":100},[],{"trials":6601,"activeCount":100},[6602],{"nctId":6603,"briefTitle":6604,"status":112,"phases":6605,"primaryCompletion":6606,"completion":6607,"start":6608,"enrollment":1254,"conditions":6609,"interventions":6610},"NCT02686593","Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML",[90],"2018-03-31","2018-05-01","2016-02-01",[1462],[6594],{"trials":6612,"activeCount":100},[],{"trials":6614,"activeCount":100},[],{"trials":6616,"activeCount":100},[],{"intervention":6618,"totalTrials":137,"cells":6619},"Oral arsenic Trioxide, ATRA and ascorbic acid",{"EARLY_PHASE1":6620,"PHASE1":6622,"PHASE2":6624,"PHASE3":6633,"PHASE4":6635,"NA":6637},{"trials":6621,"activeCount":100},[],{"trials":6623,"activeCount":100},[],{"trials":6625,"activeCount":100},[6626],{"nctId":6627,"briefTitle":6628,"status":164,"phases":6629,"primaryCompletion":1488,"completion":1070,"start":6630,"enrollment":709,"conditions":6631,"interventions":6632},"NCT03624270","Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia",[90],"2018-08-15",[1406],[6618],{"trials":6634,"activeCount":100},[],{"trials":6636,"activeCount":100},[],{"trials":6638,"activeCount":100},[],{"intervention":6640,"totalTrials":137,"cells":6641},"Decitabine",{"EARLY_PHASE1":6642,"PHASE1":6644,"PHASE2":6646,"PHASE3":6656,"PHASE4":6658,"NA":6660},{"trials":6643,"activeCount":100},[],{"trials":6645,"activeCount":100},[],{"trials":6647,"activeCount":100},[6648],{"nctId":6649,"briefTitle":6650,"status":164,"phases":6651,"primaryCompletion":4174,"completion":6652,"start":2397,"enrollment":1340,"conditions":6653,"interventions":6655},"NCT03080766","The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and\u002For Monosomal Karyotype",[90],"2021-12-28",[1462,6654],"Complex Karyotype",[6640],{"trials":6657,"activeCount":100},[],{"trials":6659,"activeCount":100},[],{"trials":6661,"activeCount":100},[],{"intervention":6663,"totalTrials":137,"cells":6664},"Melatonin",{"EARLY_PHASE1":6665,"PHASE1":6667,"PHASE2":6679,"PHASE3":6681,"PHASE4":6683,"NA":6685},{"trials":6666,"activeCount":100},[],{"trials":6668,"activeCount":100},[6669],{"nctId":6670,"briefTitle":6671,"status":2650,"phases":6672,"primaryCompletion":2495,"completion":2495,"start":6673,"enrollment":6674,"conditions":6675,"interventions":6677},"NCT03995004","The Effect of Melatonin on Postoperative Pain Reduction After Orthognathic Surgery",[89],"2022-10",87,[6676],"Effect of Drugs",[6663,6678],"Dexamethasone Sodium Sulphate 4mg\u002F1mL",{"trials":6680,"activeCount":100},[],{"trials":6682,"activeCount":100},[],{"trials":6684,"activeCount":100},[],{"trials":6686,"activeCount":100},[],{"intervention":6678,"totalTrials":137,"cells":6688},{"EARLY_PHASE1":6689,"PHASE1":6691,"PHASE2":6697,"PHASE3":6699,"PHASE4":6701,"NA":6703},{"trials":6690,"activeCount":100},[],{"trials":6692,"activeCount":100},[6693],{"nctId":6670,"briefTitle":6671,"status":2650,"phases":6694,"primaryCompletion":2495,"completion":2495,"start":6673,"enrollment":6674,"conditions":6695,"interventions":6696},[89],[6676],[6663,6678],{"trials":6698,"activeCount":100},[],{"trials":6700,"activeCount":100},[],{"trials":6702,"activeCount":100},[],{"trials":6704,"activeCount":100},[],{"intervention":6706,"totalTrials":137,"cells":6707},"Lithium carbonate",{"EARLY_PHASE1":6708,"PHASE1":6710,"PHASE2":6720,"PHASE3":6722,"PHASE4":6724,"NA":6726},{"trials":6709,"activeCount":100},[],{"trials":6711,"activeCount":100},[6712],{"nctId":6713,"briefTitle":6714,"status":112,"phases":6715,"primaryCompletion":6716,"completion":6716,"start":5890,"enrollment":1340,"conditions":6717,"interventions":6719},"NCT00431171","Safety and Pharmacokinetics Study of Oral Lithium in Patients With Chronic Spinal Cord Injury",[89],"2010-01",[6718],"Spinal Cord Injuries",[6706],{"trials":6721,"activeCount":100},[],{"trials":6723,"activeCount":100},[],{"trials":6725,"activeCount":100},[],{"trials":6727,"activeCount":100},[],{"intervention":6729,"totalTrials":137,"cells":6730},"SARS-CoV-2 DNA Vaccine",{"EARLY_PHASE1":6731,"PHASE1":6733,"PHASE2":6742,"PHASE3":6744,"PHASE4":6746,"NA":6748},{"trials":6732,"activeCount":100},[],{"trials":6734,"activeCount":100},[6735],{"nctId":6736,"briefTitle":6737,"status":164,"phases":6738,"primaryCompletion":1775,"completion":6739,"start":2877,"enrollment":386,"conditions":6740,"interventions":6741},"NCT05102643","A Study to Evaluate Safety & Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19",[89],"2022-12",[2865],[6729],{"trials":6743,"activeCount":100},[],{"trials":6745,"activeCount":100},[],{"trials":6747,"activeCount":100},[],{"trials":6749,"activeCount":100},[],{"intervention":6751,"totalTrials":137,"cells":6752},"DelNS1-nCoV-RBD LAIV",{"EARLY_PHASE1":6753,"PHASE1":6755,"PHASE2":6766,"PHASE3":6768,"PHASE4":6770,"NA":6772},{"trials":6754,"activeCount":100},[],{"trials":6756,"activeCount":100},[6757],{"nctId":6758,"briefTitle":6759,"status":164,"phases":6760,"primaryCompletion":6761,"completion":6761,"start":6762,"enrollment":6763,"conditions":6764,"interventions":6765},"NCT04809389","A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19",[89],"2022-09","2021-03-29",115,[2865],[6751],{"trials":6767,"activeCount":100},[],{"trials":6769,"activeCount":100},[],{"trials":6771,"activeCount":100},[],{"trials":6773,"activeCount":100},[],{"intervention":6775,"totalTrials":137,"cells":6776},"Listerine mouthrinse",{"EARLY_PHASE1":6777,"PHASE1":6779,"PHASE2":6790,"PHASE3":6792,"PHASE4":6794,"NA":6796},{"trials":6778,"activeCount":100},[],{"trials":6780,"activeCount":100},[6781],{"nctId":6782,"briefTitle":6783,"status":112,"phases":6784,"primaryCompletion":1053,"completion":4405,"start":6785,"enrollment":415,"conditions":6786,"interventions":6788},"NCT01637948","Controlled Clinical Trial of Traditional Chinese Medicine Mouthrinse",[89],"2010-10",[6787],"Gingivitis",[6775,6789],"Chinese Medicine mouthrinse",{"trials":6791,"activeCount":100},[],{"trials":6793,"activeCount":100},[],{"trials":6795,"activeCount":100},[],{"trials":6797,"activeCount":100},[],{"intervention":6789,"totalTrials":137,"cells":6799},{"EARLY_PHASE1":6800,"PHASE1":6802,"PHASE2":6808,"PHASE3":6810,"PHASE4":6812,"NA":6814},{"trials":6801,"activeCount":100},[],{"trials":6803,"activeCount":100},[6804],{"nctId":6782,"briefTitle":6783,"status":112,"phases":6805,"primaryCompletion":1053,"completion":4405,"start":6785,"enrollment":415,"conditions":6806,"interventions":6807},[89],[6787],[6775,6789],{"trials":6809,"activeCount":100},[],{"trials":6811,"activeCount":100},[],{"trials":6813,"activeCount":100},[],{"trials":6815,"activeCount":100},[],{"intervention":6817,"totalTrials":137,"cells":6818},"Intraperitoneal docetaxel",{"EARLY_PHASE1":6819,"PHASE1":6821,"PHASE2":6831,"PHASE3":6833,"PHASE4":6835,"NA":6837},{"trials":6820,"activeCount":100},[],{"trials":6822,"activeCount":100},[6823],{"nctId":6824,"briefTitle":6825,"status":112,"phases":6826,"primaryCompletion":3783,"completion":4799,"start":1828,"enrollment":3543,"conditions":6827,"interventions":6830},"NCT02024841","Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis",[89],[6828,6829],"Gastric Cancer","Peritoneal Carcinomatosis",[6817],{"trials":6832,"activeCount":100},[],{"trials":6834,"activeCount":100},[],{"trials":6836,"activeCount":100},[],{"trials":6838,"activeCount":100},[],{"intervention":6840,"totalTrials":137,"cells":6841},"Microdrop Mydrin-P",{"EARLY_PHASE1":6842,"PHASE1":6854,"PHASE2":6856,"PHASE3":6858,"PHASE4":6860,"NA":6862},{"trials":6843,"activeCount":100},[6844],{"nctId":6845,"briefTitle":6846,"status":112,"phases":6847,"primaryCompletion":6848,"completion":6848,"start":6849,"enrollment":26,"conditions":6850,"interventions":6852},"NCT06288321","A Study Investigating Whether Low Dose Eyedrops for Pupil Dilation is as Effective and Safe as Standard Dose Eyedrops in Examination for Retinopathy of Prematurity.",[88],"2023-03-22","2022-08-10",[6851],"Retinopathy of Prematurity",[6840,6853],"Standard Mydrin-P",{"trials":6855,"activeCount":100},[],{"trials":6857,"activeCount":100},[],{"trials":6859,"activeCount":100},[],{"trials":6861,"activeCount":100},[],{"trials":6863,"activeCount":100},[],{"intervention":6853,"totalTrials":137,"cells":6865},{"EARLY_PHASE1":6866,"PHASE1":6872,"PHASE2":6874,"PHASE3":6876,"PHASE4":6878,"NA":6880},{"trials":6867,"activeCount":100},[6868],{"nctId":6845,"briefTitle":6846,"status":112,"phases":6869,"primaryCompletion":6848,"completion":6848,"start":6849,"enrollment":26,"conditions":6870,"interventions":6871},[88],[6851],[6840,6853],{"trials":6873,"activeCount":100},[],{"trials":6875,"activeCount":100},[],{"trials":6877,"activeCount":100},[],{"trials":6879,"activeCount":100},[],{"trials":6881,"activeCount":100},[],{"intervention":6883,"totalTrials":137,"cells":6884},"Olaparib",{"EARLY_PHASE1":6885,"PHASE1":6895,"PHASE2":6897,"PHASE3":6899,"PHASE4":6901,"NA":6903},{"trials":6886,"activeCount":100},[6887],{"nctId":6888,"briefTitle":6889,"status":112,"phases":6890,"primaryCompletion":4438,"completion":4438,"start":6891,"enrollment":1340,"conditions":6892,"interventions":6894},"NCT05320757","Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients",[88],"2022-04-01",[6893],"Endometrial Cancer",[6883],{"trials":6896,"activeCount":100},[],{"trials":6898,"activeCount":100},[],{"trials":6900,"activeCount":100},[],{"trials":6902,"activeCount":100},[],{"trials":6904,"activeCount":100},[],{"intervention":3923,"totalTrials":2486,"cells":6906},{"EARLY_PHASE1":6907,"PHASE1":6909,"PHASE2":6911,"PHASE3":6913,"PHASE4":6915,"NA":6947},{"trials":6908,"activeCount":100},[],{"trials":6910,"activeCount":100},[],{"trials":6912,"activeCount":100},[],{"trials":6914,"activeCount":100},[],{"trials":6916,"activeCount":100},[6917,6927,6931,6940],{"nctId":6918,"briefTitle":6919,"status":112,"phases":6920,"primaryCompletion":6921,"completion":6922,"start":6923,"enrollment":415,"conditions":6924,"interventions":6925},"NCT03597997","Effects of TIVA With Propofol Versus Inhalational Anaesthesia on Postoperative Pain After Hepatectomy",[92],"2021-07-15","2021-12-01","2018-08-27",[3947],[3923,6926],"Sevoflurane",{"nctId":3917,"briefTitle":3918,"status":112,"phases":6928,"primaryCompletion":3497,"completion":3497,"start":3785,"enrollment":635,"conditions":6929,"interventions":6930},[92],[3921],[3904,3923],{"nctId":6932,"briefTitle":6933,"status":112,"phases":6934,"primaryCompletion":6935,"completion":6935,"start":6936,"enrollment":4532,"conditions":6937,"interventions":6938},"NCT03058341","Effect of Total Intravenous Anaesthesia With Propofol on Postoperative Pain After Bilateral Third Molar Surgery",[92],"2018-03-30","2016-12-23",[3947],[6939,6926],"propofol",{"nctId":6941,"briefTitle":6942,"status":164,"phases":6943,"primaryCompletion":1070,"completion":4437,"start":6944,"enrollment":2570,"conditions":6945,"interventions":6946},"NCT04002271","Total Knee Replacement TIVA With Robotic Arm Assisted",[92],"2020-07-22",[3947],[3923,6926],{"trials":6948,"activeCount":100},[6949,6956,6965,6972],{"nctId":6950,"briefTitle":6951,"status":6537,"phases":6952,"primaryCompletion":2822,"completion":2580,"start":6953,"enrollment":100,"conditions":6954,"interventions":6955},"NCT03058354","Study to Investigate TIVA With Propofol on Postoperative Pain and Side Effects",[],"2017-01-01",[3947],[3923],{"nctId":6957,"briefTitle":6958,"status":112,"phases":6959,"primaryCompletion":5012,"completion":5012,"start":6960,"enrollment":6961,"conditions":6962,"interventions":6963},"NCT03875872","Comparison of Postoperative Outcomes Between Surgeries Anaesthetized With Propofol and Inhalational Anaesthetics",[],"2019-02-11",3922,[2584],[3923,6964],"inhalation anaesthetics",{"nctId":6966,"briefTitle":6967,"status":164,"phases":6968,"primaryCompletion":1070,"completion":4199,"start":538,"enrollment":1874,"conditions":6969,"interventions":6971},"NCT04540666","VR Sedation in Third Molar Surgery",[93],[6970],"Anesthesia",[3923],{"nctId":6973,"briefTitle":6974,"status":164,"phases":6975,"primaryCompletion":1642,"completion":2923,"start":6976,"enrollment":6977,"conditions":6978,"interventions":6980},"NCT04601961","Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients",[93],"2020-03-04",220,[6979,1086],"Circulating Tumor Cell",[3923,6926],{"intervention":575,"totalTrials":2533,"cells":6982},{"EARLY_PHASE1":6983,"PHASE1":6985,"PHASE2":6987,"PHASE3":6989,"PHASE4":6991,"NA":7009},{"trials":6984,"activeCount":100},[],{"trials":6986,"activeCount":100},[],{"trials":6988,"activeCount":100},[],{"trials":6990,"activeCount":100},[],{"trials":6992,"activeCount":100},[6993,6997,7001,7005],{"nctId":3153,"briefTitle":3154,"status":2650,"phases":6994,"primaryCompletion":3156,"completion":3156,"start":3157,"enrollment":3158,"conditions":6995,"interventions":6996},[92],[3160],[575,3140,3162],{"nctId":3735,"briefTitle":3736,"status":112,"phases":6998,"primaryCompletion":3738,"completion":3738,"start":3739,"enrollment":3740,"conditions":6999,"interventions":7000},[92],[573,3742,3743],[3722,3745,575],{"nctId":2576,"briefTitle":2577,"status":112,"phases":7002,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":7003,"interventions":7004},[92],[2584],[1243,575],{"nctId":4244,"briefTitle":4245,"status":112,"phases":7006,"primaryCompletion":4247,"completion":4248,"start":4249,"enrollment":4250,"conditions":7007,"interventions":7008},[92],[2584],[4231,575],{"trials":7010,"activeCount":100},[7011],{"nctId":566,"briefTitle":567,"status":112,"phases":7012,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":7013,"interventions":7014},[93],[573],[67,575],{"intervention":6926,"totalTrials":492,"cells":7016},{"EARLY_PHASE1":7017,"PHASE1":7019,"PHASE2":7021,"PHASE3":7023,"PHASE4":7025,"NA":7039},{"trials":7018,"activeCount":100},[],{"trials":7020,"activeCount":100},[],{"trials":7022,"activeCount":100},[],{"trials":7024,"activeCount":100},[],{"trials":7026,"activeCount":100},[7027,7031,7035],{"nctId":6918,"briefTitle":6919,"status":112,"phases":7028,"primaryCompletion":6921,"completion":6922,"start":6923,"enrollment":415,"conditions":7029,"interventions":7030},[92],[3947],[3923,6926],{"nctId":6932,"briefTitle":6933,"status":112,"phases":7032,"primaryCompletion":6935,"completion":6935,"start":6936,"enrollment":4532,"conditions":7033,"interventions":7034},[92],[3947],[6939,6926],{"nctId":6941,"briefTitle":6942,"status":164,"phases":7036,"primaryCompletion":1070,"completion":4437,"start":6944,"enrollment":2570,"conditions":7037,"interventions":7038},[92],[3947],[3923,6926],{"trials":7040,"activeCount":100},[7041],{"nctId":6973,"briefTitle":6974,"status":164,"phases":7042,"primaryCompletion":1642,"completion":2923,"start":6976,"enrollment":6977,"conditions":7043,"interventions":7044},[93],[6979,1086],[3923,6926],{"intervention":1867,"totalTrials":492,"cells":7046},{"EARLY_PHASE1":7047,"PHASE1":7049,"PHASE2":7051,"PHASE3":7053,"PHASE4":7055,"NA":7074},{"trials":7048,"activeCount":100},[],{"trials":7050,"activeCount":100},[],{"trials":7052,"activeCount":100},[],{"trials":7054,"activeCount":100},[],{"trials":7056,"activeCount":100},[7057,7066],{"nctId":7058,"briefTitle":7059,"status":164,"phases":7060,"primaryCompletion":3156,"completion":3156,"start":7061,"enrollment":834,"conditions":7062,"interventions":7065},"NCT05079061","A Trial of Sublingual Misoprostol to Reduce Primary Postpartum Haemorrhage After Vaginal Delivery",[92],"2022-04",[7063,1867,7064],"Primary Postpartum Hemorrhage","Delivery Complication",[1867],{"nctId":7067,"briefTitle":7068,"status":112,"phases":7069,"primaryCompletion":7070,"completion":7070,"start":2504,"enrollment":415,"conditions":7071,"interventions":7073},"NCT01156688","A Prospective Randomized Comparison Trial on the Use of Mifepristone With Sublingual or Buccal Misoprostol for Medical Abortions of Less Than 9 Weeks Gestation",[92],"2011-08",[7072],"Abortion, Legal",[1867,1867],{"trials":7075,"activeCount":100},[7076,7080],{"nctId":1858,"briefTitle":1859,"status":164,"phases":7077,"primaryCompletion":1861,"completion":1861,"start":1862,"enrollment":1254,"conditions":7078,"interventions":7079},[93],[1864],[1866,1814,1867],{"nctId":7081,"briefTitle":7082,"status":112,"phases":7083,"primaryCompletion":7084,"completion":7084,"start":7085,"enrollment":7086,"conditions":7087,"interventions":7089},"NCT01199159","Preoperative Misoprostol in Reducing Blood Loss in Total Abdominal Hysterectomy (TAH)",[93],"2008-04","2007-01",77,[7088],"Hysterectomy",[1867,7090],"Vitamin B 6",{"intervention":7092,"totalTrials":151,"cells":7093},"Pioglitazone",{"EARLY_PHASE1":7094,"PHASE1":7096,"PHASE2":7098,"PHASE3":7100,"PHASE4":7102,"NA":7112},{"trials":7095,"activeCount":100},[],{"trials":7097,"activeCount":100},[],{"trials":7099,"activeCount":100},[],{"trials":7101,"activeCount":100},[],{"trials":7103,"activeCount":100},[7104],{"nctId":7105,"briefTitle":7106,"status":112,"phases":7107,"primaryCompletion":7108,"completion":2608,"start":4674,"enrollment":144,"conditions":7109,"interventions":7111},"NCT00745225","Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients",[92],"2014-10",[7110],"End-stage Renal Disease",[7092],{"trials":7113,"activeCount":100},[7114],{"nctId":7115,"briefTitle":7116,"status":112,"phases":7117,"primaryCompletion":7118,"completion":1828,"start":570,"enrollment":7119,"conditions":7120,"interventions":7122},"NCT00745914","Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients",[93],"2013-09",22,[4226,7121],"Diabetes",[7092],{"intervention":7124,"totalTrials":151,"cells":7125},"Esomeprazole",{"EARLY_PHASE1":7126,"PHASE1":7128,"PHASE2":7130,"PHASE3":7132,"PHASE4":7144,"NA":7146},{"trials":7127,"activeCount":100},[],{"trials":7129,"activeCount":100},[],{"trials":7131,"activeCount":100},[],{"trials":7133,"activeCount":100},[7134],{"nctId":7135,"briefTitle":7136,"status":112,"phases":7137,"primaryCompletion":591,"completion":5741,"start":7138,"enrollment":7139,"conditions":7140,"interventions":7143},"NCT01873079","PPI for Prevention of Post-sphincterotomy Bleeding",[91],"2013-04",185,[7141,7142],"Bleeding","ERCP",[7124],{"trials":7145,"activeCount":100},[],{"trials":7147,"activeCount":100},[7148],{"nctId":7149,"briefTitle":7150,"status":3540,"phases":7151,"primaryCompletion":6303,"completion":6303,"start":7152,"enrollment":151,"conditions":7153,"interventions":7157},"NCT02840929","Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents",[93],"2016-07",[7154,7155,7156],"OGD","Gastric Ulcer Induced by Anti-platelet Agent","Duodenal Ulcer Induced by Anti-platelet Agent",[7124],{"intervention":7159,"totalTrials":151,"cells":7160},"Silver Diamine Fluoride",{"EARLY_PHASE1":7161,"PHASE1":7163,"PHASE2":7165,"PHASE3":7167,"PHASE4":7173,"NA":7175},{"trials":7162,"activeCount":100},[],{"trials":7164,"activeCount":100},[],{"trials":7166,"activeCount":100},[],{"trials":7168,"activeCount":100},[7169],{"nctId":1310,"briefTitle":1311,"status":164,"phases":7170,"primaryCompletion":1313,"completion":1313,"start":1314,"enrollment":1315,"conditions":7171,"interventions":7172},[90,91],[1317],[1319,1320],{"trials":7174,"activeCount":100},[],{"trials":7176,"activeCount":100},[7177],{"nctId":7178,"briefTitle":7179,"status":164,"phases":7180,"primaryCompletion":7181,"completion":6237,"start":7182,"enrollment":7183,"conditions":7184,"interventions":7185},"NCT03185104","Silver Diamine Fluoride for Caries Prevention in Removable Partial Dentures Wearers",[93],"2017-06-30","2013-11-01",196,[4408,2065],[7159,7186],"Distilled Water",{"intervention":7188,"totalTrials":151,"cells":7189},"Nicotine replacement therapy (NRT) sampling",{"EARLY_PHASE1":7190,"PHASE1":7192,"PHASE2":7194,"PHASE3":7196,"PHASE4":7198,"NA":7200},{"trials":7191,"activeCount":100},[],{"trials":7193,"activeCount":100},[],{"trials":7195,"activeCount":100},[],{"trials":7197,"activeCount":100},[],{"trials":7199,"activeCount":100},[],{"trials":7201,"activeCount":100},[7202,7210],{"nctId":7203,"briefTitle":7204,"status":112,"phases":7205,"primaryCompletion":2822,"completion":6171,"start":7206,"enrollment":7207,"conditions":7208,"interventions":7209},"NCT03717051","Use of Nicotine Replacement Therapy (NRT) Sample and Brief Smoking Cessation Advice for Recruiting Smokers",[93],"2018-10-13",834,[16],[7188],{"nctId":7211,"briefTitle":7212,"status":112,"phases":7213,"primaryCompletion":5318,"completion":7214,"start":5126,"enrollment":635,"conditions":7215,"interventions":7216},"NCT02491086","Motivating Smokers at Outdoor Public Smoking Hotspots to Have Quit Attempt With Nicotine Replacement Therapy Sampling",[93],"2016-09",[16],[7188],{"intervention":4953,"totalTrials":151,"cells":7218},{"EARLY_PHASE1":7219,"PHASE1":7221,"PHASE2":7223,"PHASE3":7225,"PHASE4":7231,"NA":7233},{"trials":7220,"activeCount":100},[],{"trials":7222,"activeCount":100},[],{"trials":7224,"activeCount":100},[],{"trials":7226,"activeCount":100},[7227],{"nctId":4946,"briefTitle":4947,"status":112,"phases":7228,"primaryCompletion":4949,"completion":4949,"start":4801,"enrollment":144,"conditions":7229,"interventions":7230},[91],[4951],[4935,4953,4954,4955],{"trials":7232,"activeCount":100},[],{"trials":7234,"activeCount":100},[7235],{"nctId":7236,"briefTitle":7237,"status":112,"phases":7238,"primaryCompletion":3944,"completion":3944,"start":4405,"enrollment":7239,"conditions":7240,"interventions":7242},"NCT01508884","Intradermal Trivalent Influenza Vaccine With Imiquimod",[93],93,[7241],"Chronic Illness",[7243,7244,7243,4953,7243,4953],"influenza vaccine","Imiquimod",{"intervention":7246,"totalTrials":151,"cells":7247},"Quadruple therapy",{"EARLY_PHASE1":7248,"PHASE1":7250,"PHASE2":7252,"PHASE3":7254,"PHASE4":7256,"NA":7258},{"trials":7249,"activeCount":100},[],{"trials":7251,"activeCount":100},[],{"trials":7253,"activeCount":100},[],{"trials":7255,"activeCount":100},[],{"trials":7257,"activeCount":100},[],{"trials":7259,"activeCount":100},[7260,7270],{"nctId":7261,"briefTitle":7262,"status":112,"phases":7263,"primaryCompletion":6785,"completion":7264,"start":7265,"enrollment":2624,"conditions":7266,"interventions":7268},"NCT01306786","Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori Eradication",[93],"2011-02","2008-11",[7267],"Helicobacter Pylori Infection",[7246,7269],"Triple therapy",{"nctId":7271,"briefTitle":7272,"status":112,"phases":7273,"primaryCompletion":4414,"completion":3944,"start":1053,"enrollment":7274,"conditions":7275,"interventions":7276},"NCT01760824","Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication",[93],391,[7267],[7277,7246],"Sequential therapy",{"intervention":7279,"totalTrials":151,"cells":7280},"Genetic Risk Estimate",{"EARLY_PHASE1":7281,"PHASE1":7283,"PHASE2":7285,"PHASE3":7287,"PHASE4":7289,"NA":7291},{"trials":7282,"activeCount":100},[],{"trials":7284,"activeCount":100},[],{"trials":7286,"activeCount":100},[],{"trials":7288,"activeCount":100},[],{"trials":7290,"activeCount":100},[],{"trials":7292,"activeCount":100},[7293,7306],{"nctId":7294,"briefTitle":7295,"status":112,"phases":7296,"primaryCompletion":7297,"completion":3335,"start":7298,"enrollment":7299,"conditions":7300,"interventions":7305},"NCT05524909","Full-scale Intervention Study: Genetic Risk Communication and Wearables",[93],"2025-04-30","2022-11-01",355,[7301,7302,7303,7304,146],"Fitness Trackers","Physical Activity","Exercise","Genetic Predisposition to Disease",[7279],{"nctId":7307,"briefTitle":7308,"status":164,"phases":7309,"primaryCompletion":7310,"completion":7311,"start":7312,"enrollment":1598,"conditions":7313,"interventions":7315},"NCT04879758","Intervention Study: Genetic Risk Communication and Wearables",[93],"2023-12","2024-05","2021-07-07",[7301,7314,7303,7304,146],"Sedentary Behavior",[7279],{"intervention":7317,"totalTrials":151,"cells":7318},"Fluoxetine",{"EARLY_PHASE1":7319,"PHASE1":7321,"PHASE2":7323,"PHASE3":7325,"PHASE4":7327,"NA":7329},{"trials":7320,"activeCount":100},[],{"trials":7322,"activeCount":100},[],{"trials":7324,"activeCount":100},[],{"trials":7326,"activeCount":100},[],{"trials":7328,"activeCount":100},[],{"trials":7330,"activeCount":100},[7331,7340],{"nctId":7332,"briefTitle":7333,"status":112,"phases":7334,"primaryCompletion":7335,"completion":7335,"start":7336,"enrollment":7337,"conditions":7338,"interventions":7339},"NCT01174394","Electroacupuncture Combined With Antidepressants for Post-stroke Depression",[93],"2013-02","2010-05",43,[33,35],[7317],{"nctId":7341,"briefTitle":7342,"status":112,"phases":7343,"primaryCompletion":5397,"completion":5397,"start":1861,"enrollment":7344,"conditions":7345,"interventions":7347},"NCT01479920","A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture",[93],36,[7346,33],"Major Depressive Disorder",[7317],{"intervention":7349,"totalTrials":137,"cells":7350},"5% O2",{"EARLY_PHASE1":7351,"PHASE1":7353,"PHASE2":7355,"PHASE3":7357,"PHASE4":7359,"NA":7361},{"trials":7352,"activeCount":100},[],{"trials":7354,"activeCount":100},[],{"trials":7356,"activeCount":100},[],{"trials":7358,"activeCount":100},[],{"trials":7360,"activeCount":100},[],{"trials":7362,"activeCount":100},[7363],{"nctId":7364,"briefTitle":7365,"status":164,"phases":7366,"primaryCompletion":7367,"completion":7367,"start":7368,"enrollment":7369,"conditions":7370,"interventions":7372},"NCT04424784","Influence of Manipulation of Oocytes and Embryos in Low Oxygen Tension on Assisted Reproduction Technology Outcome",[93],"2023-06","2021-03-22",1160,[7371],"Embryo Hypoxia",[7349],{"intervention":7374,"totalTrials":137,"cells":7375},"Anti-CD20 antibody",{"EARLY_PHASE1":7376,"PHASE1":7378,"PHASE2":7380,"PHASE3":7382,"PHASE4":7384,"NA":7386},{"trials":7377,"activeCount":100},[],{"trials":7379,"activeCount":100},[],{"trials":7381,"activeCount":100},[],{"trials":7383,"activeCount":100},[],{"trials":7385,"activeCount":100},[],{"trials":7387,"activeCount":100},[7388],{"nctId":7389,"briefTitle":7390,"status":112,"phases":7391,"primaryCompletion":7392,"completion":7393,"start":7394,"enrollment":7395,"conditions":7396,"interventions":7399},"NCT03155984","Optimizing HBV Management During Anti-CD20 Antibodies",[],"2017-06-01","2017-12-01","2013-10-01",83,[7397,7398,4890],"Liver Dysfunction","Immune Suppression",[7374],{"intervention":7401,"totalTrials":137,"cells":7402},"Targeted therapy",{"EARLY_PHASE1":7403,"PHASE1":7405,"PHASE2":7407,"PHASE3":7409,"PHASE4":7411,"NA":7413},{"trials":7404,"activeCount":100},[],{"trials":7406,"activeCount":100},[],{"trials":7408,"activeCount":100},[],{"trials":7410,"activeCount":100},[],{"trials":7412,"activeCount":100},[],{"trials":7414,"activeCount":100},[7415],{"nctId":7416,"briefTitle":7417,"status":164,"phases":7418,"primaryCompletion":1991,"completion":7419,"start":5011,"enrollment":2089,"conditions":7420,"interventions":7425},"NCT05177666","a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors",[],"2024-03-30",[7421,7422,7423,7424],"Feasibility","Effectiveness","Safety","Targeted Molecular Therapy",[7401],{"intervention":7427,"totalTrials":137,"cells":7428},"Genetic Risk Estimate+Health Coaching",{"EARLY_PHASE1":7429,"PHASE1":7431,"PHASE2":7433,"PHASE3":7435,"PHASE4":7437,"NA":7439},{"trials":7430,"activeCount":100},[],{"trials":7432,"activeCount":100},[],{"trials":7434,"activeCount":100},[],{"trials":7436,"activeCount":100},[],{"trials":7438,"activeCount":100},[],{"trials":7440,"activeCount":100},[7441],{"nctId":7442,"briefTitle":7443,"status":164,"phases":7444,"primaryCompletion":1159,"completion":7445,"start":1170,"enrollment":7446,"conditions":7447,"interventions":7450},"NCT05789966","Fullscale_Intervention Study: Genetic Risk Communication in Coronary Heart Disease and Wearables",[93],"2026-06-01",414,[7301,7448,7304,7449],"Sedentary Time","Coronary Heart Disease",[7427],{"intervention":7452,"totalTrials":137,"cells":7453},"morphine",{"EARLY_PHASE1":7454,"PHASE1":7456,"PHASE2":7458,"PHASE3":7460,"PHASE4":7462,"NA":7464},{"trials":7455,"activeCount":100},[],{"trials":7457,"activeCount":100},[],{"trials":7459,"activeCount":100},[],{"trials":7461,"activeCount":100},[],{"trials":7463,"activeCount":100},[],{"trials":7465,"activeCount":100},[7466],{"nctId":7467,"briefTitle":7468,"status":3540,"phases":7469,"primaryCompletion":2822,"completion":7470,"start":3497,"enrollment":2099,"conditions":7471,"interventions":7472},"NCT02773472","Electroacupuncture for Laparoscopic\u002F Robotic Colorectal Surgery",[93],"2020-03-24",[2584],[7452],{"intervention":7474,"totalTrials":137,"cells":7475},"NRT-S",{"EARLY_PHASE1":7476,"PHASE1":7478,"PHASE2":7480,"PHASE3":7482,"PHASE4":7484,"NA":7486},{"trials":7477,"activeCount":100},[],{"trials":7479,"activeCount":100},[],{"trials":7481,"activeCount":100},[],{"trials":7483,"activeCount":100},[],{"trials":7485,"activeCount":100},[],{"trials":7487,"activeCount":100},[7488],{"nctId":7489,"briefTitle":7490,"status":112,"phases":7491,"primaryCompletion":2862,"completion":4174,"start":7492,"enrollment":7493,"conditions":7494,"interventions":7496},"NCT04001972","Interactive Communication Technologies and Nicotine Replacement Therapy Sampling for Smokers",[93],"2019-08-19",664,[16,7495],"Tobacco Use Cessation",[7474],{"intervention":7498,"totalTrials":137,"cells":7499},"38% SDF treatment",{"EARLY_PHASE1":7500,"PHASE1":7502,"PHASE2":7504,"PHASE3":7506,"PHASE4":7508,"NA":7510},{"trials":7501,"activeCount":100},[],{"trials":7503,"activeCount":100},[],{"trials":7505,"activeCount":100},[],{"trials":7507,"activeCount":100},[],{"trials":7509,"activeCount":100},[],{"trials":7511,"activeCount":100},[7512],{"nctId":7513,"briefTitle":7514,"status":112,"phases":7515,"primaryCompletion":7516,"completion":7516,"start":7517,"enrollment":7518,"conditions":7519,"interventions":7520},"NCT05655286","Effectiveness of SDF With Different Post-treatment Protocols in Arresting Dental Caries",[93],"2024-05-20","2023-01-01",254,[4408],[7498],{"intervention":7522,"totalTrials":137,"cells":7523},"S-OIV H1N1 vaccine",{"EARLY_PHASE1":7524,"PHASE1":7526,"PHASE2":7528,"PHASE3":7530,"PHASE4":7532,"NA":7534},{"trials":7525,"activeCount":100},[],{"trials":7527,"activeCount":100},[],{"trials":7529,"activeCount":100},[],{"trials":7531,"activeCount":100},[],{"trials":7533,"activeCount":100},[],{"trials":7535,"activeCount":100},[7536],{"nctId":7537,"briefTitle":7538,"status":112,"phases":7539,"primaryCompletion":7540,"completion":7540,"start":6716,"enrollment":7541,"conditions":7542,"interventions":7544},"NCT01049490","Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device",[93],"2010-06",262,[7543],"Influenza Infection",[7522],{"intervention":7546,"totalTrials":137,"cells":7547},"Antidepressant",{"EARLY_PHASE1":7548,"PHASE1":7550,"PHASE2":7552,"PHASE3":7554,"PHASE4":7556,"NA":7558},{"trials":7549,"activeCount":100},[],{"trials":7551,"activeCount":100},[],{"trials":7553,"activeCount":100},[],{"trials":7555,"activeCount":100},[],{"trials":7557,"activeCount":100},[],{"trials":7559,"activeCount":100},[7560],{"nctId":7561,"briefTitle":7562,"status":112,"phases":7563,"primaryCompletion":7564,"completion":7565,"start":7566,"enrollment":7567,"conditions":7568,"interventions":7570},"NCT02644161","Can Acupuncture Treat Post-stroke Depression?",[93],"2018-07","2018-10","2015-10",91,[35,33,7569],"Stroke Sequelae",[7546],{"intervention":7572,"totalTrials":137,"cells":7573},"sevelamer hydrochloride",{"EARLY_PHASE1":7574,"PHASE1":7576,"PHASE2":7578,"PHASE3":7580,"PHASE4":7582,"NA":7584},{"trials":7575,"activeCount":100},[],{"trials":7577,"activeCount":100},[],{"trials":7579,"activeCount":100},[],{"trials":7581,"activeCount":100},[],{"trials":7583,"activeCount":100},[],{"trials":7585,"activeCount":100},[7586],{"nctId":7587,"briefTitle":7588,"status":112,"phases":7589,"primaryCompletion":7108,"completion":7590,"start":7591,"enrollment":709,"conditions":7592,"interventions":7593},"NCT00745589","Sevelamer Hydrochloride in Peritoneal Dialysis Patients",[93],"2015-01","2008-07",[4226],[7572],{"intervention":7595,"totalTrials":137,"cells":7596},"indocyanine green",{"EARLY_PHASE1":7597,"PHASE1":7599,"PHASE2":7601,"PHASE3":7603,"PHASE4":7605,"NA":7607},{"trials":7598,"activeCount":100},[],{"trials":7600,"activeCount":100},[],{"trials":7602,"activeCount":100},[],{"trials":7604,"activeCount":100},[],{"trials":7606,"activeCount":100},[],{"trials":7608,"activeCount":100},[7609],{"nctId":7610,"briefTitle":7611,"status":164,"phases":7612,"primaryCompletion":2841,"completion":1872,"start":5318,"enrollment":386,"conditions":7613,"interventions":7615},"NCT02669485","The Impact of Indocyanine Green-enhanced Fluorescence Imaging on Bowel Transection in Left-sided Colorectal Resection",[93],[7614],"Anastomotic Leak",[7595],{"intervention":7617,"totalTrials":137,"cells":7618},"H1N1 convalescent plasma and oseltamivir",{"EARLY_PHASE1":7619,"PHASE1":7621,"PHASE2":7623,"PHASE3":7625,"PHASE4":7627,"NA":7629},{"trials":7620,"activeCount":100},[],{"trials":7622,"activeCount":100},[],{"trials":7624,"activeCount":100},[],{"trials":7626,"activeCount":100},[],{"trials":7628,"activeCount":100},[],{"trials":7630,"activeCount":100},[7631],{"nctId":7632,"briefTitle":7633,"status":112,"phases":7634,"primaryCompletion":569,"completion":569,"start":5497,"enrollment":2170,"conditions":7635,"interventions":7636},"NCT01306773","Convalescent Plasma Treatment in Severe 2009 H1N1 Infection",[93],[6175],[7617,7637],"Oral Oseltamivir alone",{"intervention":7637,"totalTrials":137,"cells":7639},{"EARLY_PHASE1":7640,"PHASE1":7642,"PHASE2":7644,"PHASE3":7646,"PHASE4":7648,"NA":7650},{"trials":7641,"activeCount":100},[],{"trials":7643,"activeCount":100},[],{"trials":7645,"activeCount":100},[],{"trials":7647,"activeCount":100},[],{"trials":7649,"activeCount":100},[],{"trials":7651,"activeCount":100},[7652],{"nctId":7632,"briefTitle":7633,"status":112,"phases":7653,"primaryCompletion":569,"completion":569,"start":5497,"enrollment":2170,"conditions":7654,"interventions":7655},[93],[6175],[7617,7637],{"intervention":7657,"totalTrials":137,"cells":7658},"Non-invasive Preimplantation genetic testing for aneuploidy status",{"EARLY_PHASE1":7659,"PHASE1":7661,"PHASE2":7663,"PHASE3":7665,"PHASE4":7667,"NA":7669},{"trials":7660,"activeCount":100},[],{"trials":7662,"activeCount":100},[],{"trials":7664,"activeCount":100},[],{"trials":7666,"activeCount":100},[],{"trials":7668,"activeCount":100},[],{"trials":7670,"activeCount":100},[7671],{"nctId":7672,"briefTitle":7673,"status":112,"phases":7674,"primaryCompletion":7675,"completion":7676,"start":611,"enrollment":7677,"conditions":7678,"interventions":7680},"NCT04474522","RCT of niPGT for Aneuploidy and Morphology Compared With Morphology Alone in IVF",[93],"2023-05-30","2025-03-24",517,[7679],"Preimplantation Diagnosis",[7657],{"intervention":7682,"totalTrials":137,"cells":7683},"DNA screening before Pregnancy",{"EARLY_PHASE1":7684,"PHASE1":7686,"PHASE2":7688,"PHASE3":7690,"PHASE4":7692,"NA":7694},{"trials":7685,"activeCount":100},[],{"trials":7687,"activeCount":100},[],{"trials":7689,"activeCount":100},[],{"trials":7691,"activeCount":100},[],{"trials":7693,"activeCount":100},[],{"trials":7695,"activeCount":100},[7696],{"nctId":7697,"briefTitle":7698,"status":112,"phases":7699,"primaryCompletion":7700,"completion":7700,"start":7152,"enrollment":635,"conditions":7701,"interventions":7703},"NCT02742116","Evaluation of the Implementation of Expanded Carrier Screening Before Pregnancy in Hong Kong",[],"2016-10",[7702],"Genetic Testing",[7682],{"intervention":7705,"totalTrials":137,"cells":7706},"Cytoxan-containing chemotherapy regimens",{"EARLY_PHASE1":7707,"PHASE1":7709,"PHASE2":7711,"PHASE3":7713,"PHASE4":7715,"NA":7717},{"trials":7708,"activeCount":100},[],{"trials":7710,"activeCount":100},[],{"trials":7712,"activeCount":100},[],{"trials":7714,"activeCount":100},[],{"trials":7716,"activeCount":100},[],{"trials":7718,"activeCount":100},[7719],{"nctId":7720,"briefTitle":7721,"status":112,"phases":7722,"primaryCompletion":2993,"completion":5317,"start":7566,"enrollment":7239,"conditions":7723,"interventions":7728},"NCT02457039","Acupuncture Prevents Chemobrain in Breast Cancer Patients",[93],[7724,7725,7726,7727],"Chemo-brain","Drug-Related Side Effects and Adverse Reactions","Mild Cognitive Impairment","Breast Cancer",[7705],{"intervention":7730,"totalTrials":137,"cells":7731},"Biologics",{"EARLY_PHASE1":7732,"PHASE1":7734,"PHASE2":7736,"PHASE3":7738,"PHASE4":7740,"NA":7742},{"trials":7733,"activeCount":100},[],{"trials":7735,"activeCount":100},[],{"trials":7737,"activeCount":100},[],{"trials":7739,"activeCount":100},[],{"trials":7741,"activeCount":100},[],{"trials":7743,"activeCount":100},[7744],{"nctId":7745,"briefTitle":7746,"status":164,"phases":7747,"primaryCompletion":6673,"completion":6739,"start":7748,"enrollment":1874,"conditions":7749,"interventions":7751},"NCT04399382","A Clinical Study to Evaluate the Efficacy of Biologics in SpA",[],"2022-01-12",[7750],"Spondyloarthritis (SpA)",[7730],{"intervention":7753,"totalTrials":137,"cells":7754},"Text message",{"EARLY_PHASE1":7755,"PHASE1":7757,"PHASE2":7759,"PHASE3":7761,"PHASE4":7763,"NA":7765},{"trials":7756,"activeCount":100},[],{"trials":7758,"activeCount":100},[],{"trials":7760,"activeCount":100},[],{"trials":7762,"activeCount":100},[],{"trials":7764,"activeCount":100},[],{"trials":7766,"activeCount":100},[7767],{"nctId":7768,"briefTitle":7769,"status":112,"phases":7770,"primaryCompletion":167,"completion":536,"start":2372,"enrollment":7771,"conditions":7772,"interventions":7773},"NCT03870906","Smoking Cessation Programme in Workplaces in Hong Kong (Phase IV)",[93],556,[16],[7753],{"intervention":7775,"totalTrials":137,"cells":7776},"Schroth SSE with Bracing",{"EARLY_PHASE1":7777,"PHASE1":7779,"PHASE2":7781,"PHASE3":7783,"PHASE4":7785,"NA":7787},{"trials":7778,"activeCount":100},[],{"trials":7780,"activeCount":100},[],{"trials":7782,"activeCount":100},[],{"trials":7784,"activeCount":100},[],{"trials":7786,"activeCount":100},[],{"trials":7788,"activeCount":100},[7789],{"nctId":7790,"briefTitle":7791,"status":164,"phases":7792,"primaryCompletion":115,"completion":115,"start":7793,"enrollment":117,"conditions":7794,"interventions":7796},"NCT03305185","Efficacy of Scoliosis Specific Exercise in Patients With Adolescent Idiopathic Scoliosis During Bracing",[93],"2017-12-18",[7795],"Adolescent Idiopathic Scoliosis",[7775],{"intervention":7798,"totalTrials":137,"cells":7799},"Tenofovir disoproxil",{"EARLY_PHASE1":7800,"PHASE1":7802,"PHASE2":7804,"PHASE3":7806,"PHASE4":7808,"NA":7810},{"trials":7801,"activeCount":100},[],{"trials":7803,"activeCount":100},[],{"trials":7805,"activeCount":100},[],{"trials":7807,"activeCount":100},[],{"trials":7809,"activeCount":100},[],{"trials":7811,"activeCount":100},[7812],{"nctId":7813,"briefTitle":7814,"status":112,"phases":7815,"primaryCompletion":7816,"completion":1829,"start":7084,"enrollment":7817,"conditions":7818,"interventions":7819},"NCT01728935","Tenofovir in Asian Chronic Hepatitis B Patients",[93],"2012-11",141,[2678],[7798],{"intervention":7821,"totalTrials":137,"cells":7822},"Fluarix Tetra",{"EARLY_PHASE1":7823,"PHASE1":7825,"PHASE2":7827,"PHASE3":7829,"PHASE4":7831,"NA":7833},{"trials":7824,"activeCount":100},[],{"trials":7826,"activeCount":100},[],{"trials":7828,"activeCount":100},[],{"trials":7830,"activeCount":100},[],{"trials":7832,"activeCount":100},[],{"trials":7834,"activeCount":100},[7835],{"nctId":7836,"briefTitle":7837,"status":164,"phases":7838,"primaryCompletion":7839,"completion":7840,"start":1838,"enrollment":7841,"conditions":7842,"interventions":7843},"NCT05315024","Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children",[93],"2023-09-30","2023-10-30",72,[468],[7821,7844],"Imiquimod cream",{"intervention":7844,"totalTrials":137,"cells":7846},{"EARLY_PHASE1":7847,"PHASE1":7849,"PHASE2":7851,"PHASE3":7853,"PHASE4":7855,"NA":7857},{"trials":7848,"activeCount":100},[],{"trials":7850,"activeCount":100},[],{"trials":7852,"activeCount":100},[],{"trials":7854,"activeCount":100},[],{"trials":7856,"activeCount":100},[],{"trials":7858,"activeCount":100},[7859],{"nctId":7836,"briefTitle":7837,"status":164,"phases":7860,"primaryCompletion":7839,"completion":7840,"start":1838,"enrollment":7841,"conditions":7861,"interventions":7862},[93],[468],[7821,7844],{"intervention":7864,"totalTrials":137,"cells":7865},"Ping On Ointment",{"EARLY_PHASE1":7866,"PHASE1":7868,"PHASE2":7870,"PHASE3":7872,"PHASE4":7874,"NA":7876},{"trials":7867,"activeCount":100},[],{"trials":7869,"activeCount":100},[],{"trials":7871,"activeCount":100},[],{"trials":7873,"activeCount":100},[],{"trials":7875,"activeCount":100},[],{"trials":7877,"activeCount":100},[7878],{"nctId":7879,"briefTitle":7880,"status":112,"phases":7881,"primaryCompletion":7882,"completion":570,"start":3945,"enrollment":7883,"conditions":7884,"interventions":7886},"NCT00812604","Analgesic Ointment on Temporomandibular Joint and Masticatory Muscle Pain",[93],"2008-06",55,[7885],"Temporomandibular Disorders",[7864,7887],"Vaseline",{"intervention":7887,"totalTrials":137,"cells":7889},{"EARLY_PHASE1":7890,"PHASE1":7892,"PHASE2":7894,"PHASE3":7896,"PHASE4":7898,"NA":7900},{"trials":7891,"activeCount":100},[],{"trials":7893,"activeCount":100},[],{"trials":7895,"activeCount":100},[],{"trials":7897,"activeCount":100},[],{"trials":7899,"activeCount":100},[],{"trials":7901,"activeCount":100},[7902],{"nctId":7879,"briefTitle":7880,"status":112,"phases":7903,"primaryCompletion":7882,"completion":570,"start":3945,"enrollment":7883,"conditions":7904,"interventions":7905},[93],[7885],[7864,7887],{"intervention":1878,"totalTrials":137,"cells":7907},{"EARLY_PHASE1":7908,"PHASE1":7910,"PHASE2":7912,"PHASE3":7914,"PHASE4":7916,"NA":7918},{"trials":7909,"activeCount":100},[],{"trials":7911,"activeCount":100},[],{"trials":7913,"activeCount":100},[],{"trials":7915,"activeCount":100},[],{"trials":7917,"activeCount":100},[],{"trials":7919,"activeCount":100},[7920],{"nctId":1869,"briefTitle":1870,"status":164,"phases":7921,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":1874,"conditions":7922,"interventions":7923},[93],[1876,614],[1814,1878],{"intervention":7186,"totalTrials":137,"cells":7925},{"EARLY_PHASE1":7926,"PHASE1":7928,"PHASE2":7930,"PHASE3":7932,"PHASE4":7934,"NA":7936},{"trials":7927,"activeCount":100},[],{"trials":7929,"activeCount":100},[],{"trials":7931,"activeCount":100},[],{"trials":7933,"activeCount":100},[],{"trials":7935,"activeCount":100},[],{"trials":7937,"activeCount":100},[7938],{"nctId":7178,"briefTitle":7179,"status":164,"phases":7939,"primaryCompletion":7181,"completion":6237,"start":7182,"enrollment":7183,"conditions":7940,"interventions":7941},[93],[4408,2065],[7159,7186],{"intervention":7943,"totalTrials":137,"cells":7944},"ARIPiprazole Injection [Abilify]",{"EARLY_PHASE1":7945,"PHASE1":7947,"PHASE2":7949,"PHASE3":7951,"PHASE4":7953,"NA":7955},{"trials":7946,"activeCount":100},[],{"trials":7948,"activeCount":100},[],{"trials":7950,"activeCount":100},[],{"trials":7952,"activeCount":100},[],{"trials":7954,"activeCount":100},[],{"trials":7956,"activeCount":100},[7957],{"nctId":7958,"briefTitle":7959,"status":112,"phases":7960,"primaryCompletion":7961,"completion":7961,"start":7962,"enrollment":1815,"conditions":7963,"interventions":7965},"NCT05169268","Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia",[],"2026-01-31","2022-02-01",[4443,7964],"Anxiety Depression",[7943,7966],"Brexpiprazole",{"intervention":7966,"totalTrials":137,"cells":7968},{"EARLY_PHASE1":7969,"PHASE1":7971,"PHASE2":7973,"PHASE3":7975,"PHASE4":7977,"NA":7979},{"trials":7970,"activeCount":100},[],{"trials":7972,"activeCount":100},[],{"trials":7974,"activeCount":100},[],{"trials":7976,"activeCount":100},[],{"trials":7978,"activeCount":100},[],{"trials":7980,"activeCount":100},[7981],{"nctId":7958,"briefTitle":7959,"status":112,"phases":7982,"primaryCompletion":7961,"completion":7961,"start":7962,"enrollment":1815,"conditions":7983,"interventions":7984},[],[4443,7964],[7943,7966],{"intervention":7986,"totalTrials":137,"cells":7987},"RCO group",{"EARLY_PHASE1":7988,"PHASE1":7990,"PHASE2":7992,"PHASE3":7994,"PHASE4":7996,"NA":7998},{"trials":7989,"activeCount":100},[],{"trials":7991,"activeCount":100},[],{"trials":7993,"activeCount":100},[],{"trials":7995,"activeCount":100},[],{"trials":7997,"activeCount":100},[],{"trials":7999,"activeCount":100},[8000],{"nctId":8001,"briefTitle":8002,"status":164,"phases":8003,"primaryCompletion":8004,"completion":8005,"start":8006,"enrollment":8007,"conditions":8008,"interventions":8009},"NCT04382638","Effectiveness of Three Dimensional Correction During in Bracing in Adolescent Idiopathic Scoliosis",[93],"2025-07-03","2025-12-03","2022-07-02",134,[7795],[7986],{"intervention":8011,"totalTrials":137,"cells":8012},"nicotine gum or nicotine patch",{"EARLY_PHASE1":8013,"PHASE1":8015,"PHASE2":8017,"PHASE3":8019,"PHASE4":8021,"NA":8023},{"trials":8014,"activeCount":100},[],{"trials":8016,"activeCount":100},[],{"trials":8018,"activeCount":100},[],{"trials":8020,"activeCount":100},[],{"trials":8022,"activeCount":100},[],{"trials":8024,"activeCount":100},[8025],{"nctId":8026,"briefTitle":8027,"status":164,"phases":8028,"primaryCompletion":8029,"completion":5785,"start":8030,"enrollment":6417,"conditions":8031,"interventions":8032},"NCT03717662","Promoting Women's Health: A Gender Specific Smoking Cessation Program for Female Smokers in Hong Kong",[93],"2024-10-01","2006-04-01",[16],[8011],{"intervention":8034,"totalTrials":137,"cells":8035},"mRNA BNT162b2 vaccine",{"EARLY_PHASE1":8036,"PHASE1":8038,"PHASE2":8040,"PHASE3":8042,"PHASE4":8044,"NA":8046},{"trials":8037,"activeCount":100},[],{"trials":8039,"activeCount":100},[],{"trials":8041,"activeCount":100},[],{"trials":8043,"activeCount":100},[],{"trials":8045,"activeCount":100},[],{"trials":8047,"activeCount":100},[8048],{"nctId":8049,"briefTitle":8050,"status":112,"phases":8051,"primaryCompletion":4487,"completion":507,"start":8052,"enrollment":8053,"conditions":8054,"interventions":8055},"NCT05599555","Community-based Sero-epidemiological Study of COVID-19",[],"2022-04-28",9600,[5447],[8034,8056],"CoronaVac vaccine",{"intervention":8056,"totalTrials":137,"cells":8058},{"EARLY_PHASE1":8059,"PHASE1":8061,"PHASE2":8063,"PHASE3":8065,"PHASE4":8067,"NA":8069},{"trials":8060,"activeCount":100},[],{"trials":8062,"activeCount":100},[],{"trials":8064,"activeCount":100},[],{"trials":8066,"activeCount":100},[],{"trials":8068,"activeCount":100},[],{"trials":8070,"activeCount":100},[8071],{"nctId":8049,"briefTitle":8050,"status":112,"phases":8072,"primaryCompletion":4487,"completion":507,"start":8052,"enrollment":8053,"conditions":8073,"interventions":8074},[],[5447],[8034,8056],{"intervention":8076,"totalTrials":137,"cells":8077},"Timolol",{"EARLY_PHASE1":8078,"PHASE1":8080,"PHASE2":8082,"PHASE3":8084,"PHASE4":8086,"NA":8088},{"trials":8079,"activeCount":100},[],{"trials":8081,"activeCount":100},[],{"trials":8083,"activeCount":100},[],{"trials":8085,"activeCount":100},[],{"trials":8087,"activeCount":100},[],{"trials":8089,"activeCount":100},[8090],{"nctId":8091,"briefTitle":8092,"status":112,"phases":8093,"primaryCompletion":4384,"completion":6261,"start":8094,"enrollment":8095,"conditions":8096,"interventions":8099},"NCT04868175","Interval Intraocular Pressure in Intravitreal Injection Study",[93],"2019-10-01",64,[8097,8098],"Glaucoma","Intraocular Pressure",[8076,8100,8101],"Travatan","Hypromellose",{"intervention":8100,"totalTrials":137,"cells":8103},{"EARLY_PHASE1":8104,"PHASE1":8106,"PHASE2":8108,"PHASE3":8110,"PHASE4":8112,"NA":8114},{"trials":8105,"activeCount":100},[],{"trials":8107,"activeCount":100},[],{"trials":8109,"activeCount":100},[],{"trials":8111,"activeCount":100},[],{"trials":8113,"activeCount":100},[],{"trials":8115,"activeCount":100},[8116],{"nctId":8091,"briefTitle":8092,"status":112,"phases":8117,"primaryCompletion":4384,"completion":6261,"start":8094,"enrollment":8095,"conditions":8118,"interventions":8119},[93],[8097,8098],[8076,8100,8101],{"intervention":8101,"totalTrials":137,"cells":8121},{"EARLY_PHASE1":8122,"PHASE1":8124,"PHASE2":8126,"PHASE3":8128,"PHASE4":8130,"NA":8132},{"trials":8123,"activeCount":100},[],{"trials":8125,"activeCount":100},[],{"trials":8127,"activeCount":100},[],{"trials":8129,"activeCount":100},[],{"trials":8131,"activeCount":100},[],{"trials":8133,"activeCount":100},[8134],{"nctId":8091,"briefTitle":8092,"status":112,"phases":8135,"primaryCompletion":4384,"completion":6261,"start":8094,"enrollment":8095,"conditions":8136,"interventions":8137},[93],[8097,8098],[8076,8100,8101],{"intervention":8139,"totalTrials":137,"cells":8140},"Universal antibiotic prophylaxis",{"EARLY_PHASE1":8141,"PHASE1":8143,"PHASE2":8145,"PHASE3":8147,"PHASE4":8149,"NA":8151},{"trials":8142,"activeCount":100},[],{"trials":8144,"activeCount":100},[],{"trials":8146,"activeCount":100},[],{"trials":8148,"activeCount":100},[],{"trials":8150,"activeCount":100},[],{"trials":8152,"activeCount":100},[8153],{"nctId":8154,"briefTitle":8155,"status":112,"phases":8156,"primaryCompletion":4674,"completion":4674,"start":8157,"enrollment":8158,"conditions":8159,"interventions":8163},"NCT01842100","To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy",[93],"1999-09",2193,[8160,8161,8162],"Induced Abortion","Postaboral Pelvic Inflammatory Disease","Sexually Transmitted Infections",[8139],{"intervention":1961,"totalTrials":137,"cells":8165},{"EARLY_PHASE1":8166,"PHASE1":8168,"PHASE2":8170,"PHASE3":8172,"PHASE4":8174,"NA":8176},{"trials":8167,"activeCount":100},[],{"trials":8169,"activeCount":100},[],{"trials":8171,"activeCount":100},[],{"trials":8173,"activeCount":100},[],{"trials":8175,"activeCount":100},[],{"trials":8177,"activeCount":100},[8178],{"nctId":1953,"briefTitle":1954,"status":112,"phases":8179,"primaryCompletion":1956,"completion":1956,"start":1957,"enrollment":1254,"conditions":8180,"interventions":8181},[93],[1959],[62,1961],{"intervention":8183,"totalTrials":137,"cells":8184},"Iron Isomaltoside",{"EARLY_PHASE1":8185,"PHASE1":8187,"PHASE2":8189,"PHASE3":8191,"PHASE4":8193,"NA":8195},{"trials":8186,"activeCount":100},[],{"trials":8188,"activeCount":100},[],{"trials":8190,"activeCount":100},[],{"trials":8192,"activeCount":100},[],{"trials":8194,"activeCount":100},[],{"trials":8196,"activeCount":100},[8197],{"nctId":8198,"briefTitle":8199,"status":3540,"phases":8200,"primaryCompletion":2041,"completion":2041,"start":8201,"enrollment":8202,"conditions":8203,"interventions":8205},"NCT03610230","Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients",[93],"2019-02-01",16,[8204],"Iron Deficiency Anemia Treatment",[8183,8206],"Iron sucrose",{"intervention":8206,"totalTrials":137,"cells":8208},{"EARLY_PHASE1":8209,"PHASE1":8211,"PHASE2":8213,"PHASE3":8215,"PHASE4":8217,"NA":8219},{"trials":8210,"activeCount":100},[],{"trials":8212,"activeCount":100},[],{"trials":8214,"activeCount":100},[],{"trials":8216,"activeCount":100},[],{"trials":8218,"activeCount":100},[],{"trials":8220,"activeCount":100},[8221],{"nctId":8198,"briefTitle":8199,"status":3540,"phases":8222,"primaryCompletion":2041,"completion":2041,"start":8201,"enrollment":8202,"conditions":8223,"interventions":8224},[93],[8204],[8183,8206],{"intervention":8226,"totalTrials":137,"cells":8227},"Sequencing of ctDNA in plasma",{"EARLY_PHASE1":8228,"PHASE1":8230,"PHASE2":8232,"PHASE3":8234,"PHASE4":8236,"NA":8238},{"trials":8229,"activeCount":100},[],{"trials":8231,"activeCount":100},[],{"trials":8233,"activeCount":100},[],{"trials":8235,"activeCount":100},[],{"trials":8237,"activeCount":100},[],{"trials":8239,"activeCount":100},[8240],{"nctId":8241,"briefTitle":8242,"status":164,"phases":8243,"primaryCompletion":1872,"completion":1872,"start":4610,"enrollment":635,"conditions":8244,"interventions":8246},"NCT03090815","Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma",[],[8245],"Adenocarcinoma of Lung (Disorder)",[8226],{"intervention":8248,"totalTrials":137,"cells":8249},"Video+brief smoking cessation+pamphlet",{"EARLY_PHASE1":8250,"PHASE1":8252,"PHASE2":8254,"PHASE3":8256,"PHASE4":8258,"NA":8260},{"trials":8251,"activeCount":100},[],{"trials":8253,"activeCount":100},[],{"trials":8255,"activeCount":100},[],{"trials":8257,"activeCount":100},[],{"trials":8259,"activeCount":100},[],{"trials":8261,"activeCount":100},[8262],{"nctId":8263,"briefTitle":8264,"status":112,"phases":8265,"primaryCompletion":8266,"completion":4886,"start":1235,"enrollment":8267,"conditions":8268,"interventions":8269},"NCT03236025","A Video-led Smoking Cessation Intervention in Helping Male Smokers Whose Partners Got Pregnant to Quit Smoking",[93],"2018-10-31",1023,[16],[8248,8270],"Text-message+brief smoking cessation+pamphlet",{"intervention":8270,"totalTrials":137,"cells":8272},{"EARLY_PHASE1":8273,"PHASE1":8275,"PHASE2":8277,"PHASE3":8279,"PHASE4":8281,"NA":8283},{"trials":8274,"activeCount":100},[],{"trials":8276,"activeCount":100},[],{"trials":8278,"activeCount":100},[],{"trials":8280,"activeCount":100},[],{"trials":8282,"activeCount":100},[],{"trials":8284,"activeCount":100},[8285],{"nctId":8263,"briefTitle":8264,"status":112,"phases":8286,"primaryCompletion":8266,"completion":4886,"start":1235,"enrollment":8267,"conditions":8287,"interventions":8288},[93],[16],[8248,8270],{"intervention":7269,"totalTrials":137,"cells":8290},{"EARLY_PHASE1":8291,"PHASE1":8293,"PHASE2":8295,"PHASE3":8297,"PHASE4":8299,"NA":8301},{"trials":8292,"activeCount":100},[],{"trials":8294,"activeCount":100},[],{"trials":8296,"activeCount":100},[],{"trials":8298,"activeCount":100},[],{"trials":8300,"activeCount":100},[],{"trials":8302,"activeCount":100},[8303],{"nctId":7261,"briefTitle":7262,"status":112,"phases":8304,"primaryCompletion":6785,"completion":7264,"start":7265,"enrollment":2624,"conditions":8305,"interventions":8306},[93],[7267],[7246,7269],{"intervention":6964,"totalTrials":137,"cells":8308},{"EARLY_PHASE1":8309,"PHASE1":8311,"PHASE2":8313,"PHASE3":8315,"PHASE4":8317,"NA":8319},{"trials":8310,"activeCount":100},[],{"trials":8312,"activeCount":100},[],{"trials":8314,"activeCount":100},[],{"trials":8316,"activeCount":100},[],{"trials":8318,"activeCount":100},[],{"trials":8320,"activeCount":100},[8321],{"nctId":6957,"briefTitle":6958,"status":112,"phases":8322,"primaryCompletion":5012,"completion":5012,"start":6960,"enrollment":6961,"conditions":8323,"interventions":8324},[],[2584],[3923,6964],{"intervention":8326,"totalTrials":137,"cells":8327},"Prednisolone and\u002For AZA\u002FMMF",{"EARLY_PHASE1":8328,"PHASE1":8330,"PHASE2":8332,"PHASE3":8334,"PHASE4":8336,"NA":8338},{"trials":8329,"activeCount":100},[],{"trials":8331,"activeCount":100},[],{"trials":8333,"activeCount":100},[],{"trials":8335,"activeCount":100},[],{"trials":8337,"activeCount":100},[],{"trials":8339,"activeCount":100},[8340],{"nctId":8341,"briefTitle":8342,"status":112,"phases":8343,"primaryCompletion":536,"completion":536,"start":8344,"enrollment":8345,"conditions":8346,"interventions":8347},"NCT04870359","Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation",[93],"2016-04-21",49,[1600],[8326],{"intervention":8349,"totalTrials":137,"cells":8350},"Nicotine replacement therapy sampling",{"EARLY_PHASE1":8351,"PHASE1":8353,"PHASE2":8355,"PHASE3":8357,"PHASE4":8359,"NA":8361},{"trials":8352,"activeCount":100},[],{"trials":8354,"activeCount":100},[],{"trials":8356,"activeCount":100},[],{"trials":8358,"activeCount":100},[],{"trials":8360,"activeCount":100},[],{"trials":8362,"activeCount":100},[8363],{"nctId":8364,"briefTitle":8365,"status":112,"phases":8366,"primaryCompletion":6172,"completion":2580,"start":8367,"enrollment":8368,"conditions":8369,"interventions":8370},"NCT03671707","Brief Advice, Nicotine Replacement Therapy Sampling and Active Referral (BANSAR) for Smoking Fathers",[93],"2018-10-10",1053,[16,7495],[8349],{"intervention":8372,"totalTrials":137,"cells":8373},"Blood tests",{"EARLY_PHASE1":8374,"PHASE1":8376,"PHASE2":8378,"PHASE3":8380,"PHASE4":8382,"NA":8384},{"trials":8375,"activeCount":100},[],{"trials":8377,"activeCount":100},[],{"trials":8379,"activeCount":100},[],{"trials":8381,"activeCount":100},[],{"trials":8383,"activeCount":100},[],{"trials":8385,"activeCount":100},[8386],{"nctId":8387,"briefTitle":8388,"status":164,"phases":8389,"primaryCompletion":1966,"completion":8390,"start":8391,"enrollment":8392,"conditions":8393,"interventions":8398},"NCT03275363","The University of Hong Kong Neurocognitive Disorder Cohort",[],"2022-01-04","2014-09-01",500,[8394,7726,8395,8396,8397],"Neurocognitive Disorder","Alzheimer Dementia","Vascular Dementia","Age-related Cognitive Decline",[8372],{"intervention":8400,"totalTrials":137,"cells":8401},"Human chorionic gonadotrophin",{"EARLY_PHASE1":8402,"PHASE1":8404,"PHASE2":8406,"PHASE3":8408,"PHASE4":8410,"NA":8412},{"trials":8403,"activeCount":100},[],{"trials":8405,"activeCount":100},[],{"trials":8407,"activeCount":100},[],{"trials":8409,"activeCount":100},[],{"trials":8411,"activeCount":100},[],{"trials":8413,"activeCount":100},[8414],{"nctId":8415,"briefTitle":8416,"status":112,"phases":8417,"primaryCompletion":1873,"completion":1873,"start":8418,"enrollment":8419,"conditions":8420,"interventions":8421},"NCT01931384","A Study of Human Chorionic Gonadotrophin as Luteal Phase Support in Frozen Embryo Transfer",[93],"2012-07",450,[614],[8400],{"intervention":8423,"totalTrials":137,"cells":8424},"TIV 2010\u002F2011 influenza vaccine",{"EARLY_PHASE1":8425,"PHASE1":8427,"PHASE2":8429,"PHASE3":8431,"PHASE4":8433,"NA":8435},{"trials":8426,"activeCount":100},[],{"trials":8428,"activeCount":100},[],{"trials":8430,"activeCount":100},[],{"trials":8432,"activeCount":100},[],{"trials":8434,"activeCount":100},[],{"trials":8436,"activeCount":100},[8437],{"nctId":8438,"briefTitle":8439,"status":112,"phases":8440,"primaryCompletion":7264,"completion":7264,"start":3738,"enrollment":3337,"conditions":8441,"interventions":8442},"NCT01304563","2010\u002F2011 Trivalent Influenza Vaccination",[93],[468],[8423,8423,8423,8443],"INT",{"intervention":8443,"totalTrials":137,"cells":8445},{"EARLY_PHASE1":8446,"PHASE1":8448,"PHASE2":8450,"PHASE3":8452,"PHASE4":8454,"NA":8456},{"trials":8447,"activeCount":100},[],{"trials":8449,"activeCount":100},[],{"trials":8451,"activeCount":100},[],{"trials":8453,"activeCount":100},[],{"trials":8455,"activeCount":100},[],{"trials":8457,"activeCount":100},[8458],{"nctId":8438,"briefTitle":8439,"status":112,"phases":8459,"primaryCompletion":7264,"completion":7264,"start":3738,"enrollment":3337,"conditions":8460,"interventions":8461},[93],[468],[8423,8423,8423,8443],{"intervention":8463,"totalTrials":137,"cells":8464},"EXD",{"EARLY_PHASE1":8465,"PHASE1":8467,"PHASE2":8469,"PHASE3":8471,"PHASE4":8473,"NA":8475},{"trials":8466,"activeCount":100},[],{"trials":8468,"activeCount":100},[],{"trials":8470,"activeCount":100},[],{"trials":8472,"activeCount":100},[],{"trials":8474,"activeCount":100},[],{"trials":8476,"activeCount":100},[8477],{"nctId":8478,"briefTitle":8479,"status":112,"phases":8480,"primaryCompletion":569,"completion":4315,"start":8481,"enrollment":8482,"conditions":8483,"interventions":8485},"NCT00799734","Chinese Medicine Therapy on Menopausal Symptoms",[93],"2009-04",108,[8484],"Menopause",[8463],{"intervention":7090,"totalTrials":137,"cells":8487},{"EARLY_PHASE1":8488,"PHASE1":8490,"PHASE2":8492,"PHASE3":8494,"PHASE4":8496,"NA":8498},{"trials":8489,"activeCount":100},[],{"trials":8491,"activeCount":100},[],{"trials":8493,"activeCount":100},[],{"trials":8495,"activeCount":100},[],{"trials":8497,"activeCount":100},[],{"trials":8499,"activeCount":100},[8500],{"nctId":7081,"briefTitle":7082,"status":112,"phases":8501,"primaryCompletion":7084,"completion":7084,"start":7085,"enrollment":7086,"conditions":8502,"interventions":8503},[93],[7088],[1867,7090],{"intervention":8505,"totalTrials":137,"cells":8506},"Avelumab",{"EARLY_PHASE1":8507,"PHASE1":8509,"PHASE2":8511,"PHASE3":8513,"PHASE4":8515,"NA":8517},{"trials":8508,"activeCount":100},[],{"trials":8510,"activeCount":100},[],{"trials":8512,"activeCount":100},[],{"trials":8514,"activeCount":100},[],{"trials":8516,"activeCount":100},[],{"trials":8518,"activeCount":100},[8519],{"nctId":8520,"briefTitle":8521,"status":112,"phases":8522,"primaryCompletion":414,"completion":8523,"start":4439,"enrollment":8524,"conditions":8525,"interventions":8527},"NCT03826589","Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy",[93],"2024-07-01",23,[8526],"Cervical Cancer",[8505,8528],"Axitinib",{"intervention":8528,"totalTrials":137,"cells":8530},{"EARLY_PHASE1":8531,"PHASE1":8533,"PHASE2":8535,"PHASE3":8537,"PHASE4":8539,"NA":8541},{"trials":8532,"activeCount":100},[],{"trials":8534,"activeCount":100},[],{"trials":8536,"activeCount":100},[],{"trials":8538,"activeCount":100},[],{"trials":8540,"activeCount":100},[],{"trials":8542,"activeCount":100},[8543],{"nctId":8520,"briefTitle":8521,"status":112,"phases":8544,"primaryCompletion":414,"completion":8523,"start":4439,"enrollment":8524,"conditions":8545,"interventions":8546},[93],[8526],[8505,8528],{"intervention":8548,"totalTrials":137,"cells":8549},"Intrauterine lidocaine",{"EARLY_PHASE1":8550,"PHASE1":8552,"PHASE2":8554,"PHASE3":8556,"PHASE4":8558,"NA":8560},{"trials":8551,"activeCount":100},[],{"trials":8553,"activeCount":100},[],{"trials":8555,"activeCount":100},[],{"trials":8557,"activeCount":100},[],{"trials":8559,"activeCount":100},[],{"trials":8561,"activeCount":100},[8562],{"nctId":8563,"briefTitle":8564,"status":112,"phases":8565,"primaryCompletion":2526,"completion":2526,"start":3785,"enrollment":2089,"conditions":8566,"interventions":8567},"NCT02355522","Trial of Local Lidocaine Gel and Intrauterine Lidocaine Infusion for Pain Relief During Saline Infusion Sonohysterography",[93],[3245],[8548,8568,8569,8570],"Lidocaine gel","KY jelly","Intrauterine normal saline",{"intervention":8568,"totalTrials":137,"cells":8572},{"EARLY_PHASE1":8573,"PHASE1":8575,"PHASE2":8577,"PHASE3":8579,"PHASE4":8581,"NA":8583},{"trials":8574,"activeCount":100},[],{"trials":8576,"activeCount":100},[],{"trials":8578,"activeCount":100},[],{"trials":8580,"activeCount":100},[],{"trials":8582,"activeCount":100},[],{"trials":8584,"activeCount":100},[8585],{"nctId":8563,"briefTitle":8564,"status":112,"phases":8586,"primaryCompletion":2526,"completion":2526,"start":3785,"enrollment":2089,"conditions":8587,"interventions":8588},[93],[3245],[8548,8568,8569,8570],{"intervention":8569,"totalTrials":137,"cells":8590},{"EARLY_PHASE1":8591,"PHASE1":8593,"PHASE2":8595,"PHASE3":8597,"PHASE4":8599,"NA":8601},{"trials":8592,"activeCount":100},[],{"trials":8594,"activeCount":100},[],{"trials":8596,"activeCount":100},[],{"trials":8598,"activeCount":100},[],{"trials":8600,"activeCount":100},[],{"trials":8602,"activeCount":100},[8603],{"nctId":8563,"briefTitle":8564,"status":112,"phases":8604,"primaryCompletion":2526,"completion":2526,"start":3785,"enrollment":2089,"conditions":8605,"interventions":8606},[93],[3245],[8548,8568,8569,8570],{"intervention":8570,"totalTrials":137,"cells":8608},{"EARLY_PHASE1":8609,"PHASE1":8611,"PHASE2":8613,"PHASE3":8615,"PHASE4":8617,"NA":8619},{"trials":8610,"activeCount":100},[],{"trials":8612,"activeCount":100},[],{"trials":8614,"activeCount":100},[],{"trials":8616,"activeCount":100},[],{"trials":8618,"activeCount":100},[],{"trials":8620,"activeCount":100},[8621],{"nctId":8563,"briefTitle":8564,"status":112,"phases":8622,"primaryCompletion":2526,"completion":2526,"start":3785,"enrollment":2089,"conditions":8623,"interventions":8624},[93],[3245],[8548,8568,8569,8570],{"intervention":8626,"totalTrials":137,"cells":8627},"Hyperimmune intravenous immunoglobulin",{"EARLY_PHASE1":8628,"PHASE1":8630,"PHASE2":8632,"PHASE3":8634,"PHASE4":8636,"NA":8638},{"trials":8629,"activeCount":100},[],{"trials":8631,"activeCount":100},[],{"trials":8633,"activeCount":100},[],{"trials":8635,"activeCount":100},[],{"trials":8637,"activeCount":100},[],{"trials":8639,"activeCount":100},[8640],{"nctId":8641,"briefTitle":8642,"status":112,"phases":8643,"primaryCompletion":8644,"completion":8645,"start":6716,"enrollment":8646,"conditions":8647,"interventions":8649},"NCT01617317","H-IVIG Treatment for Severe H1N1 2009",[93],"2011-11","2012-05",34,[8648],"Novel 2009 Influenza A (H1N1) Infection",[8626,8650],"Intravenous immunoglobulin",{"intervention":8650,"totalTrials":137,"cells":8652},{"EARLY_PHASE1":8653,"PHASE1":8655,"PHASE2":8657,"PHASE3":8659,"PHASE4":8661,"NA":8663},{"trials":8654,"activeCount":100},[],{"trials":8656,"activeCount":100},[],{"trials":8658,"activeCount":100},[],{"trials":8660,"activeCount":100},[],{"trials":8662,"activeCount":100},[],{"trials":8664,"activeCount":100},[8665],{"nctId":8641,"briefTitle":8642,"status":112,"phases":8666,"primaryCompletion":8644,"completion":8645,"start":6716,"enrollment":8646,"conditions":8667,"interventions":8668},[93],[8648],[8626,8650],{"intervention":8670,"totalTrials":137,"cells":8671},"Aspirin, desmopressin",{"EARLY_PHASE1":8672,"PHASE1":8674,"PHASE2":8676,"PHASE3":8678,"PHASE4":8680,"NA":8682},{"trials":8673,"activeCount":100},[],{"trials":8675,"activeCount":100},[],{"trials":8677,"activeCount":100},[],{"trials":8679,"activeCount":100},[],{"trials":8681,"activeCount":100},[],{"trials":8683,"activeCount":100},[8684],{"nctId":8685,"briefTitle":8686,"status":112,"phases":8687,"primaryCompletion":8418,"completion":7118,"start":8688,"enrollment":709,"conditions":8689,"interventions":8695},"NCT01382134","Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction",[93],"2011-07",[8690,8691,8692,8693,8694],"Platelet Dysfunction","Hemodilution","Mild Hypothermia","NSAID","Desmopressin",[8670],{"intervention":8697,"totalTrials":137,"cells":8698},"paricalcitol",{"EARLY_PHASE1":8699,"PHASE1":8701,"PHASE2":8703,"PHASE3":8705,"PHASE4":8707,"NA":8709},{"trials":8700,"activeCount":100},[],{"trials":8702,"activeCount":100},[],{"trials":8704,"activeCount":100},[],{"trials":8706,"activeCount":100},[],{"trials":8708,"activeCount":100},[],{"trials":8710,"activeCount":100},[8711],{"nctId":8712,"briefTitle":8713,"status":112,"phases":8714,"primaryCompletion":4315,"completion":4315,"start":3943,"enrollment":709,"conditions":8715,"interventions":8717},"NCT00796679","Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease",[93],[8716],"Chronic Kidney Disease",[8697],{"intervention":7243,"totalTrials":137,"cells":8719},{"EARLY_PHASE1":8720,"PHASE1":8722,"PHASE2":8724,"PHASE3":8726,"PHASE4":8728,"NA":8730},{"trials":8721,"activeCount":100},[],{"trials":8723,"activeCount":100},[],{"trials":8725,"activeCount":100},[],{"trials":8727,"activeCount":100},[],{"trials":8729,"activeCount":100},[],{"trials":8731,"activeCount":100},[8732],{"nctId":7236,"briefTitle":7237,"status":112,"phases":8733,"primaryCompletion":3944,"completion":3944,"start":4405,"enrollment":7239,"conditions":8734,"interventions":8735},[93],[7241],[7243,7244,7243,4953,7243,4953],{"intervention":7244,"totalTrials":137,"cells":8737},{"EARLY_PHASE1":8738,"PHASE1":8740,"PHASE2":8742,"PHASE3":8744,"PHASE4":8746,"NA":8748},{"trials":8739,"activeCount":100},[],{"trials":8741,"activeCount":100},[],{"trials":8743,"activeCount":100},[],{"trials":8745,"activeCount":100},[],{"trials":8747,"activeCount":100},[],{"trials":8749,"activeCount":100},[8750],{"nctId":7236,"briefTitle":7237,"status":112,"phases":8751,"primaryCompletion":3944,"completion":3944,"start":4405,"enrollment":7239,"conditions":8752,"interventions":8753},[93],[7241],[7243,7244,7243,4953,7243,4953],{"intervention":8755,"totalTrials":137,"cells":8756},"Amoxicillin",{"EARLY_PHASE1":8757,"PHASE1":8759,"PHASE2":8761,"PHASE3":8763,"PHASE4":8765,"NA":8767},{"trials":8758,"activeCount":100},[],{"trials":8760,"activeCount":100},[],{"trials":8762,"activeCount":100},[],{"trials":8764,"activeCount":100},[],{"trials":8766,"activeCount":100},[],{"trials":8768,"activeCount":100},[8769],{"nctId":8770,"briefTitle":8771,"status":164,"phases":8772,"primaryCompletion":4799,"completion":4799,"start":2526,"enrollment":8202,"conditions":8773,"interventions":8775},"NCT02830347","Changes in Resistome After Dental Extraction and Amoxicillin.",[],[8774],"Impacted Third Molar Tooth",[8755],{"intervention":8777,"totalTrials":137,"cells":8778},"Discontinue methotrexate",{"EARLY_PHASE1":8779,"PHASE1":8781,"PHASE2":8783,"PHASE3":8785,"PHASE4":8787,"NA":8789},{"trials":8780,"activeCount":100},[],{"trials":8782,"activeCount":100},[],{"trials":8784,"activeCount":100},[],{"trials":8786,"activeCount":100},[],{"trials":8788,"activeCount":100},[],{"trials":8790,"activeCount":100},[8791],{"nctId":8792,"briefTitle":8793,"status":164,"phases":8794,"primaryCompletion":2580,"completion":8795,"start":8796,"enrollment":1254,"conditions":8797,"interventions":8800},"NCT04168619","MTX-related Liver Toxicity in Psoriasis Patients, Using Ultrasound-based Techniques as a Diagnostic Tool",[],"2021-07-12","2019-06-10",[8798,8799],"Psoriasis","Liver Fibrosis",[8777],{"intervention":7277,"totalTrials":137,"cells":8802},{"EARLY_PHASE1":8803,"PHASE1":8805,"PHASE2":8807,"PHASE3":8809,"PHASE4":8811,"NA":8813},{"trials":8804,"activeCount":100},[],{"trials":8806,"activeCount":100},[],{"trials":8808,"activeCount":100},[],{"trials":8810,"activeCount":100},[],{"trials":8812,"activeCount":100},[],{"trials":8814,"activeCount":100},[8815],{"nctId":7271,"briefTitle":7272,"status":112,"phases":8816,"primaryCompletion":4414,"completion":3944,"start":1053,"enrollment":7274,"conditions":8817,"interventions":8818},[93],[7267],[7277,7246],{"intervention":8820,"totalTrials":137,"cells":8821},"platelet rich plasma",{"EARLY_PHASE1":8822,"PHASE1":8824,"PHASE2":8826,"PHASE3":8828,"PHASE4":8830,"NA":8832},{"trials":8823,"activeCount":100},[],{"trials":8825,"activeCount":100},[],{"trials":8827,"activeCount":100},[],{"trials":8829,"activeCount":100},[],{"trials":8831,"activeCount":100},[],{"trials":8833,"activeCount":100},[8834],{"nctId":8835,"briefTitle":8836,"status":164,"phases":8837,"primaryCompletion":1070,"completion":4199,"start":2496,"enrollment":386,"conditions":8838,"interventions":8840},"NCT05538364","Epidural Platelet Rich Plasma Injection for Herpes Zoster",[],[8839],"Acute Herpes Zoster Neuropathy",[8820]]